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Abstract 
The ubiquitin-proteasome system plays an important role in a wide variety of cellular 
processes including gene regulation, cell cycle and DNA damage sensing/repair. The 
degradation of cellular proteins through the ubiquitin-proteasome pathway is a highly 
complex and tightly regulated process. Recently, much research has focused on a class of 
proteins known as the UBA-UBL domain proteins which contain two functional domains 
related to ubiquitin: the ubiquitin-associated (UBA) and the ubiquitin-like (UBL) domains. 
The ability of these proteins to interact with both ubiquitin and the proteasome through 
both domains generated the interesting proposition whereby proteins belonging to this 
group may act as ‘shuttle factors’ bridging ubiquitinated substrates to the proteasome for 
degradation. These “shuttle factors” may thus contribute to the level of specificity and 
regulation to the complex mechanism of selective protein degradation through the 
ubiquitin-proteasome system. 
The yeast DNA Damage Inducible gene 1 product or Ddi1 belongs to the UBA-UBL class 
of proteins. We have identified the human homologues of this protein which we have 
designated, hDDI1 and hDDI2. Our characterisation studies have indicated a putative 
function for the latter protein in the regulation of the tumour suppressor protein, p53, 
through the ubiquitin-proteasome pathway. 
Specific antibodies against both hDDI and hDDI2 were raised and utilised in 
immunoprecipitation and western blotting experiments. Utilising these antibodies, we have 
shown that the expression of hDDI1 is expressed at very high levels in the testis. hDDI2 is 
ubiquitously expressed. Analysis of human cell lines at the protein and mRNA level also 
showed that hDDI2 is expressed in all of the cell lines examined. As hDDI1 is not present 
to any detectable level in human cell lines, our subsequent studies have focussed on the 
more widely expressed hDDI2. 
Given that yeast Ddi1 interacts with the proteasome, we examined the interaction between 
hDDI2 and the proteasome. Our results showed that hRPN13, a subunit of the 26S 
proteasome, can be co-immunoprecipitated in the same complex as endogenous hDDI2 in 
U2OS cells and that this was a direct interaction was shown through in vitro binding 
studies.  
We employed siRNA-mediated knockdown of hDDI2 and studied its phenotype in cells. 
Using a real time cell analyser platform to measure cell growth, we showed that 
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knockdown of endogenous hDDI2 led to growth retardation in U2OS cells when compared 
to control cells. Additionally, cells depleted of hDDI2 displayed reduced cell survival after 
exposure to DNA damage. 
We studied the effect of hDDI2 knockdown on the proteasome-mediated degradation of 
the tumour suppressor protein, p53, a well studied substrate of the ubiquitin-proteasome 
pathway. Previous studies have shown that the ubiquitination of p53 leads to its 
subsequent degradation by the proteasome. We found that knockdown of endogenous 
hDDI2 caused an acceleration in the degradation of p53 which led to the dysregulation of 
p53 levels in U2OS cells. The p53 protein plays an important role in the DNA damage 
pathway. Upon DNA damage, p53 levels are stabilised and activated to induce 
downstream DNA damage repair genes. In our study, we found that the depletion of 
endogenous hDDI2 before exposure of U2OS cells to DNA damage abrogated the 
stabilisation of p53.  
Lastly, we performed a proteomic analysis of hDDI2 interacting proteins in mouse liver 
tissue and U2OS cell lysates using anti-DDI2 antibodies. Several putative interacting 
proteins including different subunits of the proteasome were identified. 
Our findings suggest a role for hDDI2 in the regulation of the tumour suppressor protein, 
p53 through the ubiquitin-proteasome pathway. We propose a model by which the 
interaction of hDDI2 with the proteasome serves as an important regulator in maintaining 
the cellular levels of p53. Future work aims to investigate the mechanisms that are 
involved in the regulation of p53 by hDDI2 and also identify other factors that are involved 
in this regulation.  
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Chapter 1 Introduction 
1.1 Protein degradation – an overview 
Protein degradation or proteolysis serves to ensure that levels of proteins within the cell 
are regulated in accordance with their function and need, thus playing an important role in 
cellular homeostasis. It also functions to destroy proteins that have been misfolded or 
mutated, both of which can be toxic to the cell.  
Early studies initially proposed the lysosome as the main site for protein degradation. The 
discovery of the lysosome in the 1950s as a protease-containing, membrane-enclosed 
cytoplasmic organelle, presented an attractive proposition. Furthermore, the lysosome 
provided a degradation environment in a compartmentalised space separate to the 
cytoplasm. This notion, however, met with much debate. Subsequently it became apparent 
that proteases of non-lysosomal origin existed (Reddy et al. 1975). Additionally, the non-
selective nature of lysosomal degradation could not explain the differences in half-life of 
proteins within the cell. 
Proteolysis through lysosomal proteases is an exergonic process that does not require 
energy. Several decades after the discovery of the lysosome, Goldberg et al. (1976) 
argued that protein degradation within the context of a cell requires energy in an ATP-
dependent manner. His group showed that the depletion of ATP in cells led to a marked 
decrease in protein degradation. Although the study did not show any requirement for 
energy in lysosomal degradation, it was suggested that energy might have been required 
for the transport of proteins into the lysosome. It was, however, demonstrated that protein 
degradation in bacterial cells lacking lysosomes also required energy. In 1977, Etlinger 
and Goldberg (1977) then made a key discovery and showed that cell-free extracts from 
reticulocytes could selectively degrade proteins in non-lysosomal conditions. This 
furthered the notion of the existence of a parallel proteolytic system in cells.  Since then, a 
far more complex and intricate system has been unravelled which we now know as the 
ubiquitin-proteasome system. 
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1.2 Ubiquitination of a protein tags it for degradation 
A protein substrate that is destined for degradation by the proteasome is firstly tagged by 
the small 76 amino acid protein called ubiquitin. The use of ubiquitin as a proteolytic signal 
is perhaps the most prominent feature of the ubiquitin-proteasome system. Degradation of 
proteins through this pathway occurs in two discrete steps (Glickman and Ciechanover 
2002). The initial step involves the covalent conjugation of multiple ubiquitin molecules to 
the target protein through a process called ubiquitination while the second step involves 
the recognition of the ubiquitinated protein by the proteasome, a large multiunit complex in 
which degradation of the protein occurs (Glickman and Ciechanover 2002).  
Ubiquitin is conjugated to a target protein through an isopeptide bond between the C-
terminal glycine residue (G76) of ubiquitin and a lysine residue of the target protein. The 
process of ubiquitination requires the action of a cascade of enzymes; an E1 ubiquitin-
activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-protein ligase. 
Firstly, through an ATP-dependent process, the C-terminus of ubiquitin forms a thioester 
bond with the catalytic cysteine of the E1 enzyme. Once activated, ubiquitin is then 
transferred to the catalytic cysteine of the E2 enzyme. Lastly, the E3 ligase then binds both 
the ubiquitin-charged E2 enzyme and target protein to catalyse the formation of an 
isopeptide bond between the C-terminus glycine of ubiquitin and the lysine residue of the 
target protein. This process and the ubiquitin-proteasome system are depicted in Figure 
1.1. 
  









Figure 1.1 The ubiquitin-proteasome pathway for protein degradation. 
The protein substrate destined for degradation is ubiquitinated by a cascade of enzymes 
(E1, E2 and E3) in an ATP dependent manner. The ubiquitinated substrate is then 
recognised by the 26S proteasome and subsequently degraded to generate free ubiquitin 
and peptides.   
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1.3 Multiple forms of ubiquitination exist 
The process of ubiquitination was initially identified as a process that tags a protein with 
the ubiquitin peptide to signal a protein for degradation (Ciechanover et al. 1980; 
Ciechanover et al. 1981). For many years after the initial discovery of ubiquitin, 
ubiquitination of a protein was perceived solely as a proteasomal degradation signal. 
Recent studies have shown, however, that the ubiquitination of a protein does not 
necessarily lead to its degradation by the proteasome. Subsequently, it has been shown 
that ubiquitination is more than just a signal for proteasomal degradation. What was 
thought to be a rather straight forward and linear pathway has now unravelled to become a 
complex signalling pathway that is involved in a wide range of biological functions such as 
protein localisation, receptor trafficking, DNA repair, cell cycle progression, gene 
transcription and apoptosis (Deshaies and Joazeiro 2009; Kirkin et al. 2009; Raiborg and 
Stenmark 2009; Ulrich and Walden 2010; Winget and Mayor 2010). How a single, simple 
protein can govern a whole myriad of cellular functions depends on the type of ubiquitin 
modification and chain linkage formed. Ubiquitination, as a post-translational protein 
modification, can exist in multiple forms. In general, there are three forms of ubiquitination: 
mono-ubiquitination, multi-mono-ubiquitination and poly-ubiquitination (Figure 1.2A). 
 
1.3.1 Modification of a protein through mono-ubiquitination 
The attachment of a single ubiquitin moiety to a protein is called mono-ubiquitination and 
involves the formation of an isopeptide bond between the α-carboxyl group on the C-
terminal glycine residue of ubiquitin, and the ε-amino group on a lysine residue of the 
target protein. A protein may also be multi-mono-ubiquitinated, where mono-ubiquitination 
occurs at multiple sites on a protein. One known consequence of mono-ubiquitination is 
the endocytosis of cell-surface receptors, an action found to be independent of the 
proteasome (Hicke 1997). Furthermore, it has also been shown that multi-mono-
ubiquitination can also occur at various sites on the same cell-surface receptor to trigger 
its internalisation and subsequent degradation by the lysosome, or recycling to the cell 
surface (Raiborg and Stenmark 2009). Studies have also shown that ubiquitin itself is 
sufficient to act as an internalisation signal; fusion of ubiquitin to a mutant cell surface 
protein, α-factor receptor lacking any lysine residue, led to its efficient internalisation 
(Terrell et al. 1998; Shih et al. 2000). Another group of proteins that have been found to be 
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mono-ubiquitinated are the histone family of proteins. Histones are a family of small, highly 
conserved proteins that are found in all eukaryotic cells. They associate with DNA to form 
nucleosomes. The mono-ubiquitination of specific histones was found to cause them to 
conform to an open structure allowing for DNA transcription and replication factors to have 
access to the DNA (Robzyk et al. 2000).  
  







Figure 1.2 The different types and sites of ubiquitination  
A. The three general forms of ubiquitination: i) Mono-ubiquitination, ii) Multi-mono-
ubiquitination and iii) Poly-ubiquitination. In each case, an isopeptide bond is formed 
between the C-terminal glycine residue of ubiquitin and the ε-amino group of a lysine 
residue on the target protein.  
B. Schematic representation of the different lysines on a ubiquitin molecule. For poly-
ubiquitination, additional ubiquitin moieties can be attached to any of the seven 
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1.3.2 Modification of a protein through poly-ubiquitination  
Another form of ubiquitination is poly-ubiquitination, where additional ubiquitin moieties are 
attached to an internal lysine residue of the initial ubiquitin moiety, resulting in the 
formation of a tandem repeat of ubiquitin molecules. The protein sequence of ubiquitin is 
highly conserved amongst species; human ubiquitin differs by only 3 amino acid residues 
compared to its yeast counterpart. It contains seven lysine residues all of which can 
potentially act as conjugation sites in a poly-ubiquitin chain (Peng et al. 2003) (Figure 
1.2B). Thus, the formation of a poly-ubiquitin chain can be defined by the seven possible 
lysine attachment sites on the ubiquitin peptide. Poly-ubiquitin chains can therefore be of 
homotypic chains, where all the ubiquitin molecules are linked through the same lysine 
residues, or heterotypic chains, where ubiquitin molecules are linked through different 
lysine residues (Dikic et al. 2009).  
Amongst the different types of ubiquitin chain, the lysine K48 polyubiquitin chain was the 
first to be discovered, and is the best characterised. Early studies found that for ubiquitin to 
act as a signal to degrade proteins, a lysine K48 polyubiquitin linkage was essential (Chau 
et al. 1989). To further emphasise its importance in protein degradation, yeast strains 
harbouring mutant ubiquitin defective in forming K48 ubiquitin linkages showed a dramatic 
loss of protein degradation activity (Finley et al. 1994). Furthermore, the minimum 
conformation of ubiquitin chain that can be recognised by the proteasome is a tetrameric 
chain of ubiquitin linked through the K48 lysine residue (Thrower et al. 2000). 
The existence of various forms of ubiquitin chain linkage presents another level of 
complexity to the ubiquitination system, which was initially thought to be a distinct signal 
for proteasomal degradation. The use of mass spectrometry-based proteomics in studying 
ubiquitination has proved useful in analysing the various ubiquitin chain linkages. A large 
scale proteomics study in yeast cells expressing His-tagged ubiquitin found that ubiquitin 
exist in a diverse state of polyubiquitin chains (Peng et al. 2003). Peng et al (Peng et al. 
2003) showed that this diversity was brought about by the ability for ubiquitin to be 
modified at the seven internal lysine residues (Peng et al. 2003). The study also identified 
1,075 candidate substrates. (Peng et al. 2003). Prior to this study, the only two linkage 
chains that had been identified in vivo were the typical lysine K48 type chain involved in 
protein degradation and the lysine K63 type chain.  Spence et al (1995) showed that 
ubiquitin chains linked through the K63 lysine residue of ubiquitin did not commit a protein 
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for proteasomal degradation and showed that  mutants that lacked the ability to form the 
K63 linkage showed defects in DNA damage repair. Since then many studies have also 
investigated the non-proteolytic function of ubiquitination. The epidermal growth factor 
(EGF) receptor, for example, was found to be poly-ubiquitinated through the K63 linkage 
chain, which in turn acts as an internalisation signal (Huang et al. 2006). In another study 
the K63 type chain was shown to play an important role in signal transduction along the 
NF-κB pathway, activating the IκB kinase through the formation of the K63 type ubiquitin 
chain (Deng et al. 2000). 
While it has been well established that the typical K48 type ubiquitin chain plays an 
important role in tagging proteins for proteasomal degradation and the K63 type ubiquitin 
chain is implicated in non-proteolytic functions, the role of the other types of ubiquitin 
linkage chains are not clear. In a more recent quantitative proteomics-based study, which 
investigated the relative abundance of ubiquitin chain linkages in yeast, it was found that 
the K48 ubiquitin chain could only account for 29% of the total ubiquitin chain linkages (Xu 
et al. 2009). This study also showed that K63 type chains accounted for a further 17% 
while, surprisingly, K11 type chains were at nearly the same level of abundance as K48 
chains at 28%. K6, K27, K29 and K33, on the other hand, had lower levels or abundance 
at 11, 9, 3 and 3%, respectively (Xu et al. 2009). It was also found that non-K63 type 
chains, like the K11 chain,  may also be involved in proteasomal degradation (Xu et al. 
2009), a role seemingly redundant with the typical K48 type chain. 
In contrast to homotypic polyubiquitin chains, ubiquitin chains that are of mixed linkages 
are difficult to characterise. Firstly, ubiquitin chains of mixed linkages are difficult to isolate. 
Furthermore, the proportion of mixed linkage chains in the total pool may only be a minute 
amount. An obvious issue that has been addressed, however, is whether these mixed 
linkage chains can support protein degradation. Assays performed in vitro have shown that 
substrates tagged with mixed chain linkages show a poor rate of degradation by purified 
proteasomes (Kim et al. 2007). 
 
1.4 Ubiquitin-binding domains 
With the many different types of ubiquitination, it is important that the cell differentiate 
between them to achieve their distinct functionalities. To do so, ubiquitination products are 
recognised by specialised ubiquitin-binding domains (UBDs) that form transient, non-
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covalent linkage with ubiquitin and ubiquitin linkage chains (Dikic et al. 2009). UBDs are 
functionally and structurally diverse with over twenty different families identified so far with 
five typical structural folds between them, including α-helical structures, zinc fingers (ZnF), 
the ubiquitin conjugating (UBC) domains present in E2 enzymes and plekstrin homology 
(PH) folds (Dikic et al. 2009). To adapt to the many different types of ubiquitin chains and 
linkages, different mechanisms have evolved to achieve the specificity in UBD-ubiquitin 
interaction. For example, certain UBDs that bind specific chain linkages (e.g. K48 ubiquitin 
chains) may have low binding affinity to mono-ubiquitin. Due to the wide and diverse range 
of UBDs currently known (estimated to be more than 150 proteins), only key UBDs with 
relevance to the ubiquitin-proteasome pathway will be discussed. 
 
1.4.1 Ubiquitin associated (UBA) domain 
The ubiquitin associated (UBA) domain was the first ubiquitin-binding domain described 
(Hofmann and Bucher 1996). Its structure has also been intensively characterised in a 
wide range of proteins containing this domain (Dieckmann et al. 1998; Wilkinson et al. 
2001; Mueller and Feigon 2002). In yeast, UBA domain containing proteins Rad23, Dsk2 
and Ddi1 have been shown to bind polyubiquitin chains (Wilkinson et al. 2001; Funakoshi 
et al. 2002; Raasi and Pickart 2003) with selectivity for the K48 type chain (Lowe et al. 
2006). Structural studies have shown that the UBA domain of the human protein, hHR23A, 
forms an independent structure comprising a compact three α-helix bundle (Mueller and 
Feigon 2002).  
 
1.4.2 Ubiquitin interacting motif (UIM) 
The ubiquitin interacting motif (UIM) was first mapped as the region on the proteasomal 
subunit, Rpn10, which is responsible for binding ubiquitin (Young et al. 1998). It has been 
shown to have preference for ubiquitin chains containing four or more ubiquitin monomers 
(Young et al. 1998). UIMs, often found in tandem repeats within the same protein, are 
made up of a stretch of about 20 amino acid residues (Hofmann and Falquet 2001). As it is 
such a short sequence motif, UIMs are unlikely to form an independent fold. However, it 
has been shown that UIMs form α-helices that are embedded into different protein folds 
(Swanson et al. 2003; Hirano et al. 2006). The specificity of the UIM on Rpn10 was 
   10 
 
investigated and found to show preference for K48 and K63-type poly-ubiquitin chains 
(Wang et al. 2005), providing evidence for the recruitment of ubiquitinated substrates to 
the proteasome for degradation. UIMs have also been found in a wide variety of proteins 
including the endosomal protein, Vps27 (Swanson et al. 2003), and the DNA repair factor, 
Rap80 (Sobhian et al. 2007). 
 
1.4.3 Pleckstrin-like receptor for ubiquitin (PRU) domain 
A more recently discovered class of the UBD is the PRU or Pleckstrin-like receptor for 
ubiquitin domain. The PRU domain was identified on the proteasomal subunit, hRPN13, 
and was found to be conserved at its N-terminal (Husnjak et al. 2008). The PRU domain of 
hRPN13 is based on homology to the Plekstrin-homology domain (PHD) fold found in 
many signalling molecules as well as structural molecules (Ingley and Hemmings 1994; 
Saraste and Hyvonen 1995). Structural analysis of the PRU domain of hRPN13 showed a 
structure made up of four stranded twisted anti-parallel β-sheets (Schreiner et al. 2008). A 
unique feature that distinguishes the PRU domain from other known UBDs is that the 
ubiquitin is bound to loops within the fold structure as opposed to α-helices found in UBA 
and UIM domains (as mentioned above). As a component of the proteasome, it has also 
been found that the PRU domain of hRPN13 can bind K48 chains with high affinity 
(Husnjak et al. 2008). 
 
1.5 The ubiquitination cascade 
Regardless of the type of ubiquitin linkage chain formed, or the final outcome that results 
from the formation of the ubiquitin chain, the process of ubiquitination requires the 
concerted effort of at least three types of enzymes in the ubiquitin-conjugation cascade: 
E1, E2 and E3. The process begins with the activation of a ubiquitin molecule through an 
ATP-dependent reaction catalysed by the E1 ubiquitin-activating enzyme before being 
transferred to the E2 ubiquitin-conjugating enzyme. A third enzyme, E3 ubiquitin-protein 
ligating enzyme then initiates the formation of an isopeptide bond between ubiquitin and 
the target protein (Figure 1.3). Conversely, the ubiquitinated state of a protein may be 
reversed through the action of enzymes called deubiquitinating enzymes (DUBs), which 
act by cleaving and disassembling ubiquitin from proteins and ubiquitin chains. The active 
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state of ubiquitin chain assembly and disassembly makes ubiquitination a dynamic 
process, thus adding an extra level of regulation and selectivity to the system. With a wide 
range of cellular processes being regulated by the ubiquitin system, it is expected that any 
dysregulation of the system would contribute to the pathogenesis of human disease, either 
directly or indirectly (Glickman and Ciechanover 2002).  
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Figure 1.3 The process of ubiquitination involves a cascade of enzymes. 
Ubiquitin is activated by the E1 ubiquitin-activating enzyme through an ATP-dependent 
process before being transferred to the E2 ubiquitin-conjugating enzyme. The E3 ubiquitin 
ligase enzyme then initiates the formation of an isopeptide bond between ubiquitin and the 
target protein. The ubiquitination process repeats itself until at least 4 molecules of 
ubiquitin are attached to a substrate protein before being recognised by the proteasome 
and subsequently degraded. Figure obtained from (Nandi et al. 2006). 
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1.5.1 The ubiquitin-activating enzyme, E1 
The E1 ubiquitin-activating enzyme catalyses the first step of the ubiquitination process. In 
an ATP dependent process, the E1 enzyme activates ubiquitin by first adenylating the 
carboxyl-terminal glycine residue of ubiquitin and forming an E1-ubiquitin thiolester 
intermediate (Haas and Rose 1982). Once activated, ubiquitin is then transferred to a 
cysteine residue on the second enzyme, E2 (Hershko et al. 1983). In simple organisms 
such as yeast, the E1 enzyme is encoded by a single gene (McGrath et al. 1991). In 
humans, however, different isoforms of the E1 protein exist, indicating the presence of a 
more complex system in higher organisms (Cook and Chock 1992; Pelzer et al. 2007). 
The significance and importance of the ubiquitination system was first realised when a 
mouse cell line expressing a defective, temperature sensitive mutant of the E1 enzyme 
displayed cell cycle arrest and failure to degrade short-lived proteins when grown at 
restrictive temperatures (Finley et al. 1984).  
 
1.5.2 The ubiquitin-conjugating enzyme, E2 
The second enzyme in the ubiquitination cascade is the E2 ubiquitin-conjugating enzyme. 
It catalyses the covalent attachment of the activated ubiquitin to either an E3-ubiquitin 
intermediate or directly to the target protein, depending on the nature of the E3 (reviewed 
in the next section). The function of the E2 enzyme lies at the heart of the ubiquitination 
cascade as E2s are responsible for both the selection of specific E3 ligases and the 
modification of target proteins. Unlike the E1 enzyme, E2 enzymes are more diverse. 
Generally, each E2 interacts with a number of E3 ligases implicating them in the 
ubiquitination of a specific subset of target proteins. The yeast genome encodes 13 distinct 
E2 proteins, termed Ubc1-13. In humans and higher organisms, the number and diversity 
of E2s are much greater with at least 38 E2s identified (Ye and Rape 2009). The common 
characteristic of an E2 enzyme is the 14-16 kDa core called the ubiquitin-conjugating 
(UBC) domain that is ~35% conserved amongst the different family members (Weissman 
2001). The UBC domain that interacts with E1s also contains the catalytic cysteine residue 
that binds activated ubiquitin (Ye and Rape 2009). Domain mapping studies have shown 
that the amino- and carboxyl- terminal extension regions flanking the core UBC domain of 
E2s are responsible for facilitating interactions with specific E3s (Mathias et al. 1998; Xie 
and Varshavsky 1999). Structural studies have, however, revealed overlapping regions on 
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E2 enzymes that interact with both E1 and E3 enzymes, suggesting that E2s might 
dissociate from E1 after having received the activated ubiquitin before proceeding to 
interact with the E3 ligase for substrate-ubiquitin conjugation (Haas and Siepmann 1997).  
 
1.5.3 The ubiquitin-protein ligase, E3 
While a certain degree of specificity exists within the E2 enzymes, much of it is conferred 
by the E3 ubiquitin-protein ligase. The large pool of E3s present in humans (at least 600-
1000 known E3s) attest to its importance in maintaining the specificity of the ubiquitination 
process. The E3 ubiquitin-protein ligase facilitates the transfer of ubiquitin from the E2 
enzyme to a substrate protein. With the many E3s present, they can be broadly classified 
into 2 types based on the domain type that is present: HECT (Homologous to the E6-AP 
Carboxyl terminal) domain- and RING (Really Interesting New Gene) finger-containing 
E3s. One major distinction between the two types of E3s is the mode of action in which 
they function, which will be discussed briefly.  
 
1.5.3.1 HECT domain E3 
E3s from this family of proteins have a characteristic HECT domain in their C-terminal 
region of approximately 350 amino acid residues. The first member of this family that was 
identified was the E6-AP or E6-associated protein (Huibregtse et al. 1993). Shortly after, 
several other proteins that share the same characteristic present in their C-terminal were 
also identified and thus named the HECT domain or the domain homologous to the E6-AP 
carboxyl terminus (Huibregtse et al. 1995). HECT E3s differ from other E3s whereby the 
conserved cysteine residue of the HECT domain forms a thiol-ester intermediate with 
ubiquitin before catalysing substrate ubiquitination (Huibregtse et al. 1995). Of the different 
types of E3s identified, only a small proportion belongs to the HECT E3 family. In humans, 
28 different HECT E3s have been identified (Rotin and Kumar 2009). As the HECT domain 
is present on the C-terminal of these proteins, their N-terminal contains one or more 
protein-protein interaction domains, which presumably determine substrate specificity of 
the different HECT E3s (Rotin and Kumar 2009).  
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1.5.3.2 RING finger motif-containing E3 
The majority of E3s belong to the RING finger class of E3 proteins with a recent study 
determining that about 95% of all known E3s belong to this subclass (Li et al. 2008). 
Unlike HECT domain E3s, ubiquitination mediated by the RING E3 ubiquitin-ligases does 
not involve an E3-ubiquitin intermediate. Instead, RING E3s act as molecular scaffolds that 
bring together components of the ubiquitination system into close proximity with a specific 
substrate, and in turn facilitate the ubiquitination of the substrate. Recent structural studies 
have determined that the RING domain functions in the recognition of E2 enzymes (Zheng 
et al. 2000; Brzovic et al. 2003; Dominguez et al. 2004). The RING domain was first 
discovered in Ring1 and at the same time 27 other proteins were also shown to possess 
the same conserved domain (Lovering et al. 1993). As many of the identified proteins had 
functions in DNA binding, the RING domain was initially thought to mediate binding to 
DNA. It was only realised several years later that the RING domain protein, Rad18, could 
promote ubiquitination of histones (Bailly et al. 1997). Since then, the involvement of RING 
domain containing proteins as E3 ubiquitin-protein ligases became more apparent (Bailly 
et al. 1997; Potuschak et al. 1998; Zachariae et al. 1998).  
The RING domain has been described as a pattern of conserved cysteine and histidine 
residues, which form a cross brace structure that allows for the binding of two zinc ions 
(Borden 2000). RING E3s can further be classified into two subgroups; (1) single-subunit 
RING E3s and (2) multi-subunit RING E3s. Single-subunit RING E3s are standalone 
proteins that, in addition to their RING domains, have the capacity to recognise target 
substrates for ubiquitination. Examples of single-subunit RING E3s are MDM2 (Boyd et al. 
2000), Ubr1 (Kwon et al. 1998) and Parkin (Shimura et al. 2000), which contain both the 
RING finger domain as well as the substrate recognition site on the same protein. 
 On the other hand, multi-unit RING E3s are composed of a complex of two or more 
subunits. RING E3s from this subtype all contain a small RING finger protein and a 
member of the Cullin family of proteins amongst their different components. Examples of 
the multi-subunit RING E3s are the SCF (Skp1-Cullin-F-box protein), cyclosome/APC 
(Anaphase promoting complex) and the VHL-CBC (von Hippel-Lindau-Cul2/elongin 
B/elongin C) complex (Weissman 2001; Deshaies and Joazeiro 2009). In SCF E3 
complexes, the specific ubiquitination of a large and diverse group of target substrates is 
defined by members of the large family of F-box proteins (Bai et al. 1996). The VHL-CBC 
E3 complexes are structurally related to the SCF E3s; the elongin B and C replaces the 
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adaptor protein, Skp1 (Lisztwan et al. 1999), and the Socs (suppressor of cytokine 
signalling) box replaces the F-box protein (Kamura et al. 1998). The APC E3 ligases, 
similar to the SCF complex play a crucial role in cell-cycle progression. One distinction 
between the two types is that SCF is active throughout the cell cycle while APC is mainly 
recruited for the progression and exit of mitosis (Castro et al. 2005). The basic 
components of an APC complex are similar to that of the SCF and VHL-CBC, with the 
presence of the RING domain and cullin subunits. However, the additional and more 
elaborate subunits present on the APC complex make it a more complicated subject, with 
yeast having at least 11 subunits making up the APC complex (Page and Hieter 1999). 
With limited information about how each subunit contributes to the complex, it has been 
thought to have adaptor roles similar to the Skp1 subunit of the SCF complex (Weissman 
2001).  
 
1.6 The Proteasome – a machine for degradation 
At the heart of the protein degradation system is the 26S proteasome, a large multi-protein 
2.5MDa complex consisting of at least 66 proteins that are highly conserved amongst 
eukaryotes (Xie 2010). Based on its structure, the 26S proteasome can be divided into two 
subcomplexes: the 20S core particle (CP), which houses protease subunits, and the 19S 
regulatory particle (RP), which acts to regulate the function of the 20S CP. The 19S RP is 
attached at one or both ends of the 20S CP to form the RP1CP or RP2CP. Yoshimura et 
al. (1993) first reported that purified 26S proteasomes can be visualised by electron 
microscopy as dumbbell-shaped structures having a cylindrical core (20S CP) with two 
rectangular domains attached at both ends (19S RP).  
 
1.6.1 The 20S Core Particle 
The 20S CP is a large, cylinder-shaped structure with a molecular weight of about 700 
kDa. The breakdown of proteins through proteolysis occurs in the chamber of the 20S CP. 
The 20S CP is made up of four stacked heptameric rings (Figure 1.4) that are composed 
of two different types of subunits, the structurally similar α subunits and the predominantly 
catalytic β subunits (Groll et al. 1997). The outer two rings are made up of seven distinct α 
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subunits (α1 – α7), which act as docking sites for the 19S regulatory particle (Smith et al. 
2007). Additionally, the N-terminal of the α subunit also acts as a gate, regulating the 
access of proteins into the inner chamber of the 20S CP (Groll et al. 2000). Seven distinct 
β- subunits make up the two inner heptameric rings (β1 – β7). The β-type subunits contain 
active sites that are positioned to face the hollow chamber of the 20S CP. In eukaryotes, 
however, only the β1, β2 and β5 subunits are proteolytically active (Groll et al. 1997), thus 
each eukaryotic proteasome contains six active sites. The proteolytic activity of the three 
different subunits has been found to be unique to each subunit; the β1 subunit providing a 
caspase-like activity, the β2 subunit providing a trypsin-like activity and the β5 providing a 
chymotrypsin-like activity (Heinemeyer et al. 1997). The combination of the different types 
of proteolytic activities provided by the different subunits ensures the efficient degradation 
of a broad variety of peptide sequences. In mammals, an alternate version of the 
proteasome referred to as an “immunoproteasome” also exists within the immune system. 
Upon activation of the immune system through the signalling of interferon-γ, a change in 
the subunit composition of the 20S CP occurs by the replacement of proteolytically active 
β subunits with alternative LMP (also referred to as βi) subunits. These LMP subunits are 
highly homologous to their β- subunit counterparts and are incorporated into the 
corresponding position within the heptameric ring of the newly-assembled proteasome 
(Bochtler et al. 1999).  
 
  











Figure 1.4 Schematic representation of the different subunits making up the 26S 
proteasome.  
The 26S proteasome is made up of: the 20S Core particle (CP) and the 19S Regulatory 
particle (RP). The 20S CP is composed of two inner β-rings and two outer α-rings, each 
being made up of seven subunits (α1-7, β1-7). The 19S RP is formed by the Lid 
subcomplex and the base subcomplex. Specific subunits making up these two 
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1.6.2 The 19S Regulatory Particle 
The 19S RP regulates, selects and prepares substrates for degradation. Based on its 
structure, it can be disassociated into the base and the lid subcomplexes (Glickman and 
Ciechanover 2002; Finley 2009). The subunit composition of the 19S RP is highly similar 
across species, with at least 19 known subunits identified (Glickman and Ciechanover 
2002; Finley 2009). The 19S RP weighs approximately 1MDa and can assemble at either 
end of the 20S CP to form the 26S proteasome (DeMartino et al. 1994; Peters et al. 1994). 
In extraction experiments in yeast, purified proteasomes are found as a mixture of free 
20S CP, singly capped (RP1CP) and doubly capped (RP2CP) (Glickman et al. 1998). In 
vivo, however, the majority of proteasomes exist as doubly capped (RP2CP) (Russell et al. 
1999) structures.   
The base of the 19S RP is situated proximally to the 20S CP and is comprised of a ring of 
six ATPases from the AAA family (ATPase Associated with a variety of cellular Activities). 
In yeast, the six ATPases present in the base subcomplex can be designated as Rpt1-6 
(for Regulatory Particle Triple-A protein). The ring of ATPases is responsible for the 
unwinding and unfolding of substrate proteins and therefore assisting in their passage 
through to the narrow gated opening of the catalytic core particle (Navon and Goldberg 
2001). In addition, the Rpt subunits also contribute to the structure of the proteasome. The 
C-terminal of the Rpt subunits attach themselves to specific α-subunits of the 20S CP 
creating an opening into the central chamber of the 20S CP (Smith et al. 2007; Gillette et 
al. 2008; Rabl et al. 2008). In addition to the six ATPases, Rpn1, 2, 10 and 13 (Regulatory 
Particle Non-ATPase) also make up the base of the 19S RP.  The Rpn1 and Rpn2 
subunits are thought to function as scaffold proteins, providing a platform for a variety of 
proteasomal-associated proteins important for proteasome activity (Finley 2009). Rpn10 
and Rpn13, on the other hand, have been shown to be ubiquitin receptors (Elsasser et al. 
2004; Kang et al. 2007; Husnjak et al. 2008). Both Rpn10 and Rpn13 are able to bind poly-
ubiquitin chains via the UIM and PRU domains, respectively. Numerous studies have 
looked at the characterisation of these domains in binding ubiquitin moieties (Hofmann and 
Falquet 2001; Walters et al. 2002; Mueller and Feigon 2003; Husnjak et al. 2008). As 
intrinsic ubiquitin receptors, both Rpn10 and Rpn13 are thought to be responsible for the 
recognition and docking of ubiquitinated proteins to the proteasome. 
The lid subcomplex of the 19S RP is composed of nine different non-ATPases and is 
located distally to the 20S core complex. The specific functions for all except one subunit 
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of the lid subcomplex are currently unclear. Nonetheless, the degradation of a 
ubiquitinated protein by the proteasome requires an intact lid indicating the importance of 
the lid subcomplex as a whole (Glickman et al. 1998). To date, the only known subunit with 
an assigned function is Rpn11. Rpn11 possesses a known DUB activity and has been 
shown to be critical for the functioning of the proteasome (Verma et al. 2002; Yao and 
Cohen 2002). The presence of a DUB on the proteasome allows for the detachment of the 
protein substrate from its ubiquitin tag and this early step prior to the actual degradation is 
thought to be governed by at least the Rpn11 subunit (Verma et al. 2002; Yao and Cohen 
2002). Although the function of the other subunits that make up the lid subcomplex is not 
known, it has been proposed that they play a structural role, allowing binding and docking 
of ubiquitinated substrates to the proteasome.  
 
1.7 The ubiquitin-proteasome system is implicated in human disease 
The ubiquitin-proteasome system has emerged as a fundamental mechanism involved in 
the regulation of a vast and diverse array of cellular processes. It is therefore not 
surprising that aberrations in the system contribute, either directly or indirectly, to the 
pathogenesis of many diseases. Because of the vast scope of cellular processes targeted 
by the ubiquitin-proteasome system, a wide spectrum of disease-causing phenotypes has 
been attributed to defects at various points in the pathway. The role of the ubiquitin-
proteasome system has been described in numerous human diseases ranging from 
cancer and viral infection to neurodegenerative, autoimmune, metabolic and genetic 
disorders (Schwartz and Ciechanover 1999; Ciechanover 2003). The pathogenesis of 
human diseases that are associated with the ubiquitin-proteasome pathway can be 
classified into two groups: (1) the stabilisation of a target protein resulting in a loss of 
function and (2) the accelerated degradation of a target protein resulting in a gain of 
function (Glickman and Ciechanover 2002). The following sections will discuss a brief 
overview of the implications this pathway has on human health. 
 
1.7.1 The ubiquitin-proteasome system in cancer 
Impairment to the ubiquitination and deubiquitination process have been directly 
associated with the etiology of many cancers. The ubiquitin-proteasome pathway is a 
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highly specific pathway that is involved in the regulation of cellular processes such as cell 
cycle progression, inhibition and promotion of apoptosis and expression of transcription 
factors. These processes are important factors in the progression of cancer. The initiation 
of cancer may either be through an increase in stabilisation of an oncoprotein (such as N-
myc, c-myc, c-fos, c-jun and Src) or the accelerated destabilisation of a tumour suppressor 
protein (such as p53 and p27).  
In the case of cervical carcinomas caused by the human papilloma virus (HPV), the level 
of the tumour suppressor protein, p53, is extremely low. Through extensive research, it is 
now known that in HPV-positive cells, p53 is targeted for ubiquitin-mediated degradation 
by the HPV oncoprotein, E6 (Scheffner et al. 1990). E6 partners with the HECT domain, 
E3 ubiquitin-ligase, E6AP (Huibregtse et al. 1991) thus promoting the recruitment of p53 to 
this complex, resulting in its ubiquitination and subsequent degradation by the 26S 
proteasome (Scheffner et al. 1990; Scheffner et al. 1993). 
 
1.7.2 The ubiquitin-proteasome system in genetic disorders 
Cystic fibrosis and Liddle syndrome are two genetic disorders in which mutations result in 
the dysregulation of the ubiquitin-proteasome system. The most common mutation of the 
cystic fibrosis gene, CFTR (Cystic fibrosis transmembrane regulator) is the deletion of the 
phenylalanine residue at position 508 (∆F508) (Ward et al. 1995). The CFTR protein is 
expressed at the epithelial surface of cells and functions as a chloride ion channel. Despite 
displaying normal ion-channel function, the mutant CFTR∆F508, is not targeted to the cell 
surface, but instead is retained in the endoplasmic reticulum, where it undergoes 
degradation through the ubiquitin-proteasome pathway (Jensen et al. 1995; Ward et al. 
1995).  
A hereditary form of hypertension, Liddle syndrome, is caused by a mutation in the proline-
rich motif of the β and γ subunits of the epithelial sodium channel (ENaC) of the kidney 
(Staub et al. 1996). ENaC is regulated by the ubiquitin-proteasome pathway through the 
Nedd4, E3 ubiquitin-ligase, which recognises the proline-rich motif of the ENaC complex 
(Staub et al. 1997). The mutant proline-rich motif causes an inability of Nedd4 to initiate 
ubiquitination of the ENaC subunits, therefore causing them to accumulate. The onset of 
hypertension results from excessive Na+ and H2O reabsorption through the accumulated 
ENaC channels.  
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1.7.3 The ubiquitin-proteasome system in neurodegenerative diseases 
A link between the ubiquitin-proteasome system and neurodegenerative diseases has also 
been described. The accumulation of ubiquitin conjugates and/or inclusion bodies 
associated with ubiquitin has been reported in many neurodegenerative diseases, such as 
the neurofibrillary tangles of Alzheimer’s disease, brainstem Lewy bodies in Parkinson’s 
disease and nuclear inclusions in Huntington’s disease (Schwartz and Ciechanover 1999; 
Glickman and Ciechanover 2002). However, it is of note that in all these cases, the 
observed aberration in the ubiquitin system is not directly linked to the pathology of the 
disease. Rather, in many cases, the accumulation of ubiquitin substrates and inclusion 
bodies may be secondary and is caused by the cell’s unsuccessful attempts at removing 
damaged and abnormal proteins through the ubiquitin-proteasome pathway. 
 
1.8 The ‘shuttle factor’ hypothesis – regulators of the ubiquitin-proteasome 
system? 
The process of ubiquitination and the events leading to the degradation of a target protein 
have been well studied. The mechanism that underlies the specificity and the regulation of 
such an event, is however, less understood. As of recently, there has been much focus on 
a group of proteins called the UBA-UBL domain proteins known for bearing two functional 
domains on the same protein related to ubiquitin. UBA-UBL domain proteins have been 
shown to be able to interact with the proteasome through their UBL domain (Schauber et 
al. 1998; Elsasser et al. 2002) and poly-ubiquitinated substrates via their UBA domain 
(Bertolaet et al. 2001; Wilkinson et al. 2001). As such, UBA-UBL domain proteins have 
been hypothesised to act as ‘shuttle factors’ bridging ubiquitinated substrates to the 
proteasome for degradation. Members of this family in yeast include Ddi1, Rad23 and 
Dsk2. Amongst the three proteins, Ddi1 has been the least studied. The subsequent 
chapters in this thesis will look at the characterisation of human homologues of Ddi1 with 
an emphasis on its hypothesised role as a regulator of the ubiquitin-proteasome pathway. 
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1.9 Aims and Hypothesis 
Given the extreme complexity surrounding the ubiquitin-proteasome pathway, much is still 
unknown about how the cell undertakes the function of protein degradation in such a 
specific and precise manner. Previous work performed in our laboratory has identified two 
novel proteins, human DNA Damage Inducible 1 (hDDI1) and human DNA Damage 
Inducible 2 (hDDI2), as human homologues to the yeast Ddi1 protein. In yeast, Ddi1 has 
been implicated in various cellular roles such as DNA damage (Liu et al. 1997), protein 
trafficking (Lustgarten and Gerst 1999) and also the ubiquitin-proteasome pathway 
(Bertolaet et al. 2001; Clarke et al. 2001; Gabriely et al. 2008; Husnjak et al. 2008). To 
date, its putative role in the various functions has not been extensively explored, as 
evidenced by the lack of literature in regards to Ddi1. Nevertheless, the association of Ddi1 
with various cellular processes suggests an important role. The yeast Ddi1 protein has 
domains that are related to the ubiquitin-proteasome pathway and as such have also been 
shown to be functionally relevant (Bertolaet et al. 2001; Gabriely et al. 2008). This led us to 
hypothesise that hDDI1 and hDDI2 proteins play important regulatory roles in cellular 
processes through their association with the ubiquitin-proteasome pathway. 
 
The aims of this project were: - 
1) To undertake a molecular and cellular characterisation of hDDI1 and hDDI2. 
Through bioinformatic approaches, we analysed the sequences of hDDI1 and 
hDDI2 to identify any known domains that are of any significance, in particular, to 
the ubiquitin-proteasome pathway. The expression of hDDI1/2 mRNA and protein 
levels was also studied in different tissues and cell lines. 
 
2) To investigate the role of hDDI1 and hDDI2 in the ubiquitin-proteasome 
pathway. We investigated a putative role for hDDI1 and hDDI2 in the ubiquitin-
proteasome pathway. The interactions of these proteins with the proteasome were 
studied and the domains of the proteins that are required for interactions were 
mapped. To assign a role for hDDI1/2 proteins in the ubiquitin-proteasome pathway, 
we silenced hDDI1/2 using a siRNA-mediated approach and studied the effect this 
had on the pathway. 
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3) To identify hDDI2 interacting proteins. Large scale immunoprecipitation of hDDI2 
was performed and using a mass spectrometry proteomics approach, hDDI2 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Chemicals and reagents used in this study are listed in Table 2.1 below. 
Table 2.1 Reagents used in this research 
Reagents Supplier 
4’,6-Diamidino-2-phenylindole (DAPI) Sigma 
Acetic Acid Merck 
Acetone  AJAX Chemicals 
Acrylamide Bio-Rad 
Agar BD Biosciences 
Ammonium Chloride Sigma 
Ammonium Sulphate Merck 
Ampicillin Sigma 
Bicinchoninic Acid Pierce 
Big Dye Terminator Mix Applied Biosystems 
Bromophenol Blue ICN Biomedical 
Calcium Chloride Sigma 
Chloroform AJAX Chemicals 
CNBr-activated Sepharose 4B GE Healthcare 
Coomassie Brilliant Blue R-250 Bio-Rad 
DNA ladder New England Biolabs 
Ethidium Bromide Sigma 
Ethylenediaminetetraacetic Acid (EDTA) APS Chemicals 
Foetal Bovine Serum  Invitrogen Life Technologies 
FuGENE HD Transfection reagent Roche 
Glutathione 4B Sepharose GE Healthcare 
Glycerol AR Chem Supply 
Glycine AR Chem Supply 
HEPES Sigma 
Hydrochloric Acid  AJAX Chemicals 
Imidazole Sigma 
Kanamycin Sigma 
Lipofectamine RNAiMAX Invitrogen Life Technologies 
Magnesium Chloride AJAX Chemicals 
MES Buffer Amresco 
Methanol HistoLab 
Nonidet P-40 (NP40) Sigma 
Novex sharp pre-stained protein Invitrogen Life Technologies 




(PMSF)  Sigma 
Protease Inhibitor Cocktail Sigma 
Protein A/G Sepharose Fast Flow  GE Healthcare 
Restriction enzymes New England Biolabs 
Sodium Azide Sigma 
Sodium Dodecyl Sulfate (SDS) Bio-Rad 
Sodium Hydrogen Carbonate AJAX Chemicals 
Sodium Hydroxide AJAX Chemicals 
Streptomycin Sigma 
Sucrose Merck 
T4 DNA Ligase New England Biolabs 
Tris Sigma 
Triton X-100 Sigma 
Trizol Reagent Invitrogen Life Technologies 
Trypsin Gibco 






Anti-DDI2-rabbit In house 
Anti-DDI2-sheep In house 
Anti-p53 BD Biosciences 
Anti-GAPDH Millipore 
Anti-MYC New England Biolabs 
Anti-RPN13 Biomol 
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2.1.3 Plasmids 
Plasmids used in this study were either obtained commercially, cloned in house or 












Primers used in this research were synthesised and purchased from Sigma Aldrich. Table 
2.2 and Table 2.3 show qRT-PCR primers that were used in this research for human and 
mouse genes, respectively. Table 2.4 shows primers that were used to clone hDDI1, 
hDDI2 and hRPN13 into expression vectors. 
Table 2.2 qRT-PCR primers for human genes 
Primer Name Sequence (5' to 3') 
hDDI1 qPCR Forward TATGCTCCGGAGACATCAATG 
hDDI1 qPCR Reverse ACCATCCTAGAGCATAAGGGCA 
hDDI1 qPCR Forward ACACAACGTGCTACCTCAAGGC 
hDDI1 qPCR Reverse CTGCTCCTCAGGACTTGGTAGG 
hDDI1 gDNA Forward CATGTGTTAAATAGGCTTTGAAGGG 
hDDI1 gDNA Reverse GTGTGCTGTTTGGAACCTAGA 
hDDI2 qPCR Forward CTGGACATGCTTAAACGGCA 
hDDI2 qPCR Reverse CCG TAC ATC CTC TCT TCC A 
hDDI2 qPCR Forward AGAGGATGTACGGCCAGAGG 
hDDI2 qPCR Reverse AATGATGACATTCCCAGTGAGG 
hβActin qPCR Forward CAGGCACCAGGGCGTG 
hβActin qPCR Reverse GCCCACATAGGAATCCTTCTGA 
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Table 2.3 qRT-PCR primers for mouse genes 
Primer Name Sequence (5' to 3') 
mDdi1 qPCR Forward TTTCACTGGGTCTGGGTCG 
mDdi1 qPCR Reverse CGTTGATGATGGTGATAATGGT 
mDdi2 qPCR Forward TACGGCCAGAGGAAATTGCA 
mDdi2 qPCR Reverse ACTCCAGCTGCAGCACACA 
mβActin qPCR Forward GAC GGC CAA GTC ATC ACT ATT G 
mβActin qPCR Reverse CCA CAG GAT TCC ATA CCC AAG A 
 
 
Table 2.4 Cloning primers used for hDDI1, hDDI2 and hRPN13 
Primer Name Sequence (5' to 3') 
hRPN13 full length with BamH1 
forward primer AAGGATCCATGACGACCTCAGGCGCG 
hRPN13 Full length with Xba1 
reverse Primer GCTCTAGATCAGTCCAGGCTCATGTCCTC 




hRPN13 Full length with Xho1  
forward primer AACTCGAGATGACGACCTCAGGCGCGCTC 
C-terminal of hRPN13 with Xho1 
forward primer AACTCGAGCTAGGCGGTGAGGGTGGCCTG 
UBL domain of hDDI1 with BamH1 
forward primer CGGGATCCATGCTGATCACCGTGTACTGC 
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2.1.5 siRNA 
Stealth siRNA were obtained from Invitrogen. 
siRNA Sequence 
hDDI2siRNA #1 AGC UAU ACU ACU GAA AUC UAU UCG G 
hDDI2siRNA #2 UAA UAU AAA GCA UCA CUA CUU GCC C 
hDDI2siRNA #3 CAC CCA GAA GAU UAU UGG AGG GGU A 
hHR23BsiRNA GGU CAA CCA CAG CCU GAC UUU CUC U 
For each siRNA transfection and experiment performed, Stealth RNAi negative control 
(Invitrogen) was used as negative control. The exact sequence of Stealth RNAi negative 
control was not disclosed by manufacturer but its sequence is not homologous to anything 
in the vertebrate transcriptome.  
2.2 Methods 
2.2.1 Cloning  
2.2.1.1 Polymerase chain reaction 
For cloning into expression vectors, the genes of interest were amplified using polymerase 
chain reaction (PCR), utilising cloning primers designed with specific restriction enzyme 
sites at the 5’ end of the primers (refer to table of cloning primers). Template DNA was 
cloned from pre-existing plasmids, cDNA or specific expressed sequence tags (ESTs) 
corresponding to the gene of interest, obtained commercially. PCR reactions were 
performed in 50µL volumes made up as follows: 1U Pfu, 0.5mM dNTP, 200nM each for 
forward cloning primer and reverse cloning primer made up in 1X Pfu buffer. Cycling 
parameters for the PCR reaction were: initial denaturation at 98°C for 1 minute, followed 
by 25 cycles of 98°C for 15 seconds, 62°C  for 30 seconds and 72°C for 1 minute, with a 
final extension at 72°C for 5 minutes.  
 
2.2.1.2 Restriction enzyme digests and ligation 
PCR product was loaded on an agarose gel (with 0.05mg/mL ethidium bromide for DNA 
visualisation) to check for size. The correct size band was then excised from the gel and 
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DNA purified using the Perfectprep Gel Cleanup kit (Eppendorf) according to the 
manufacturer’s protocol. Purified DNA was then subject to restriction enzyme digest.  
The appropriate plasmid was also digested with the same set of restriction enzymes. 
Digests reaction were set up in a 40µL volume made up as follows: 30µL purified insert 
DNA/2.5µg of vector DNA, 1X appropriate buffer 1X BSA (if required, specific to restriction 
enzyme used) and 20U of restriction enzyme (New England Biolabs).  
Ligation of the digested inserts and vectors were then carried out in a 20µL volume 
reaction using the Quick Ligation Kit (New England Biolabs). Fifty ng of plasmid DNA was 
used together with a 3-fold molar excess of insert DNA. Reactions were made up of: 1X 
Quick ligation buffer, 1uL Quick T4 DNA Ligase, appropriate amount of vector and insert 
DNA at a molar ratio of 1:3. Reactions were left at room temperature for 30 minutes then 
chilled on ice ready for transformation. 
 
2.2.1.3 Preparation of heat shock competent cells 
E.coli strains that were used in this study were DH5α, BL21 DE3, M15 PREP4 and XL1-
Blue. Cells were chemically treated to allow for uptake of plasmid DNA through the pores 
of their cell membrane when heat shocked at 42°C. Firstly, fresh bacterial cultures were 
inoculated at a 1:50 dilution in 100mL of Luria Broth (LB; 0.5% bacto-yeast extract (w/v), 
1% NaCl (w/v), 1% bacto-tryptone (w/v)). Bacterial cultures were allowed to grow at 37°C 
until the cell density reached 4-7 x 107 cells/mL (Optical Density, OD550 = 0.45-0.55). Cells 
were then chilled on ice for 15 minutes before pelleting by centrifugation at 4°C. The 
supernatant was discarded, while pelleted cells were resuspended in ice cold RF1 solution 
(100mM KCl, 50mM MnCl2.4H2O, 30mM KOAc, 10mM CaCl2.2H2O and 15% glycerol (w/v) 
pH 5.8) and incubated on ice for 1 hour. Cells were pelleted again, drained and 
resuspended in RF2 solution (10mM KCl, 10mM MOPS, 75mM CaCl2.2H20 and 15% 
glycerol (w/v)). Aliquots of cells were flash-frozen in liquid nitrogen and stored at -70°C for 
later use. 
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2.2.1.4 Bacterial plasmid transformation 
Ten µL of ligation mix or 10ng of pure plasmid were added to 100µL of competent cells in 
a pre-chilled tube and incubated on ice for 30 minutes. Cells were then heat shocked at 
42°C for 2 minutes and placed directly on ice 400µL of warm LB was then added to the 
cells and incubated in a 37°C shaker for 1 hour. Cells were then plated on LB plates 
containing appropriate antibiotics for selection and incubated at 37°C overnight.  
 
2.2.1.5 Plasmid purification from bacterial cells. 
Colonies from transformation plates were picked and cells containing the plasmid of 
interest were allowed to grow in LB containing appropriate antibiotics overnight in 5mL (for 
small scale purification) or 100mL (for large scale purification) volumes. Plasmid DNA was 
extracted using PureLink HiPure Plasmid Mini or Midi-prep kits (Invitrogen) according to 
the manufacturer’s protocol. The concentration of purified plasmids were measured using 
the Nanodrop ND-1000 (Thermo Fisher Scientific) spectrophotometer by measuring its 
absorbance at wavelength 260 and 280nm.  
 
2.2.1.6 Generation of recombinant proteins 
Recombinant proteins used in this study were expressed in E.coli bacterial cells and had 
been cloned into the pGEXKG or pQE30 vector to obtain a GST- or 6xHis-tagged fusion 
proteins. 
 
2.2.1.6.1  Purification of His-tagged proteins from M15 PREP4 cells 
M15 PREP4 cells expressing the plasmid of interest were grown in large 300mL cultures 
of LB with ampicillin (100µg/mL) and kanamycin (25µg/mL) at 37°C until OD600 reached 
between 0.8 and 1.0. The cultures were then induced to express protein using 0.5mM 
IPTG, with incubation on shaker at room temperature overnight. The next day, cells were 
pelleted and resuspended in cracking buffer (100mM HEPES-KOH pH7.3, 5mM MgCl2, 
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500mM KCl, 2mM β–mercaptoethanol, 1mM phenylmethanesulfonyl fluoride and 0.1% 
triton X-100) supplemented with 1:100 protease inhibitor cocktail (Sigma). Cells were then 
allowed to lyse on ice for 30mins before being sonicated 3 x 1 minute. Lysates were then 
snap frozen on dry ice and subsequently thawed out. The freeze-thaw cycle was repeated 
three times. Finally, lysates were centrifuged at 15, 000rpm for 30 minutes at 4°C to allow 
for separation of soluble and insoluble proteins. 
The soluble supernatant which contains the protein of interest (solubilised) was then 
purified through affinity purification. Soluble lysates were incubated with equilibrated Ni2+-
NTA beads (Qiagen) at 4°C overnight to allow for His-fusion binding. Beads were allowed 
to settle on the column and 30mL of 10mM Imidazole wash buffer (20mM HEPES, 200mM 
KCl, 10% glycerol (v/v), 10mM Imidazole and 2mM β–mercaptoethanol) was allowed to 
pass through. The protein was then eluted using 250mM Imidazole buffer (20mM HEPES, 
200mM KCl, 10% glycerol (v/v), 250mM Imidazole and 2mM β–mercaptoethanol) and 
stored at -20°C.  
 
2.2.1.6.2  Purification of GST-tagged protein from BL21 (DE3) cells 
BL21 (DE3) cells containing the pGEXKG vector containing the insert of interest were 
grown in large 300mL cultures of LB with ampicillin (100µg/mL) at 37°C until OD600 
reached between 0.8 and 1.0. The culture was then induced to express protein using 
0.5mM IPTG with incubation on shaker at room temperature overnight. The next day, cells 
were pelleted and resuspended in extraction buffer (50mM Tris pH 8.0, 0.5mM MgCl2, 
0.1% Triton X-100, 1mg/mL lysozyme, 5mM DTT, 0.5mM phenylmethanesulfonyl fluoride 
with 1:100 protease inhibitor cocktail (Sigma)).  Cells were then allowed to lyse on ice for 
30mins before being sonicated 3 x 1 minute. Lysates were then snap frozen on dry ice and 
subsequently thawed out. The freeze-thaw cycle was repeated three times. Finally, lysates 
were centrifuged at 15, 000rpm for 30 minutes at 4°C to allow for separation of soluble and 
insoluble proteins. 
The soluble supernatant containing the protein of interest (solubilised) was then purified 
through affinity purification. Soluble lysates were incubated with glutathione linked 
Sepharose beads (GE) at 4°C overnight to allow for the GST-fused to the protein of 
interest to bind with glutathione. Beads were allowed to settle in the column and 30mL of 
wash buffer (50mM Tris pH 8.0, 0.5mM MgCl2, 0.1% Triton X-100) was allowed to pass 
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through. The protein was then eluted using elution buffer (50mM Tris pH 8.0, 0.5mM 
MgCl2, 10% glycerol and 3mg/mL reduced glutathione) and stored at -20°C.  
 
2.2.1.7 Anti-DDI2 antibody generation 
Full length 6xHis-tagged hDDI2 recombinant protein was sent to the Institute of Medical 
and Veterinary Science (IMVS, South Australia, Australia) for immunisation of a rabbit and 
a sheep. The animals were given several injections with recombinant protein and test 
bleeds before a final bleed out. The serum obtained was then checked for reactivity 
against His-hDDI2 recombinant protein through western blotting. 
 
2.2.1.8 Antibody affinity purification 
The serum of immunised animals obtained from IMVS (South Australia) were affinity 
purified against His-hDDI2 protein immobilised onto Sepharose beads. To cross-link His-
hDDI2 to beads, 2mg of recombinant His-hDDI2 protein were dialysed against 5L of 
coupling buffer (100mM NaHCo3 pH8,3, 500mM NaCl) at 4°C overnight, to remove any 
free amine groups. 1g of Cyanogen Bromide-Activated (CnBr) Sepharose beads 
(Amersham Biosciences) were washed twice for 10 minutes in 1mM HCl and once in 
coupling buffer. After the washes, CnBr Sepharose beads were then incubated with 
recombinant His-hDDI2 protein at 4°C overnight with mixing to allow binding. The next 
day, protein bound beads were poured into a column and washed twice with coupling 
buffer before incubating with blocking buffer (0.1M Tris-HCl pH 8.0) for 2 hours at room 
temperature to block off active amine groups. Beads were then subjected to 3 cycles of 
alternating pH wash, 0.5M NaCl/0.1M acetate pH4 and 0.5M NaCl/0.1M Tris pH 8. The 
columns were stored in PBS containing 0.02% sodium azide at 4°C. 
Sheep or rabbit serum were diluted 1:1 with PBS. The columns were washed once with 
PBS and diluted serum added to the and incubated with mixing at room temperature. After 
binding for 2 hours, columns were washed with PBS, Wash A (0.5M NaCl, 20mM Tris pH 
7.4), Wash B (0.5% Triton X-100 (v/v), 20mM Tris pH 7.4) and Wash C (0.5M NaCl, 0.5% 
Triton X-100 (v/v), 20mM Tris pH7.4). Bound antibodies were then eluted in 200mM 
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glycine pH 2.0 and neutralised with 1M Tris pH 8.8. Eluates were concentrated using a 
Millipore Amicon Ultras MWCO 30, 000 filter by centrifugation. 
 
2.2.2 Protein procedures 
2.2.2.1 Whole cell extract preparation for western blotting 
Cells were scraped and suspended in ice cold LB240 lysis buffer (20mM HEPES pH 7.4, 
240mM NaCl, 2mM MgCl2 and 0.5% Triton X-100, 1mM phenylmethanesulfonyl fluoride, 
2mM sodium fluoride, sodium orthovanadate, 20µM MG132 (to inhibit proteasomal 
activity), 10µg/mL DNase and 1:100 protease inhibitor cocktail (Sigma-aldrich)), vortexed 
and allowed to lyse on ice for 30mins. SDS sample buffer (50mM Tris pH 6.8, 2% SDS, 
10% glycerol, 0.1% bromophenol blue and 5% β-mercaptoethanol) was added to cell 
lysates before heating at 95°C for 5 mins to denature proteins. 
 
2.2.2.2 SDS-Polyacrylamide gel electrophoresis 
Protein samples were subjected to separation based on molecular weight by sodium 
dodecyl suphate - polyacrylamide gel electrophoresis (SDS-PAGE). Protein samples made 
up in SDS sample buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol 
blue and 5% β-mercaptoethanol) were loaded on 10% SDS polyacrylamide gels and were 
run in Tris-Glycine running buffer (25mM Tris, 192mM glycine and 1% SDS). Prestained 
Novex Sharp Standard (Invitrogen) were run alongside protein samples to estimate protein 
size.  
 
2.2.2.3 Coomassie staining of SDS-PAGE gels 
To visualise protein bands, SDS-PAGE gels were stained for 15 minutes in Coomassie 
Blue stain (0.125% Coomassie Brilliant Blue R-250 (w/v), 50% methanol (v/v), 10% acetic 
acid (v/v)) followed by destaining to remove background in destain solution (25% methanol 
and 5% acetic acid).  
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2.2.2.4 Western blotting 
SDS polyacrylamide gels were electrotransferred onto nitrocellulose membrane in western 
transfer buffer (25mM Tris, 192mM glycine and 10% methanol p8.3) for 1.5 hours at 100V. 
Membranes were then blocked for 1 hour at room temperature in western blocking buffer 
(10% skim milk and PBS-0.05% Tween 20 (PBST)), followed by primary antibody  
incubation (diluted in western blocking buffer) at 4°C overnight. Membranes were then 
washed 3 x 10 minutes in PBST before incubation with horseradish peroxidase- (HRP) 
conjugated antibody diluted in western blocking buffer for 1 hour at room temperature. 
Finally, membranes were subjected to 3 x 10 minutes washes in PBST followed by a final 
incubation with Immobilon Western  Chemiluminescent Horseradish Peroxidase Substrate 
(Millipore) before being exposed to X-ray films. For immunoprecipitation experiments 
analysed by western blotting, HRP-conjugated Light Chain specific antibodies were used 
to minimise detection of the immunoprecipitating heavy chain IgG on membrane blots, 
which can often obscure protein bands between 50 and 60 kDa in size, due to its presence 
when visualised on X-ray films.  
Alternatively, fluorescent western blotting was also performed which allowed for detection 
of two proteins simultaneously on the same membrane. The secondary antibodies used 
were conjugated with infrared (IR) fluorescent dyes (IRDye800 or IRDye680) and signal 
was detected using the Odyssey Imaging System (Licor Biosciences). 
 
2.2.3 Immunoprecipitation 
Cells were lysed in 1mL of universal immunoprecipitation buffer (UIP; 50mM Tris pH 7.4, 
150mM NaCl, 2mM EDTA, 0.2% Triton X-100, 0.3% NP40) supplemented with 2mM NaF, 
2mM Na orthovanadate and 1X protease inhibitor cocktail (Sigma-Aldrich). Cells were 
allowed to lyse at 4°C for 1 hour. Lysates were then centrifuged at 14,000g for 30 minutes 
to obtain the soluble supernatant. This was then precleared in a mixture of mouse and 
rabbit serum agarose (GE) for 2 hours at 4°C. Precleared lysates were then used for 
immunoprecipitation. Generally, 1mg of total precleared protein lysate was incubated with 
1µg of antibody and immunoprecipitated overnight at 4°C. The following day, 20µL of 
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either Protein A or G Sepharose beads were added to the lysates and allowed to mix for 
another hour to capture immunoprecipitated complexes. Beads were then collected by 
centrifugation and washed four times in cold NET buffer (50mM Tris pH 8.0, 150mM NaCl, 
5mM EDTA and 0.5% NP40) to remove non-specific binding proteins. SDS Sample buffer 
was then added to the beads for analysis by SDS-PAGE and western blotting.  
 
2.2.4 In vitro binding assay 
To assay for protein-protein interactions, 200ng of GST fusion proteins were immobilised 
onto Glutathionine Sepharose beads and were incubated with 500ng of recombinant 
protein (either cleaved off from its GST-tag or a His-tagged protein) in incubation buffer 
(20mM Tris-HCl pH8.4, 150mM NaCl, 2.5mM CaCl2 and 1mM DTT). Proteins were 
allowed to bind and incubated for 4hours at 4°C. Beads were then washed three times in 
cold incubation buffer, collected and resuspended in SDS sample buffer for analysis by 
SDS-PAGE and western blotting.  
 
2.2.5 Cell biology procedures 
2.2.5.1 DNA and siRNA Transfection 
Transfection of cells were done using two types of tranfection reagent; Fugene HD 
(Roche) and Lipofectamine RNAiMAX (Invitrogen), for DNA plasmid transfection and 
siRNA duplex transfection, respectively.  
i) DNA plasmid transfection 
Cells were seeded in a fresh flask or well (depending on the scale of experiment 
performed) to obtain 80% confluency on day of transfection. For cells grown in a 6-well 
plate, Fugene HD:DNA complex were prepared at a ratio of 2µg of DNA to 3µL of Fugene 
HD (Roche) transfection reagent in 100µL of Opti-MEM (Invitrogen). Complexes were then 
allowed to form by allowing to stand at room temperature for 15 minutes. Complexes were 
then added directly to the media and cells were left to incubate for 24hrs before analysis. 
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ii) siRNA duplex transfection 
Cells were seeded in flasks or wells to obtain 30-40% confluency on day of transfection. 
For cells in a 6-well plate, 50pmol of siRNA duplexes and 5µL of Lipofectamine RNAiMAX 
were diluted in 250µL of Opti-MEM in separate tubes. The diluted siRNA and 
Lipofectamine RNAiMAX reagent were then mixed together in a 1:1 ratio and allowed to 
stand at room temperature for 15 minutes to allow for complex formation. Complexes were 
then added directly onto cells in a 6-well plate and incubated for 48hrs before analysis. In 
all siRNA knockdown experiments, Stealth RNAi negative control siRNA was also 
transfected as a negative control. 
 
2.2.5.2 Colony survival assay 
U2OS cells were seeded at low density (500-400/well) into 6 well plates and allowed to 
grow overnight. The next day cells were treated with different doses of ultraviolet (UV) 
radiation (UVC). After treatment, cells were then left to grow for approximately ten days, 
after which cell colonies had formed. Cells were washed once with PBS, fixed and stained 
using Coomassie blue stain. Colonies were counted and tallied for each dose. A colony 
was counted only when there were greater than 50 cells in the cluster.  
 
2.2.5.3 Real time cell growth assay 
Cell growth and proliferation was also assessed in real time using an xCELLigence system 
(Roche). Cells were grown in E-plates, which measure electrical impedance across 
microelectronic gold electrodes integrated into the bottom of 96 well tissue culture plates. 
Any change in the impedance across the well is measured which may be corresponded to 
changes in cell number, viability, morphology and adherence of live cells (Xing et al. 
2005).  
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2.2.6 Molecular Biology procedures  
2.2.6.1 RNA extraction and cDNA synthesis 
RNA from cell lines and tissues was extracted using Trizol reagent (Invitrogen) according 
to the manufacturer’s instruction. Total RNA (1µg) was then treated with 1U of RQ1 
RNase-free DNaseI (Promega) for 30 minutes at 37°C. The DNase reaction was then 
stopped by adding RQ1 DNase stop solution and incubating at 65°C for 10mins. For first 
strand reverse transcription, DNase treated RNA was reverse transcribed into cDNA using 
Superscript III Reverse Transcriptase (Invitrogen) in a 20µL reaction. Initially, RNA was 
incubated with 500ng oligo dT and 0.5mM dNTPs at 65°C for 5 minutes and chilled on ice 
to allow for denaturation of RNA and priming of the poly-A mRNA. For cDNA synthesis 
0.05mM DTT and Superscript III enzyme in first strand buffer were then added to the 
reaction and incubated at 50°C for 60 minutes followed by 70°C for 15 minutes. cDNA was 
then diluted in 1:10 with water prior to real time PCR.  
 
2.2.6.2 Quantitative real time PCR 
Gene expression levels were assayed using quantitative real-time PCR (qRT-PCR) using 
a SYBR green detection system in the LightCycler 480 (Roche) platform. The following 
reactions were performed: 2µL diluted cDNA, 200nM forward primer and 200nM reverse 
primer LightCycler 480 SYBR Green Mix (Roche). Reactions were performed using the 
following conditions: 2 minutes denature at 95oC followed by 45 cycles of 95oC for 15 
seconds, 55oC for 15 seconds and 72oC degrees for 15 seconds. Fluorescence detected 
due to the binding of SYBR green to double stranded DNA was measured during the 
extension steps. Amplified PCR products were routinely checked for primer dimer by 
performing melt curve analysis. The temperature was raised from 50°C to 99°C at 
1°C/minute whilst simultaneously detecting fluorescence. All reactions were performed in 
duplicate. Gene expression levels were  normalised to the reference genes (β-actin and 
HPRT) by subtracting the mean of the reference gene threshold cycles (CT) from the CT 
of the target gene (∆CT). Relative expression of the target genes were calculated by using 
the equation, 1/log2(∆CT).  
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2.2.7 Proteomic studies  
2.2.7.1 Mouse liver extraction and fractionation 
Liver obtained from a C57BL6 mouse was homogenised in 3 volumes of gradient buffer 
(20mM Hepes, 2mM EDTA and 100mM KCl) + 250mM sucrose in a Dounce homogeniser. 
Homogenates were then sieve filtered before a low speed centrifugation at 1000rpm for 10 
minutes to collect and pellet intact nucleus (P1). The supernatant (SN1) was kept as the 
total cytoplasmic fraction. The nuclear pellet (P1) was then lysed and solubilised in UIP 
buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA, 0.2% Triton X-100, 0.3% NP40) 
buffer for 2 hours at 4C before being subjected to a higher speed centrifugation at 
11000rpm for 30 minutes to collect the soluble supernatant (soluble nuclear fraction), while 
the pellet was discarded as insoluble material. The cytoplasmic fraction (SN1) was then 
further solubilised by adding 0.5% triton X-100 (vol/vol) for 2 hours at 4C before being 
subjected to high speed centrifugation at 11000rpm for 30 minutes. Only the soluble 
supernatant (soluble cytplasmic fraction) was kept and the pellet was discarded as 
insoluble material. Protein assays were performed on both fractions to determine the 
protein yield.  
 
2.2.7.2 Crosslinking of IgG to Protein G Sepharose 
Two hundred µg of either rabbit anti-DDI2 or non-specific IgG was allowed to bind to 
100µL of protein G Sepharose overnight to obtain a density of 2mg IgG/mL of protein G 
Sepharose beads. Beads were then washed twice with crosslinking buffer (0.2M 
Triethanolamine + 0.1M Sodium Borate pH 9.0) twice to remove any unbound IgG. 
Crosslinking of IgG and Protein G was initiated by incubation of beads with 5 volumes of 
20mM Dimethyl Pimelimidate (DMP) made up in crosslinking buffer for 1 hour at room 
temperature. After 1 hour, beads were then subjected to further incubation with DMP in 
crosslinking buffer for another 45 minutes at 4C.  Beads were then washed twice with 5 
volumes of blocking buffer (50mM ethanolamine-HCl pH 9.0), leaving beads in blocking 
buffer for 5 minutes on the second wash. Finally, an elution step to remove any non-
covalently bound IgG was also performed. Two volumes of elution buffer (0.1M acetic acid 
and 0.15M NaCl pH 3.0) was added to the beads and incubated for 1 hour at room 
temperature. Beads were then washed and equilibrated in PBS before use. 
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2.2.7.3 Large scale immunoprecipitation 
For large scale immunoprecipitation, anti-DDI2 or IgG crosslinked to protein G Sepharose 
beads were used. One hundred µL of beads prebound with either anti-DDI2 or IgG were 
bulked up using Sepharose beads to the volume of 500µL for ease of use and detection. 
Soluble protein extracts from either liver homogenates or U2OS cells were added directly 
to the beads in a 10mL Biorad column. The protein extract and beads mixture were then 
incubated on a rotating shaker overnight at 4C to allow for immunoprecipitation to occur. 
The next day, unbound protein was collected as flow through from the column. Beads 
were then washed 3 times with 10mL NET buffer (50mM Tris pH 8.0, 150mM NaCl, 5mM 
EDTA and 0.5% NP40). To elute immunoprecipitated protein, beads were then incubated 
with 2mL of 0.1M Glycine pH2.8 for 5 minutes. Eluates were then collected and neutralised 
immediately with 1M Tris pH 8.0.  
 
2.2.7.4 SDS-PAGE gel protein separation and trypsin digestion of bands  
Proteins retrieved upon immunoprecipitation were precipitated with acetone and 
lyophilized. Prior to electrophoresis lyophilized samples were dissolved in 40µL of NuPage 
lithium dodecyl sulphate (LDS) buffer (4X, Invitrogen), containing 10 mM DTT and heated 
at 95oC for 10 minutes. Approximately 25µL of each sample was loaded onto a gel (SDS-
PAGE, NuPage 4-12% Bis-Tris Gel, Invitrogen) and run at 200V for 35 minutes.  The gel 
was subsequently stained with SimplyBlue Safe Stain (Invitrogen). Upon destaining each 
lane containing the sample was cut using a disposable grid cutter into 25 bands and these 
bands were subsequently subjected to 3 destaining cycles of gel dehydration and 
rehydration to effectively remove the Coomassie stain (Destaining buffer: 0.1 M NH4HCO3, 
pH 8.0, 1:1 ACN:H2O). Bands were further subjected to protein reduction and alkylation 
prior to in gel trypsin digestion. (Reduction buffer: 10% TCEP in 0.1 M NH4HCO3. 
Alkylation buffer: 2.5 % w/v iodoacetamide). Reduced and alkylated bands were 
dehydrated with ACN (Acetonitrile) and subsequently air-dry for 5-10 minutes. Dehydrated 
bands were subsequently subjected to in-gel trypsin digestion (13 ng/µL trypsin in 25 mM 
NH4HCO3, pH 8.0, ~ 30µL/band) at 37
oC for 16 hours/overnight). Digestion mixture was 
transferred to a clean tube and residual peptides from bands were further extracted with 
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60%ACN/1% Formic Acid for 5 minutes and combined with the digestion mixture. 
Combined digestion mixture was standardized to approximately 20µL by using a speedvac 
concentrator. Particulate free digestion mixture (12µL) from each band was transferred to 
a clean micro-insert in a glass vial for further separation by nano liquid chromatography 
tandem mass spectrometry (LC-MS/MS). 
 
2.2.7.5 Nano LC-MS/MS separation and identification of peptides  
Nine µL of all the extracted peptides of each protein band from SDS-PAGE  were injected 
by micro AS system (Thermo) into a system consisting of two reversed-phase trap 
columns (15 cm x 100 µm in diameter (i.d) monolithic columns) (Onyx, Phenomenex) for 
large volume sample injection with high speed sample loading and desalting (desalting 
and equilibration buffer: 0.1% (v/v) formic acid and 0.05% (v/v) heptafluorobutyric acid 
(HFBA). The trap columns were connected to a 1.05 metre 100 µm i.d reversed phase 
(RP) separation or analytical monolithic column (seven 15cm x 100 µm i.d monolithic 
columns connected in series) through a nanoscale two-position, 10-port switching valve, 
the whole system is terminated by a 15 µm i.d. of nanoemitter mounted on the 
nanoelectrospray source in front of the sampling cone of the linear trap quadrupole mass 
spectrometer (LTQ XL-MS, Thermo Finnigan).  
Trapped peptides in trap for each band were eluted with a 130 minutes five-step linear 
gradient. Starting from 2% B to 36% B in 81 minutes (A: 99% H2O:1% ACN with 0.1% v/v 
formic acid; B: 95% ACN: 5% H2O with 0.1% v/v formic acid), increased to 95% B in 3 
minutes, and kept at 95% B for 10 minutes, and then to 2% B in 3 minutes and kept at 2% 
B for equilibration for 33 minutes. The column flow rate was maintained at ~ 800 nl/min 
and column temperature was maintained at room temperature. A 2.35 keV voltage 
electrospray versus the inlet of the mass spectrometer was used. LTQ-XL ms was 
operated in the data-dependent mode to switch automatically between MS and MS/MS 
(top five), 2 microscans for both full and MS/MS scans, centroid data for all scans. 
Dynamic exclusion was used with two repeated counts, 10 s repeated duration, and 60 s 
exclusion duration. For MS/MS precursor ions were activated using 35% normalized 
collision energy at the default activation q of 0.25.   
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2.2.7.6 Peptide sequence and data interpretation  
 
Spectra from LTQ-XL MS in .raw files format were analyzed by 3 algorithms, namely, 
SEQUEST (BioworksBrowser 3.3.1 SP1, Thermo Finnigan), MASCOT (Matric Science) 
and X! tandem (Scaffold, proteomeScience). SEQUEST setting: parent mass tolerance 2.0 
Da , fragment ion tolerance 1 Da, up to 2 missed cleavages, fully tryptic peptides only and 
filtered with DTAselect at the peptide level (Xcorrs>1.8(+1),2.5 (+2), 3.5 (+3). MASCOT 
setting: parent mass tolerance 0.8 Da, fragment ion tolerance 0.5 Da, miss cleavage 1, 
peptide charge 1+, 2+, and 3+, monoisotopic. X! tandem filtered peptides results with a p-
value over 0.05 then a protein probability of 0.95 was used for protein identification. Fixed 
modification was carbamidomethylation at C (Cysteine) and variable medications were 
oxidation at M (Methionine) and phosphorylation at ST (Serine, Threonine). All searches 
were against the mouse International Protein Index (IPI) database. Proteins are 
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Chapter 3 Molecular and Cellular Characterisation of human DDI1 and 
DDI2 
3.1 Introduction 
hDDI1 and hDDI2 are two novel proteins identified through a homology search using the 
yeast Ddi1 protein sequence. Here, we have undertaken a characterisation of both hDDI1 
and hDDI2 at the molecular and cellular level to assist us in understanding the cellular 
roles of these proteins. This chapter will also describe the characterisation of antibodies 
against DDI1 and DDI2 that we have generated. 
 The Ddi1 gene was first identified in yeast (S. cerevisiae) as a gene that was 
transcriptionally induced by DNA damage (Liu and Xiao 1997). Although a direct role for 
Ddi1 in the DNA damage and repair pathway has not been found, several independent 
groups have identified the same protein in other cellular processes, which potentially 
implicates Ddi1 in multiple roles. A review of the different independent studies that 
identified Ddi1 will first be presented.  
 
3.1.1  Independent identification of Ddi1 and Vsm1  
3.1.1.1 DDI1 identified as a gene induced by DNA damage 
Cells respond to DNA damage by two inter-related mechanisms: (1) by delaying cell cycle 
progression, to ensure that damaged DNA is not replicated and passed on to daughter 
cells and (2) increasing the expression of genes involved in the repair of damaged DNA. 
The DNA Damage Inducible 1 (Ddi1) gene was first identified in Saccharomyces 
cerevisiae during an attempt to study the upstream DNA sequence of another DNA 
damage inducible gene, Mag1, a 3-methyladenine DNA glycosylase, which functions to 
protect cells from killing by methylmethanesulfonate (MMS)-induced DNA replication 
blocks (Liu and Xiao 1997). Ddi1 was found to be divergently transcribed from MAG1, and 
both genes were found to be induced by the same set of damaging agents such as MMS, 
ultraviolet (UV) radiation, 4-Nitroquinoline 1-oxide (4NQO) and hydroxyurea (HU) (Liu and 
Xiao 1997). Interestingly, the upstream activating sequence (UAS) of MAG1 lies within the 
protein coding region of DDI1 (Liu et al. 1997). Although the genomic organization of both 
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genes suggest that they are transcriptionally related, it was found that MAG1 and DDI1 do 
not share the same UAS, and that the co-induction of both genes by DNA damage is 
probably regulated through other common elements in the promoter (Liu et al. 1997). 
Despite being transcriptionally induced by DNA damage, no functional role has been 
established for the DDI1 gene in the DNA damage and repair pathway. 
3.1.1.2 Ddi1 as a dosage suppressor of pds1 mutants 
In yeast, cell cycle progression to anaphase is controlled by the ubiquitin-mediated 
degradation of Pds1, an anaphase inhibitor protein (Cohen-Fix et al. 1996). In a screen to 
identify interactors of Pds1 and to study its role in cell cycle checkpoint control, the 
ubiquitin-like proteins Ddi1 and Rad23 were identified as dosage suppressors of the 
temperature sensitive mutant strain pds1-128 (Clarke et al. 2001). Here it was found that 
Rad23 and Ddi1 are structurally similar proteins, containing ubiquitin-like (UBL) domains at 
their N-terminal and ubiquitin associated (UBA) domains at their C-terminal. Interestingly, 
the ability of Ddi1 and Rad23 to rescue the phenotype in the mutant pds1 strain was found 
to be dependent on the UBA domains present on the C-terminus of both proteins (Clarke 
et al. 2001). The identification of a role for Ddi1 in the stabilization of the mutant Pds1 
protein through its UBA domain was the first report to implicate Ddi1 in the turnover of a 
protein. The exact mechanism as to how Ddi1 and Rad23 stabilize the Pds1 protein is still 
unclear although it has been hypothesised that the interaction between Ddi1 or Rad23 and 
ubiquitinated Pds1 acts to inhibit the degradation of Pds1 by the ubiquitin-proteasome 
system. Nevertheless, these novel findings implicate a role for the ubiquitin-like proteins 
Ddi1 and Rad23 in the regulation of checkpoint control, which plays a key role in DNA 
damage. 
3.1.1.3 Vsm1, a negative regulator of SNARE complexes 
SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are 
membrane-associated proteins involved in intracellular protein trafficking through their role 
in the fusion of cellular transport vesicles with the cell membrane or other cellular 
compartments (Rothman and Warren 1994). SNAREs are present on opposing 
membranes as v-SNAREs and t-SNAREs (for vesicle- and target-, respectively), and their 
interaction is thought to lead to the fusion of the two opposing membranes (Lin and 
Scheller 2000). Vsm1 (v-SNARE Master 1) was identified in yeast as a protein that 
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interacts with the v-SNARE proteins, Snc1 and Snc2 (Lustgarten and Gerst 1999). 
Deletion of the Vsm1 gene in yeast led to an increase in protein secretion into the culture 
medium, whereas its overexpression resulted in the accumulation of secretory vesicles 
(Lustgarten and Gerst 1999). Taking into account the direct interaction between Vsm1 and 
the Snc proteins, it was proposed that Vsm1 may be a negative regulator of constitutive 
exocytosis through the regulation of v-SNARE function. A further report also showed that 
interaction of Vsm1 with the t-SNARE protein Sso had an inhibitory effect on t-SNARE 
complex formation (Marash and Gerst 2003).  
Interestingly, the Vsm1 protein (Lustgarten and Gerst 1999) turned out to be the same 
protein identified as Ddi1 (Liu and Xiao 1997; Clarke et al. 2001). From these findings, it is 
likely that the differential roles in the secretory pathway and in protein degradation are 
independent of each other. The independent identification of the same protein, Vsm1/Ddi1, 
may imply it has multiple roles. As Vsm1 and Ddi1 are the same protein, it will be referred 
to as Ddi1 throughout this thesis.  
 
3.1.2 Ddi1 is a multi-domain protein implicated in multiple cellular roles 
Ddi1 has been identified in three independent reports implicating it in multiple cellular 
roles.  Ddi1 is a multi-domain protein with at least three identified domains; an N-terminal 
ubiquitin-like (UBL) domain, a C-terminal ubiquitin associated (UBA) domain and a central 
retroviral protease domain (RVP) domain.   
The UBL domain of Ddi1 shares 16% identity with ubiquitin (Bertolaet et al. 2001) and has 
been shown to be required for interaction with the proteasome (Kaplun et al. 2005). In 
contrast, the UBA domain plays an important role in the growth rescue of the Pds1 mutant 
(Clarke et al. 2001). Although no interaction has been shown, it has been proposed that 
the UBA domain of Ddi1 is involved in the interaction with ubiquitinated forms of Pds1p. An 
alternate functional role for the UBA domain has been shown in a separate study. Kaplun 
et al. (2005) showed that the UBA domain of Ddi1 interacts directly with the ubiquitinated 
forms of the Ho endonuclease and that this interaction is important in the degradation of 
ubiquitinated Ho. The Ho protein is a homing endonuclease that is involved in the repair of 
double strand breaks in DNA damage (Bakhrat et al. 2004)  
. 
   48 
 
 
The central RVP domain, on the contrary, has had little attention. Although its function has 
not been defined, its crystal structure has been solved, showing resemblance to the HIV 
protease (Sirkis et al. 2006). It was found that the RVP domain mediates the 
homodimerisation of Ddi1, which has also been confirmed in vivo by Gabriely et al (2008). 
Although no physiological function has been attributed to the RVP domain of Ddi1, the 
authors suggested that it may well be a functional protease. Given the known association 
of Ddi1 with the ubiquitin-proteasome pathway, it has also been proposed that Ddi1 act as 
a deubiquitinating enzyme, hydrolysing ubiquitinated substrates at the proteasome (Sirkis 
et al. 2006). 
3.1.3 Aims 
While the yeast Ddi1 gene and its protein product have been studied and described in the 
literature in some detail there has been a paucity of information on any potential 
mammalian orthologues. This is in contrast to mammalian orthologues of other yeast UBL 
domain proteins such as Rad23 and Dsk1 which have been studied in detail and shown to 
play important roles in many critical biological processes. For example one of the human 
homogues of Rad23, hHR23B, has a significant role in the appropriate functioning of the 
tumour suppressor p53 (Kaur et al. 2007).  Using an silico approach, Prof Nathan 
Subramaniam of the Membrane Transport Laboratory at QIMR determined that 
orthologues of the Ddi1 gene are also present in all higher eukaryotes.  The focus of this 
thesis is thus a systematic study and characterisation of the human homologues of Ddi1, 
which have been termed hDDI1 and hDDI2. 
Specifically, this chapter will address the following experimental investigations: 
1. To perform in silico analysis of hDDI1 and hDDI2 gene sequence. Using 
bioinformatics tools, we analysed the genomic and proteomic sequence of hDDI1 
and hDDI2 in relation to known genes and proteins, respectively.      
2. To characterise hDDI1 and hDDI2 antibodies. Anti-DDI1 and anti-DDI2 
antibodies have been generated. We determined the specificity of these antibodies 
in detecting both hDDI1 and hDDI2, which ensured the validity of all downstream 
applications utilising these antibodies. 
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3. To study the expression profiles for hDDI1 and hDDI2. We studied the 
expression profile of hDDI1 and hDDI2 in various tissues and cell lines. The 
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3.2  Results 
3.2.1 Identification of human homologues to yeast Ddi1 
In an attempt to identify orthologues of the yeast Ddi1, we performed a protein homology 
search of the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/). Through this approach, we identified two novel human 
proteins with overall homology to the yeast Ddi1 protein, which we have termed hDDI1 and 
hDDI2. Sequence alignment analysis of the yeast and human proteins revealed a 47% 
identity between yeast Ddi1 and hDDI1, 34% identity between yeast Ddi1 and hDDI2, and 
a 74% identity between hDDI1 and hDDI2 (Figure 3.1).  
To assign a possible role for these novel proteins, we conducted bioinformatic analyses of 
hDDI1 and hDDI2 protein sequence using the Pfam (http://pfam.sanger.ac.uk/) and MyHits 
(http://myhits.isb-sib.ch) programs. Our analysis revealed that, similar to the yeast protein, 
both hDDI1 and hDDI2 contain a UBL domain (residues 1-79, hDDI1 and hDDI2) as well 
as a retroviral protease domain (RVP, residues 238-367 for hDDI1 and residues 230-359 
for hDDI2). A UBA domain was not identified in either hDDI1 or hDDI2 using these 
programs. However, a putative ubiquitin-interacting motif (UIM) was found to be present at 
the C-terminus of hDDI2 at residues 377 to 394 (Figure 3.2).  
 
  





Figure 3.1 Protein sequence alignment of hDDI1, hDDI2 and yeast Ddi1 
hDDI1 and hDDI2 are highly homologous proteins. Protein sequence alignment reveals a 
74% identity between hDDI1 and hDDI2, 47% identity between yeast Ddi1 and hDDI1, and 
34% identity between yeast Ddi1 and hDDI2. 
 
  









Figure 3.2 Diagrammatic representation of yeast Ddi1, human DDI1 and human DDI2 
protein domains. 
Yeast Ddi1 has an ubiquitin-like domain (UBL) at its N-terminus, an ubiquitin- associated 
(UBA) domain at its C-terminus and a central retroviral protease (RVP) domain. hDDI1 and 
hDDI2 also contain a UBL and RVP domain. A putative ubiquitin interacting motif (UIM) 
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3.2.1.1 hDDI1 and hDDI2 sequence analysis 
The hDDI1 gene is located on chromosome 11q22.3.  Interestingly, hDDI1 is an intronless 
gene composed of a single exon. hDDI1 spans 2.62kb of genomic sequence (Figure 3.3) 
and encodes a predicted protein of 396 amino acid residues in length with a predicted 
molecular weight of 44.1 kDa. A search of the NCBI human EST database (August 2011) 
showed hDDI1 ESTs to be present only in testis. A restricted expression of hDDI1 ESTs 
from testis origin suggests a tissue-specific or enriched expression of hDDI1. 
hDDI2 is located on chromosome 1p36.21 and is composed of 10 exons spanning 51.55kb 
of genomic sequence (Figure 3.3). hDDI2 mRNA encodes a 399 amino acid protein, which 
has a predicted molecular weight of 44.5 kDa. Unlike hDDI1, hDDI2 ESTs can be found in 
tissues of various origin including liver, intestine, thyroid, breast and brain, suggesting that 
hDDI2 mRNA is expressed in a variety of tissues. 
A BLAST search of the NCBI database also revealed a number of putative orthologues of 
hDDI1 and hDDI2 across various species including Mus musculus, Rattus norvegius, 
Drosophila melanogaster and Arabidopsis thaliana (Table 3.1). Using the ClustalX 
program (Version 2.0.12), the sequences of these putative orthologues were aligned and a 
phlyogenetic tree (Figure 3.3) drawn using FigTree (Version 1.3.1). The presence of two 
closely related proteins in the same species can be seen in higher organisms such as 
Homo sapiens, Mus musculus and Pan troglodytes. This may indicate the occurrence of 



















Figure 3.3 Schematic diagram showing the exon-intron organisation of hDDI1 and 
hDDI2 genes. Solid boxes indicate exons while empty boxes indicate 5’ and 3’ UTR. 
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Table 3.1 . List of predicted Ddi1 orthologues. Orthologues of the Ddi1 protein were 
obtained through a BLAST search of the NCBI database. 
 
Species Common Name Protein Genebank Accession  
Ailuropoda 
melanoleuca 
Panda Ddi1 XP_002928198 
    Ddi2 XP_002921474 
Arabidopsis thaliana Plant Ddi1 NP_566451 
Aspergillus fumigatus Fungus Ddi1 XP_748905 
Callithrix jacchus Common Marmoset Ddi1 XP_002754401 
    Ddi2 XP_002807010 
Candida glabrata Haploid yeast Ddi1 XP_447545 
Danio rerio Zebrafish Ddi1 NP_938189 
Debaryomyces 
hansenii  
Marine yeast Ddi1 XP_461429.2 
Drosophila 
melanogaster 
Fruitfly Ddi1 AAF48614 
Gallus gallus Chicken Ddi2 XP_423293  
Homo sapiens Human DDI1 NP_001001711 
    DDI2 NP_115717  
Leishmania braziliensis Leishmania 
(Parasite) 
Ddi1 XP_001561444 
Leishmania major Leishmania 
(Parasite) 
Ddi1 XP_001687454 






Ddi1 XP_001377926  
    Ddi2 XP_001366214 
Mus musculus Mouse Ddi1 NP_082218   
    Ddi2 NP_001017966         
Pan troglodytes Chimpanzee Ddi1 XP_001154591.1 
    Ddi2 XP_001150145.1 
Plasmodium falciparum Malaria causing 
parasite 
Ddi1 XP_001348263      
Pongo abelii Orang utan Ddi1 XP_002822458.1 
    Ddi2 XP_002811487 
Rattus norvegius Rat Ddi1 XP_345896.2 
    Ddi2 NP_001029321        
Saccharomyces 
cerevisiae  
Budding yeast Ddi1 NP_011070  
Schizosaccharomyces 
pombe  
Fission yeast Ddi1 NP_001018195 
Xenopus laevis Frog Ddi1 NP_001079499 
 
  




Figure 3.4 Phylogenetic tree showing relationship between Ddi1 orthologues 
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3.2.2 Generation of hDDI1 antibodies 
An antibody against hDDI1 had been generated previously in the Membrane Transport 
Laboratory at QIMR. A full length recombinant hDDI1 protein (GST-hDDI1) was used to 
immunise rabbits and polyclonal antibodies against hDDI1 were affinity purified from rabbit 
serum. The more recent identification of another homolog to the yeast Ddi1 protein, 
hDDI2, prompted us to generate a second antibody to aid in the characterisation of hDDI2. 
In order to raise antibodies against hDDI2, we generated recombinant hDDI2 protein. Full 
length hDDI2 was PCR amplified and inserted into the pQE30 vector to obtain a 6xHis-
fused recombinant protein. Protein expression was induced in bacterial cells and extracts 
from cells expressing 6xHis-hDDI2 were then subjected to column purification using nickel 
beads (Ni2+-NTA resin) and purified protein eluted using Imidazole buffer (refer to 
Materials and Methods). Eluted proteins were then analysed by SDS-PAGE and stained 
with Coomassie blue stain to determine the purity of the recombinant protein (Figure 3.5). 
The recombinant 6xHis-hDDI2 was visualised as a single band at about 55kDa, similar to 
the estimated molecular weight of hDDI2.  
Purified recombinant protein was then sent to the Institute of Medical and Veterinary 
Science (IMVS) in South Australia and used to immunise both a rabbit and a sheep. 
Serum from the immunised rabbit and sheep were then affinity purified against 
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Figure 3.5 SDS-PAGE gel stained with Coomassie blue of the 6xHis-hDDI2 protein 
purification.  
Recombinant 6xHis-hDDI2 from E.coli cells were column purified using nickel beads, 
washed with 25mM imidazole buffer and eluted with 250mM imidazole buffer.  One ml 
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3.2.2.1 Specificity of DDI1 and DDI2 antibodies 
hDDI1 and hDDI2 are highly homologous, sharing 74% sequence identity between them. 
We tested whether anti-DDI1 antibodies would cross-react with hDDI2 and vice versa. 
Affinity purified DDI1 and DDI2 antibodies (anti-DDI1 rabbit, anti-DDI2 rabbit and anti-DDI2 
sheep) were analysed by western blotting for reactivity against Myc-hDDI1 and Myc-hDDI2 
constructs, transfected into and expressed in U2OS cells (Figure 3.6). Western blotting 
analysis revealed that anti-DDI1 detected only Myc-hDDI1 and not Myc-hDDI2. Similarly, 
both rabbit and sheep anti-DDI2 only detected Myc-hDDI2 and not Myc-hDDI1. 
Additionally, anti-DDI1 did not detect any endogenous proteins while rabbit and sheep 
anti-DDI2 antibodies detected a lower band of approximately 50kDa indicating the 
presence of the endogenous hDDI2 protein. To allow flexibility in downstream applications 
we generated anti-DDI2 antibodies in two different species, rabbit and sheep. Our analysis 
here showed that both antibodies have similar reactivity. In addition to detecting Myc-
hDDI2, both anti-DDI2 antibodies also detected endogenous hDDI2 expressed in 
untransfected U2OS cells. 
hDDI2 shares significant homology to its mouse and rat homologues, showing a 97% and 
84% similarity in protein sequence, respectively. Using the affinity purified rabbit anti-DDI2 
antibody, we performed western blotting on liver homogenates from human, rat and mouse 
(Figure 3.7). Our results showed that anti-DDI2 antibody detected a single band of 
approximately 52 kDa in size from all three species, indicating that while the antibody was 











Figure 3.6 Anti-DDI1 and anti-DDI2 antibodies are specific for hDDI1 and 
hDDI2, respectively.  
Whole cell lysates were prepared from U2OS cells expressing Myc-hDDI1, Myc-
hDDI2  and an untransfected control and subjected to SDS-PAGE followed by 
western blotting analysis using anti-DDI1, anti-DDI2-rabbit, anti-DDI2-sheep and 
anti-MYC antibodies. 
 







Figure 3.7 Anti-DDI2 detects DDI2 protein in human, mouse and rat liver 
homogenates. 
Liver homogenates from human, mouse and rat were loaded in equal amount and 
analysed by western blotting using anti-DDI2 antibody. A band of approximately 52kDa 
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To confirm the specificity of the antibody against hDDI2, we obtained three siRNAs 
specific to the mRNA sequence of hDDI2 (refer to Materials and Methods) and transfected 
them into U2OS cells. At 48 hours post-transfection, cells were harvested and analysed by 
Western blotting using anti-DDI2 antibodies (Figure 3.8). The 52kDa band diminished by 
up to 90% after hDDI2-siRNA transfection as compared to the scrambled control siRNA.  
This observation further confirms the specificity of the DDI2 antibody against hDDI2. 
To further characterise the antibodies that we generated, we tested their reactivity against 
native hDDI2 proteins by immunoprecipitation. Both anti-DDI2 sheep and anti-DDI2 rabbit 
antibodies were used with protein extracts from U2OS cells in an immunoprecipitation 
experiment. Immunoprecipitated proteins were then analysed by western blotting using 
anti-DDI2 antibodies (Figure 3.9). Our analysis revealed a single band of 52kDa, that can 
be detected by the anti-DDI2 immunoprecipiation, indicating that the antibody was 
specifically recognising hDDI2, detected by western blotting. Furthermore, our analysis 
also showed that both rabbit and sheep anti-DDI2 antibodies detect hDDI2 in a similar 
manner. 
  








Figure 3.8 siRNA knockdown of endogenous hDDI2 in U2OS cells shows specificity 
of anti-DDI2 antibody. 
Cell extracts from U2OS cells transfected with 3 different siRNAs specific for hDDI2 mRNA 
were loaded on a gel and analysed by western blotting using anti-DDI2 antibodies. 
Quantitation of bands are shown in the graph as normalised to the loading control, GAPDH 
and presented as a percentage of the scrambled control. 
 
  








Figure 3.9 Both rabbit and sheep anti-DDI2 antibodies can immunoprecipitate hDDI2 
from cell lysates. 
U2OS cell lysate was immunoprecipitated using rabbit and sheep anti-DDI2 antibodies and 
analysed by western blotting using the respective antibodies. 10% of the input was loaded 
as straight lysate. 
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3.2.3 Expression profile studies reveal tissue-specific expression of hDDI1 and 
ubiquitous expression of hDDI2 
3.2.3.1 Real Time PCR analysis of a normal human cDNA panel 
To gain an insight into the functions of hDDI1 and hDDI2, we investigated the tissue 
distribution profile of hDDI1 and hDDI2 in a normal human cDNA panel commercially 
obtained from Clontech. Primers specific for hDDI1 and hDDI2 were designed (refer to 
Materials and Methods) and utilised in a quantitative real time PCR experiment. To 
validate our results, two sets of primer pairs for both hDDI1 and hDDI2 were used in our 
analyses. As this cDNA panel was from a commercial source and to exclude the possibility 
of amplifying genomic DNA (gDNA),if present, in these samples, primers were designed to 
cross exon boundaries. However, the organisation of the hDDI1 gene being a single exon 
gene limited this approach. To address this limitation, we designed a primer set that 
complements the genomic sequence upstream of the hDDI1 5’UTR that does not overlap 
with the mRNA of any known genes. By design, this primer set will detect any gDNA 
contaminants in our cDNA sample.  
In our analysis, hDDI1 was found to be highly expressed in testis (Figure 3.10). 
Amplification of gDNA was also found in most of the cDNA samples albeit at different 
levels across different tissue samples. Because the hDDI1 primers cannot discriminate 
between cDNA and gDNA, true levels of hDDI1 cDNA were obtained through the 
subtraction of the obtained levels of gDNA from the obtained levels of hDDI1 cDNA. Our 
analysis here revealed the high expression of hDDI1 solely in testis. We also noted that 
cDNA samples were obtained from a commercial source and therefore we had no control 
over the preparation of samples which we have found to have been contaminated with 
gDNA. We also note that there may be slight expression of hDDI1 in the prostate and 
kidney cDNA samples. 
In contrast, hDDI2 was observed to be expressed in all tissues investigated. Similar levels 
of expression were found using two different primer sets in most of the tissues 
investigated, indicating the reproducibility of our techniques in detecting levels of hDDI2 
cDNA (Figure 3.11). In our analysis, higher levels of hDDI2 expression were observed in 
tissues such as heart, liver and smooth muscle. Although the significance of this at this 
stage is not yet known, the differential expression of hDDI2 across the different tissues 
may have also arisen as a result of the differential expression of the reference genes used. 
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To minimise the effect of normalising to a reference gene that is variable across the 
different tissues, we had taken a precautionary step by using two reference genes, HPRT 
and β-actin. The relative amount of hDDI2 expression in our analysis was calculated in 
relative expression of the average obtained from HPRT and β-actin expression (refer to 
Section 2.2.6.2) 
  



























Figure 3.10 Quantitative real time PCR analysis of hDDI1 levels in a human cDNA 
panel.  
A. Primers specific for hDDI1 were designed along with primers that specifically detect 
the gDNA sequence upstream of the hDDI1 gene. qRT-PCR was performed using 
primer sets and results were normalised to the calculated average of the reference 
genes, HPRT and β-actin. Levels of hDD1 cDNA are shown in grey while levels of 
gDNA measured are shown in black. 
B. Levels detected by hDDI1 primers were corrected for gDNA levels by substracting 
levels of gDNA. The bar graph shows corrected hDDI1 levels with high expression 
levels in testis. 
Error bars shown in each graph depicts standard deviation between the duplicates ran in 
each experiment. Graph shown is that of a representative experiment. The experiment 











Figure 3.11 Quantitative real time PCR analysis of hDDI2 levels in a human cDNA 
panel shows expression across multiple tissues. 
hDDI2 levels were measure using two sets of primers specific to hDDI2 in a human cDNA 
panel by qRT-PCR. Expression levels as measured by the two primer sets were calculated 
relative to the calculated average of the reference genes, HPRT and β-actin. Error bars 
shown in graph depicts standard deviation between the duplicates ran in the experiment. 
Graph shown is that of a representative experiment. The experiment was performed twice, 
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3.2.3.2 Mouse homologues, mDdi1 and mDdi2 have similar tissue distribution 
We also investigated the tissue distribution profile of mouse Ddi1 and Ddi2. A wildtype 
C57BL/6 mouse was sacrificed and tissues collected for analysis. To study expression 
levels of mDdi1 and mDdi2 mRNA, quantitative real time PCR using primers specific for 
mDdi1and mDdi2 was performed. Similar to the human homologue, mDdi1 is an intronless 
gene. To avoid gDNA contamination in our cDNA samples, extra precautionary steps were 
taken to ensure that RNA samples were treated with DNase. Prior to the synthesis of first 
strand cDNA, DNase-treated RNA samples were used in a conventional PCR using control 
primers of intronless genes (in this case, mDdi1) to check for the presence of gDNA. PCR 
samples were then run on an agarose gel stained with ethidium bromide to visualise the 
presence of mDdi1bands (data not shown).   
At the mRNA level, mDdi1 mRNA only amplified in testis and possibly at a very low level, 
in the lung cDNA sample whereas mDdi2 mRNA amplified in all tissues examined (Figure 
3.12). Using anti-DDI1 and anti-DDI2 antibodies in a western blotting experiment, we also 
studied mDdi1 and mDdi2 expression at the protein level (Figure 3.13). Anti-DDI1 detected 
a single band of approximately 45kDa present only in the testis, while anti-DDI2 detected a 
band of approximately 52kDa present in all tissues examined. From these findings, the 
expression profile of mDdi1 and mDdi2 correlates with the expression profile of their 
human homologues, hDDI1 and hDDI2, in that mDdi1 and hDDI1 are only expressed in 
the testis and mDdi2 and hDDI2 are expressed ubiquitously across tissues.  





Figure 3.12 Real Time PCR of mDdi1 and mDdi2 tissue distribution.  
mRNA levels of mDdi1 and mDdi2 were assessed using quantitative real time PCR. 
Expression levels as measured by mDdi1 and mDdi2 primer sets were calculated relative 
to the calculated average of the reference genes, mHprt and mβ-actin. Error bars shown in 
graph depicts standard deviation between the duplicates ran in the experiment. Graph 
shown is that of a representative experiment. The experiment was performed twice, with 
similar results on each occasion. 








Figure 3.13 Western blot analysis of mDdi1 and mDdi2 expression in mouse tissues. 
Tissues from a C57BL/6 mouse were extracted and homogenised in lysis buffer. Equal 
amounts (10µg) of protein were then loaded on a gel and analysed by western blotting 
using anti-DDI1 and anti-DDI2 antibodies. Anti-GAPDH was used as a loading control and 
was observed to be similar for both sets of western blots (not shown). 
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3.2.3.3 Expression of hDDI1 and hDDI2 in human cell lines 
We also investigated the expression of hDDI1 and hDDI2 in a number of human cell lines. 
The cell lines examined were derived from a variety of tissues including Hek293 (human 
embryonic kidney), HeLa (cervical cancer), HepG2 (human hepatocellular carcinoma), 
HFF5 (human foreskin fibroblast), MCF7 (breast adenocarcinoma), MCF10a (breast 
epithelial), PC3 (prostate cancer), SHSY5Y (bone marrow neuroblastoma), SkHep1 
(Human hepatocellular carcinoma) and U2OS (Human osteosarcoma). Using quantitative 
real time PCR, it was found that hDDI1 was not expressed in any of the human cell lines 
studied (data not shown). hDDI2, however, had a more widespread distribution being 
expressed in all cell lines studied (Figure 3.14A). To confirm hDDI2 protein expression in 
these cell lines, we performed western blotting on cell lysates and observed that hDDI2 
protein was expressed in all cell lines studied (Figure 3.14B).  
From our studies, we have shown that hDDI2 is expressed in all human cell lines 
investigated. hDDI1, on the other hand, was not found to be expressed in any of the cell 
lines that were studied. Subsequent studies in cell lines will therefore focus on hDDI2, for 
which model cell lines are presently available. 
 
  






Figure 3.14 Quantitative real time PCR and western blot showing hDDI2 expression 
in human cell lines 
A) Quantitative real time PCR using two different primer sets for hDDI2 was performed 
on human cell line showing expression of hDDI2 in all cell lines studied. 
B) Cell lysates were loaded on a gel and analysed by western blotting using anti-DDI2. 
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3.2.3.4 Intracellular localisation of hDDI2 in human cell lines 
Our expression studies have shown that hDDI2 is expressed endogenously in all cell lines 
investigated. To further study hDDI2 at the cellular level, we also investigated the cellular 
localisation of hDDI2 in cell lines. HeLa (cervical adenocarinoma), MCF10a (breast 
epithelial), SkHep1 (Human hepatocellular carcinoma), PC3 (prostate cancer) and U2OS 
(Human osteosarcoma) cells were analysed for hDDI2 expression using 
immunoflourescence microscopy, utilising rabbit anti-DDI2 antibodies. We found that 
hDDI2 localised mainly to the nucleus as punctate structures (Figure 3.15). Conversely, 
these punctate structures were also observed at a lower level in the cytoplasmic region 
(Figure 3.15). It was also apparent that the anti-DDI2 antibody staining was more intense 
in the region outside what appeared to be the nucleolus. The localisation of the nucleolus 
in this study, however, was not investigated. Granular like structures were also observed 
throughout the cytoplasm and was similar in all cells lines studied. Additionally, identical 
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Figure 3.15 Immunofluorescence microscopy analysis of hDDI2 expression in 
human cell lines.  
HeLa, MCF10a, PC3, SkHep1 and U2OS cells were stained with anti-DDI2 antibody 
(green) and visualised using Immunoflourescence techniques. Cells were also stained with 
DAPI (blue) to visualise the nucleus. 
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3.3 Discussion 
3.3.1 hDDI1 and hDDI2 are novel UBL domain-containing proteins 
Our laboratory has identified two novel proteins, hDDI1 and hDDI2 which are human 
homologues of the previously described yeast Ddi1 protein (Liu and Xiao 1997; Lustgarten 
and Gerst 1999; Clarke et al. 2001). Of the three identifiable domains of yeast Ddi1, hDDI1 
and hDDI2 contain at least two domains; the N terminus UBL domain as well as the RVP 
domain located in the central part of the protein. The conserved domain organisation in the 
yeast and human proteins suggest the importance of these domains in their respective 
roles. The UBL domain of yeast Ddi1 has been shown to interact with the proteasomal 
subunit, Rpn1 (Kaplun et al. 2005). Likewise, we hypothesised that hDDI1 and hDDI2 
could be linked to the proteasome through their UBL domains. Evidence showing this 
association will be presented in the next chapter.  Another domain present among the Ddi 
proteins is the RVP domain, a distinctive feature amongst the known UBA-UBL proteins 
(Krylov and Koonin 2001; Sirkis et al. 2006). Although the function of the RVP domain of 
Ddi1 has not been characterised, its structure in yeast has been solved and it was found to 
be very similar to the HIV protease, when in the form of a dimer (Sirkis et al. 2006). Given 
that Ddi1 can dimerise through its RVP domain (Diaz-Martinez et al. 2006; Sirkis et al. 
2006; Gabriely et al. 2008), an interesting proposition was put forth that the RVP domain of 
Ddi1 may act as a functional aspartyl protease. However, no studies have yet confirmed 
this hypothesis and further investigation into identifying a physiological substrate is still 
needed. The sequences of hDDI1 and hDDI2 in the RVP region share very strong 
homology to the yeast protein, suggesting that this region is of functional importance.  
Unlike the yeast Ddi1 protein, a UBA domain in both the human homologues was not 
detected. However, in our analysis, we have identified a putative UIM domain at the C-
terminal end of hDDI2. The UIM domain is a short highly conserved motif found to be able 
to interact with ubiquitin (Hofmann and Falquet 2001), which although is not predicted to 
form a distinctive fold, has been thought to be homologous to the UBA domain, at least in 
its ability to bind ubiquitin.  
hDDI1 and hDDI2 are evolutionary conserved proteins, showing sequence conservation in 
all eukaryotes as well as early branching protozoa, Leishmania and Plasmodium. We 
noted that the genomes of higher eukaryotes including the human genome encode for at 
least two DDI1 homologues which may indicate an occurrence of gene duplication during 
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the evolutionary process. The presence of two very similar genes in the same organism 
might be suggestive of their importance within the biology of more complex organisms. 
Evolutionary biologists have argued that duplication of genes within a genome may have 
facilitated the evolution of complexity in higher organisms with natural selection favouring 
more useful and important genes (Ohta 1989).  Additionally, other similar genes from the 
ubiquitin-like domain family of proteins like Rad23 and Dsk2 have also been shown to 
have undergone gene duplication in higher organisms (Sturm and Lienhard 1998; Tanaka 
et al. 2006). 
 
3.3.2 hDDI1 and hDDI2 have distinct expression patterns 
We have generated antibodies against hDDI1 and hDDI2, which will aid us in our 
endeavour to study both of these proteins. As hDDI1 and hDDI2 are very similar proteins, 
we also undertook a characterisation of the antibodies that we have raised. We have 
shown that anti-DDI1 and anti-DDI2 antibodies are sensitive and specific against hDDI1 
and hDDI2, respectively. Furthermore, both sheep anti-DDI2 and rabbit anti-DDI2 worked 
in a similar manner in immunoassay techniques such as western blotting, 
immunoflourescence and immunoprecipitation.  
hDDI1 and hDDI2 are very similar proteins, both in their amino acid sequence and their 
domain organisation. However, we have found that hDDI1 and hDDI2 have distinct 
expression profiles. The expression of hDDI1 is limited to the testis while hDDI2 is widely 
expressed in all tissues. We extended our studies in the mouse and have shown here that 
the mouse homologues show similar expression profiles. The function of hDDI1 within the 
testis has not yet been investigated but we speculate that it plays an important role in the 
biology of the testis. It is also of interest that in mouse studies, it was found that mDdi1 is 
specifically expressed in the Sertoli cells of the testis indicating a possible involvement in 
spermatogenesis (Membrane Transport Laboratory, unpublished data). 
The expression of hDDI2 in all tissues and human cell lines examined is indicative of an 
important role within the cell. Across the different human tissues investigated, it was also 
observed through qRT-PCR that hDDI2 is highly expressed in tissues such as skeletal 
muscle, heart and liver. Although it can be argued that the observed differences may not 
be a true difference as it takes into account the expression levels of the reference genes 
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used (in this case, HPRT and β-ACTIN), we have not ruled out the possibility that the 
function of hDDI2 may be more prominent in certain tissues. To further investigate the 
differential expression of hDDI2, we also looked at the expression of mDdi2 in mouse 
tissues. In contrast to its human orthologue, mouse Ddi2 was not found to be highly 
expressed in the heart or muscle tissues. In mouse liver, however, mDdi2 is relatively 
highly expressed compared to the other tissues studies. This may correspond to its human 
counterpart which showed relatively high expression in liver. In our studies, we 
acknowledge that hDDI2 and mDdi2 is highly expressed in liver which may be reflective of 
it playing an important role in the functioning of the liver. Thespecific role of hDDI2 or 
mDdi2 in the liver or in general, however, has not yet been determined at this stage. 
Nevertheless, on the basis that hDDI2 and its mouse orthologue are present all tissues 
investigated, we speculate that hDDI2 plays a crucial role in the functioning of a cell. Its 
specific role within a cell and within specific tissues will be of much interest coming from 
future work. 
Additionally, we also investigated the intracellular localisation of hDDI2 in human cell lines 
and showed that it predominantly localises to the nucleus. Similarly, it has been shown 
that the yeast Ddi1 primarily resides in the nucleus (Gabriely et al. 2008), an indication that 
hDDI2 and Ddi1 might function in similar ways.  
3.3.3 Summary 
We have undertaken a molecular and cellular characterisation of hDDI1 and hDDI2, 
demonstrating that hDDI1 and hDDI2 are very similar proteins but with distinct expression 
profiles. The lack of human cell line models that express hDDI1 have limited our research 
to studying hDDI2, which is widely expressed. The antibodies that we have raised have 
provided us with a vital tool to study these proteins. The current literature on yeast Ddi1 
suggests that it is involved in the ubiquitin-proteasome pathway, through a functional UBL 
and UBA domain. Through the work presented in the following chapter, we will investigate 
the link between hDDI proteins and the proteasome. 
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Chapter 4 hDDI1 and hDDI2: Novel proteasome-associated proteins 
4.1 Introduction  
Ubiquitin-like (UBL) proteins bear similarity to ubiquitin either in their structure or function 
but are distinct in their properties and are not considered ubiquitin isoforms (Hartmann-
Petersen and Gordon 2004). UBLs can be broadly classified into two groups; the type 1 
UBL called ubiquitin-like modifiers (UBLs) and the type 2 UBL called ubiquitin-domain 
proteins (UDPs). 
Type 1 UBLs are typically small 76-103 residue proteins that act as post-translational 
modifiers, conjugating to other proteins in a manner similar to ubiquitin (Hartmann-
Petersen and Gordon 2004). Additionally, type 1 UBLs are closely related to ubiquitin in 
sequence and are expressed as inactive precursor proteins similar to ubiquitin (Jentsch 
and Pyrowolakis 2000). Analogous to the process of ubiquitination, type 1 UBLs also 
undergo activation and conjugation through a cascade of enzymes with each UBL having 
a distinct set of enzymes. Type 1 UBLs play a diverse role, ranging from transcriptional 
regulation and protein targeting to autophagy (Girdwood et al. 2004; Hartmann-Petersen 
and Gordon 2004; Ohsumi and Mizushima 2004). Members of the type 1 UBLs include 
Nedd8/Rub1, Apg12, FAT10 and SUMO (refer to Figure 4.1). 
Type 2 UBLs, also referred to as ubiquitin domain proteins (UDPs), are a functionally and 
structurally heterogenous group of proteins. Members of this group of proteins share 
sequence homology only in the ubiquitin-like region called the ubiquitin-like (UBL) domain 
while other parts of the protein are seemingly unrelated to each other. In contrast to type 1 
UBLs, proteins from the type 2 UBL group do not act as post-translational modifiers. The 
UBL domain, however, forms an integral part of the protein and has been found to have a 
discrete fold similar to that of ubiquitin (Walters et al. 2002; Walters et al. 2003). Type 2 
UBLs can be found throughout the eukaryotic genome and are implicated in a diverse 
range of cellular functions. Numerous studies have found that type 2 UBLs share the 
ability to interact with the 19S proteasome, an ability that has been found to be dependent 
on their integral UBL domain (Saeki et al. 2002). 
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Through our characterisation work, we have identified putative UBL domains on hDDI1 
and hDDI2 (refer to section 3.2.1.1). Accordingly, hDDI1 and hDDI2 are considered type 2 
UBL proteins due to the presence of the integral UBL domain at their N-terminal. The 
presence of such a domain, therefore, suggests an association with the proteasome. 
Studies carried out in yeast have already implicated Ddi1 in the ubiquitin-proteasome 
pathway through its ability to interact with the proteasome. This chapter will explore the 
interaction between hDDI1/2 and the proteasome as well as the significance of the UBL 
domain in governing this interaction. Here, a brief outline into the known functions of the 
UBL domain will first be reviewed. 
 
4.1.1 Ubiquitin as a degradation signal 
The identification of a UBL domain within the open reading frame (ORF) of a protein 
sequence has been reported as early as the 1980s by numerous researchers (Toniolo et 
al. 1988; Banerji et al. 1990). During that time, it had already been known that the ubiquitin 
peptide is expressed as a precursor protein, where its C-terminal is fused to either itself or 
to ribosomal proteins (Wiborg et al. 1985; Ozkaynak et al. 1987). Free ubiquitin monomer 
is then obtained through cleavage, by the action of ubiquitin-specific proteases (Monia et 
al. 1989). Additionally, ubiquitin is encoded by multiple genes throughout the eukaryotic 
genome. Because of their homology to ubiquitin, it was thought that proteins bearing a 
ubiquitin-like domain may also be homologues to ubiquitin. However, it is an intriguing fact 
that unlike ubiquitin, UBL domains are not cleaved off but rather, form integral parts of the 
proteins that contain them.  
In an early study aimed at understanding the significance of the ubiquitin domain encoded 
within a protein sequence, Johnson et al (1992) engineered a fusion protein with a 
ubiquitin sequence at the N-terminal of a reporter protein. It was demonstrated that a 
single ubiquitin moiety fused to the N-terminal end of a subject protein marked the protein 
for a rapid increase in turnover rate as well as an increase in degradation by the 
proteasome. The same study also showed that the lysine residue of the N-terminal 
ubiquitin could act as a site of multi-ubiquitination and subsequently act as a signal for 
proteasomal degradation. Findings from this study suggested that an integral UBL domain 
may function as an autonomous degradation signal in a similar manner to the way 
ubiquitin tags proteins for proteasomal degradation. 
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Figure 4.1 Classification of Ubiquitin-like Proteins. 
1) Type 1 UBLs or ubiquitin-like modifiers act as protein modifiers (gray box) in a 
manner analogous to ubiquitin, through isopeptide linkage with their target 
protein (black box).  
2) Type 2 UBLs or ubiquitin domain proteins have integral domains that bear 
similarity to ubiquitin (grey box) in their primary sequence but do not form 
conjugates with other proteins. 
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4.1.2 A functional role for the UBL domain of Rad23 
Rad23 belongs to a class of proteins called the UBL-UBA domain proteins, so called 
because of the presence of a UBL domain and ubiquitin associated (UBA) domain within 
the same protein. Similarly, Rad23 can also be classified as a type 2 UBL as it bears an 
integral UBL domain at its N-terminus. Amongst the known type 2 UBLs, Rad23 has been 
the most studied. 
In yeast, the rad23 gene was first identified as a gene implicated in DNA damage, as 
mutants lacking the gene showed increased sensitivity to ultraviolet (UV) irradiation 
(McKnight et al. 1981), presenting a defect in the nucleotide excision repair (NER) 
pathway (Miller et al. 1982). The role of Rad23 in the NER pathway was first defined when 
one of its human homologues, hHR23B was identified as a protein tightly bound to the 
DNA repair factor, Xeroderma pigmentosum, complementation group C, also known as 
XPC (Masutani et al. 1994). To further emphasise its role in the NER pathway, Rad23 in 
yeast was also found to facilitate the complex formation between two NER proteins, Rad14 
and TFIIH (Guzder et al. 1995).   
A functional role for the UBL domain of Rad23 was first assigned through a study by 
Watkins et al. (1993). Deletion of the UBL domain from Rad23 caused an increase in 
sensitivity of yeast cells to UV irradiation (Watkins et al. 1993). The study showed that 
Rad23 required an intact UBL domain for it to play a functional role in DNA repair. 
Interestingly, it was also shown that substitution of the UBL domain with the authentic 
ubiquitin sequence restored the function of Rad23, indicating a functional homology 
between the UBL domain and ubiquitin. The authors also noted that Rad23 in yeast was 
highly stable. This finding contradicted earlier reports that supported the hypothesis that 
the UBL domain may act as a degradation signal rendering a protein unstable by targeting 
it to the proteasome for degradation (Johnson et al. 1992). A separate study also found 
that another UBL domain protein, hHR23A, the second human homologue of yeast Rad23, 
was a long lived protein (Kumar et al. 1999). This further contradicted the earlier findings 
by Johnson et al (1992). 
Like ubiquitin, the UBL domain of Rad23 can interact with the proteasome and this 
interaction was first shown by Schauber et al. (1998). Rad23 also possesses a Rad4 (XPC 
in humans) interacting domain in the central part of the protein which is also conserved in 
its human homologues, hHR23A and hHR23B (Li et al. 1997). Because of its strong 
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association with the DNA repair protein, Rad4, and its ability to interact with the 
proteasome, a regulatory role has been proposed for Rad23. This regulatory role of Rad23 
is further highlighted by the fact that the UV sensitivity caused by the deletion of the UBL 
domain may have arisen from its inability to interact with the proteasome. 
 
4.1.3 Aims 
The hypothesis guiding the work presented in this chapter is that the putative UBL domain 
of hDDI1 and hDDI2 are functional proteasomal interacting domains. To investigate this 
we studied the interaction between hDDI1/2 and the proteasome as well as its associated 
proteins. The specific aims were: 
1. To determine whether hDDI1/2 can interact with the proteasome. Using 
antibodies against specific subunits of the proteasome, we utilised techniques such 
as colocalisation using immunofluorescence microscopy, co-immunprecipitation and 
in vitro binding assays to investigate any proteasomal interaction. 
2. To establish the region(s) on hDDI1 and hDDI2 that is/are involved in 
proteasomal interaction. Truncated hDDI1 and hDDI2 proteins were expressed as 
recombinant proteins and used in assays to determine their interaction with specific 
subunits of the proteasome. 
3. To investigate the significance of the UBL domain. Full length and UBL 
truncated Myc-hDDI2 constructs were expressed in U2OS cells. Protein stability 
and intracellular localisation of the two different forms were studied and compared. 
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4.2 Results 
4.2.1 UBL domains of hDDI1 and hDDI2 share homology to ubiquitin 
hDDI1 and hDDI2 contain putative UBL domains at their N-termini (refer to Chapter 3.2.1).  
Alignment of the N-termini of these two proteins with ubiquitin shows significant homology 
(Figure 4.2). Our analysis revealed a 23.5% identity between the hDDI1 UBL domain and 
ubiquitin; and a 23.2% identity between the hDDI2 UBL domain and ubiquitin. We also 
aligned the yeast Ddi1 UBL domain with ubiquitin and showed that there was a 18.8% 
identity between the two proteins.  
hDDI1 and hDDI2, like other type 2 UBL proteins, are homologous to ubiquitin only in their 
UBL domains. The protein ubiquitin is expressed as a precursor protein fused at its C-
terminus to either itself or ribosomal proteins (Wiborg et al. 1985; Ozkaynak et al. 1987). 
Mature ubiquitin is generated by the action of deubiquitinating enzymes, which act on the 
glycine-glycine residue at the C-terminus of the ubiquitin sequence, freeing it from its C-
terminal tail sequence (Finley and Chau 1991). Sequence analysis of hDDI1 and hDDI2 
revealed the absence of the glycine-glycine residue at the C-termini of the UBL domains, 
strengthening the concept that the N-terminal UBL domains of hDDI1 and hDDI2 are 
integral UBL domains of larger proteins. 
  









Figure 4.2 N-terminal UBL domain of yeast Ddi1, hDDI1 and hDDI2 show homology 
to ubiquitin.  
Sequences were aligned using the ClustalX program. Residues shaded in black indicate 
identities while those shaded in dark grey represent strong homology and light grey 
represent weak homology.  
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4.2.2 Interaction of endogenous hDDI2 with the proteasomal subunit, hRPN13 
In yeast, an interaction has been established between Ddi1 and the proteasome (Saeki et 
al. 2002; Kaplun et al. 2005). Through our studies, we have found that only hDDI2 is 
expressed endogenously in the human cell lines that we investigated, while hDDI1 was not 
detected (refer to Chapter 3). To investigate the putative interaction between hDDI2 and 
the proteasome, we employed immunoflourescence microscopy techniques and studied 
the localisation of hDDI2 with reference to hRPN13, a recently identified subunit of the 19S 
proteasome, involved in the recognition of poly-ubiquitin chains as well as proteins 
containing integral UBL domains (Husnjak et al. 2008). 
U2OS cells were co-stained using antibodies against both hDDI2 and hRPN13 in an 
immunoflourescence experiment. Similar to the staining patterns of hDDI2, hRPN13 was 
localised to punctate structures both in the cytoplasm and nucleus with a more apparent 
staining in the nucleus (Figure 4.3). A merged image of anti-DDI2 and anti-RPN13 staining 
revealed areas in which the signals overlapped. It was also observed that not all hRPN13 
structures visualised colocalised with hDDI2, suggesting only a partial colocalisation 
between hDDI2 and hRPN13. 
To further investigate the relationship between hDDI2 and hRPN13, we then performed 
co-immunoprecipitation (Co-IP) experiments in U2OS cells to determine whether the two 
proteins interact. Protein complexes from soluble cell extracts were immunoprecipitated 
using anti-DDI2 and anti-RPN13 antibodies with rabbit IgG used as a negative control. The 
immunoprepitated protein complexes were then analysed by western blotting using anti-
DDI2 and anti-RPN13 antibodies. Our analysis revealed that hDDI2 can be co-
immunoprecipitated using anti-RPN13 antibody (Figure 4.4, Lane 2). In the reciprocal IP, 
we also observe that hRPN13 can be co-immunoprecipitated in the anti-DDI2 IP (Figure 
4.4, Lane 3). We take note that, the hRPN13 band observed in the anti-DDI2 IP is 
considerably faint which may reflect a weak interaction between these two proteins.. 
Another possibility is that in the anti-DDI2 IP, there is an imbalance of hDDI2 to hRPN13 
molecules (i.e. high hDDI2:hRPN13 ratio). Thus, it may be harder to detect hRPN13 in a 
large pool of hDDI2 molecules. Nevertheless, our results suggest that both hDDI2 and 
hRPN13 may be present in the same complex. 
  
   89 
 
 
Figure 4.3 Endogenous hDDI2 partially colocalises with the proteasomal subunit, 
hRPN13 in U2OS cells. 
Endogenous hDDI2 and hRPN13 were detected in U2OS cells by immunoflourescence 
microscopy using anti-DDI2 and anti-RPN13 respectively.  The merged images show 
colocalisation of hRPN13 with hDDI2, indicated by white solid arrows. It was also observed 









Figure 4.4 hDDI2 and hRPN13 can be co-immunoprecipitated in U2OS cells. 
U2OS cell lysate was immunoprecipitated with anti-DDI2 and anti-RPN13. Western 
blotting analysis using anti-DDI2 and anti-RPN13 showed that hDDI2 can be co-
immunoprecipitated by anti-RPN13 antibody and hRPN13 can be co-
immunoprecipitated by ant-DDI2 antibody. Lane 1 shows starting material (SM) which 
is 10% of lysate used in each IPs. Rabbit IgG was used in a control IP. Western blot 
analysis shown is from a representative experiment performed. Similar results were 
observed in  3 independent experiments. 
 
    1                   2          3        4 
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4.2.3 hDDI2 binds directly to hRPN13 through its UBL domain 
Studies of the ubiquitin-proteasome pathway have determined two intrinsic ubiquitin 
receptors on the proteasome; Rpn10 and Rpn13 (Saeki and Tanaka 2008). It has also 
been found that UBL domain proteins can efficiently bind ubiquitin receptors on the 
proteasome (Walters et al. 2002; Husnjak et al. 2008). To determine the ability of hDDI2 to 
interact directly with a known ubiquitin receptor, we performed in vitro binding assays 
using recombinant hDDI2 and hRPN13 proteins. Purified hRPN13, expressed as a GST 
fusion protein obtained from E.coli cells, was bound to glutathione Sepharose beads and 
incubated with recombinant His-hDDI2. Beads were washed extensively and bound 
proteins were then analysed by western blotting using anti-DDI2 antibodies. Our analysis 
revealed that recombinant His-hDDI2 can bind GST-hRPN13 (Figure 4.5, Lane 3). No 
binding was observed when His-hDDI2 was incubated with the negative control, GST 
protein alone (Figure 4.5, Lane 2), indicating that the interaction between hRPN13 and 
hDDI2 was specific.  
Additionally, hRPN13 has a ubiquitin binding domain called the ‘Pleckstrin-like Receptor 
for Ubiquitin’ or the PRU domain which has been shown to bind UBL domain proteins 
(Husnjak et al. 2008). In our study we also examined the ability for hDDI2 to bind the PRU 
domain of hRPN13 alone. The PRU domain lies within residues 1 to 150 in the N-terminal 
region of hRPN13. This region of hRPN13 was cloned and expressed as a protein fused to 
GST in E. coli cells. Using in vitro binding assays, we showed that the PRU domain of 
hRPN13 is sufficient for interaction with hDDI2 (Figure 4.5, Lane 4).   


















Figure 4.5 hDDI2 can bind hRPN13 directly in vitro. 
Recombinant full length RPN13, fused to GST (GST-RPN13FL) and the PRU domain of 
hRPN13 (GST-PRU-RPN13) bound to Sepharose beads were incubated with recombinant 
His-hDDI2 and allowed to bind. Bound proteins were then analysed by western blotting 
using anti-DDI2 antibody (Upper panel). GST protein alone was used as a control. The 
input lane shows 1% of the total protein used in the incubation. Recombinant proteins 
used as bait for the in vitro binding assay were also run on a gel and stained with 
Coomassie Blue to confirm their presence (lower panel). 
  
                1         2         3          
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To address the hypothesis that the UBL domain on hDDI2 governs its interaction with the 
proteasome, we performed in vitro binding assays using the N-terminal fragment (residues 
1-80) of hDDI2. In addition to hDDI2, we also investigated the ability of the UBL domain of 
hDDI1 to interact with hRPN13. The UBL domains of hDDI1 and hDDI2 share 69% identity 
and 82% similarity in their protein sequence. The N-terminal fragments of hDDI1 and 
hDDI2 were expressed as GST-fusion proteins and were bound to glutathione Sepharose 
beads before incubating with thrombin treated hRPN13 (thrombin was used to cleave off 
the GST fusion tag). Analysis of bound proteins by western blotting using anti-RPN13 
antibodies showed that hRPN13 could effectively bind to the UBL domains of hDDI1 and 
hDDI2 (Figure 4.6, Lane 3 and 4) while no binding was observed with the negative control, 
GST alone (Figure 4.6, Lane 2). 
  






Figure 4.6 The UBL domain of hDDI1 and hDDI2 are sufficient for hRPN13 binding. 
Recombinant GST-UBL hDDI1 and GST-UBL hDDI2 were bound to Sepharose beads and 
incubated with recombinant hRPN13 protein cleaved from its GST tag. Bound proteins 
were analysed by western blotting using anti-RPN13 antibodies (upper panel). 
Recombinant proteins used as bait for the in vitro binding assay were also run on a gel 
stained with Coomassie Blue to confirm their presence (lower panel). 
 
  
     1                       2          3         4 
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4.2.4 hDDI2 can interact with ubiquitin 
hDDI2 has a putative UIM domain present at the C-terminus of the protein sequence 
(residues 377-394, refer to chapter 3.2). To test for a possible interaction between hDDI2 
and ubiquitin, U2OS cells were co-transfected with Myc-hDDI2 and HA-ubiquitin 
expression vectors. Cells were harvested for protein 24 hrs post-transfection. Soluble cell 
extracts were then immunoprecipitated with anti-Myc followed by western blotting using 
anti-HA antibodies. When expressed in U2OS cells, HA-ubiquitin is visualised as a smear 
of high molecular weight bands (Lane 2, Figure ). As ubiquitin itself is a peptide of only 
8.5kDa in size, the smear of high molecular weight bands observed indicated its 
attachment to larger molecular weight proteins. Interestingly, an IP using anti-Myc antibody 
in cells expressing both Myc-hDDI2 and HA-ubiquitin could also pull down HA-ubiquitin 
conjugates when analysed by western blotting using HA antibodies (Lane 4, Figure 4.7). 
This finding suggests that hDDI2 can indeed interact with ubiquitin and like its yeast 
counterpart, it may act as an alternative ubiquitin receptor. An anti-Myc IP was also 
performed in U2OS cells transfected with Myc-hDDI2 alone without the presence of HA-
ubiquitin. This served as a negative control. 
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   1      2         3      4 
Figure 4.7 hDDI2 can interact with ubiquitin. 
U2OS cells expressing HA-Ubiquitin and Myc-hDDI2 were immunoprecipitated with 
anti-Myc antibody. Immunoprecipitated proteins were then analysed by western 
blotting using anti-HA antibody. SM indicates starting material, which is equivalent to 
10% of material used in IP. 
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4.2.5 The UBL domain of hDDI2 is not required for nuclear localisation 
We have determined that the UBL domain of hDDI2 is important for its interaction with the 
proteasome. Studies in yeast have suggested the importance of the UBL domain in the 
enrichment of Ddi1 in the nucleus (Gabriely et al. 2008). To address the importance of the 
UBL domain in the cellular localisation of hDDI2, we studied the localisation of transfected 
hDDI2 in the absence of its N-terminal UBL domain and compared it to the localisation of 
full length hDDI2. Full-length hDDI2 and truncated hDDI2 sequence lacking the UBL 
domain (residues 1-80) were cloned into the pEFIRES-NH2-DMyc vector to generate two 
different forms of hDDI2 constructs; Myc-hDDI2-FL (full length hDDI2) and Myc-
hDDI2∆UBL (truncated hDDI2 lacking the UBL domain).  U2OS cells stably expressing the 
transfected proteins were stained with both anti-Myc and anti-DDI2 antibodies and 
visualised using immunoflourescence microscopy. 
Unlike endogenous hDDI2 which localises mostly to the nucleus, over-expressed Myc-
hDDI2-FL localised predominantly to perinuclear structures (Figure 4.8, top panel). This 
observation was somewhat unexpected and requires further investigation. It is possible 
however, that the difference in localisation may be due to the protein being over-expressed 
in U2OS cells. On the other hand, Myc-hDDI2∆UBL, which is a truncated form of hDDI2 
lacking the UBL domain at its N-terminus, showed strong nuclear staining dissimilar to full 
length Myc-hDDI2-FL (Figure 4.8,bottom panel). From this experiment, it can be deduced 
that the difference in cellular localisation between the two forms of hDDI2 is caused by the 













Figure 4.8 Localisation of Myc-hDDI2FL and Myc-hDDI2∆UBL in U2OS cells. 
U2OS cells expressing Myc-hDDI2FL and Myc-hDDI2∆UBL were stained with anti-Myc 
(green) and anti-DDI2 (red) antibodies and visualised using immunoflourescence 
techniques. Myc-DDI2FL showed a perinuclear staining while its truncated form, Myc-
hDDI2∆UBL showed a more nuclear staining. Cells shown above are representative of the 
cell population observed under the microscope. Merged images are shown on the right, 
also stained with DAPI to indicate the nucleus. 
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4.2.6 Overexpression of hDDI2 with intact UBL domain renders it an unstable 
protein 
The ability of the UBL domain to localise proteins to the proteasome presents an 
opportunity for those particular proteins to be degraded. There has been evidence 
presented that supports the hypothesis that localisation to the proteasome is sufficient for 
degradation (Janse et al. 2004). Through our work on the two different forms of hDDI2, 
Myc-hDDI2FL and Myc-hDDI∆UBL, we have observed that the truncated form (Myc-
hDDI2∆UBL) consistently showed higher levels of expression compared to the full length 
form (Myc-hDDI2FL).  
To address this observation, we investigated the difference in protein stability between full 
length Myc-hDDI2FL and the truncated form, Myc-hDDI2∆UBL. U2OS cells expressing 
either Myc-hDDI2FL or Myc-hDDI2∆UBL were treated with 100µg/mL cycloheximide for 1 
to 8 hours (CHX) to block de novo protein synthesis. Cells were then harvested at different 
time points post-treatment and analysed for levels of protein expression by western 
blotting. Our analysis showed that in the absence of the UBL domain, Myc-hDDI2∆UBL, is 
a highly stable protein showing high levels of expression at 8hrs post- CHX treatment 
(Figure  4.9). Full length Myc-hDDI2FL, on the other hand, is comparatively less stable. 
This finding suggests that the over-expression of the full length form of hDDI2 with an 
intact UBL domain may render it an unstable protein while the deletion of the N-terminal 
UBL domain may affect its turnover causing it to be more stable. As a reference point, we 
also measured the stability of endogenous hDDI2 in U2OS cells. Endogenous hDDI2 was 
observed to be a stable protein, with much of the protein still present at the 8hr timepoint 
post-CHX treatment (Figure 4.9). 
  











Figure 4.9 Protein stability of full length Myc-hDDI2 compared to the truncated form 
Myc-hDDI2∆UBL. 
U2OS cells stably expressing Myc-hDDI2FL and Myc-hDDI2∆UBL were treated with 
100µg/mL cycloheximide and harvested from 1 to 8 hours post cycloheximide treatment. 
Cell extracts were then loaded on a SDS-PAGE gel and analysed for protein expression 
by western blotting using anti-Myc antibody. GAPDH was used as a loading control. 
  









Figure 4.10 Protein stability of endogenous hDDI2 in U2OS cells. 
U2OS cells were treated with 100µg/mL cycloheximide and harvested from 1 to 8 hours 
post cycloheximide treatment. Cell extracts were then loaded on a SDS-PAGE gel and 
analysed for protein expression by western blotting using anti-DDI2 antibody. GAPDH was 
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4.3 Discussion 
4.3.1 hDDI2 interacts with the proteasome via its UBL domain 
A known property of the UBL domain is its ability to interact with the proteasome. Studies 
on the yeast Rad23 protein have shown that its UBL domain is sufficient to allow an 
interaction with the 26S proteasome (Schauber et al. 1998). A physical association has 
also been shown between the proteasomal subunit, S5a with the two human homologues 
of Rad23, hHR23A and hHR23B (Hiyama et al. 1999). Furthermore, the crystal and 
solution structures of the UBL domain show strong similarities in its overall structure and 
fold characteristics to that of ubiquitin (Mueller and Feigon 2003; Chen et al. 2011), which 
further strengthens the view that UBL domains and ubiquitin have common physical 
properties.  
The hypothesis that the UBL domains of hDDI1 and hDDI2 interact with the proteasome 
was addressed in this chapter. From our expression studies (refer to Chapter 3) however, 
hDDI1 is not expressed in any of the human cell lines we tested. Although hDDI1 and 
hDDI2 are similar proteins, for the purpose of this thesis, we have focussed our attention 
on the more widely expressed homologue, hDDI2.  
Sequence analysis of hDDI2 (and also hDDI1) revealed the presence of a UBL domain at 
its N-terminus. Based on this, we initiated a study to examine the link between hDDI2 and 
the ubiquitin-proteasome pathway. We began by looking for an interaction with a known 
subunit of the 26S proteasome, hRPN13. Within the 26S proteasome, there exist at least 
two known receptors for ubiquitinated substrates; Rpn10 and the more recently identified, 
Rpn13 (Deveraux et al. 1994; Husnjak et al. 2008). Because of the presence of more than 
one ubiquitin receptor on the 26S proteasome, an overlapping and possibly also a 
redundant role in capturing ubiquitinated substrates to the proteasome has been 
proposed. Evidence that has supported this idea came from genetic studies in the rpn10∆ 
yeast deletion strain, where deletion of Rpn10 alone showed only a mild phenotype while 
the degradation and recognition of the majority of ubiquitinated substrates by the 
proteasome remained unperturbed (van Nocker et al. 1996). Moreover, when both Rpn10 
and Rpn13 were deleted, the ubiquitin-binding capacity of the proteasome was almost 
totally lost, further emphasising the prominent role of both Rpn10 and Rpn13 as ubiquitin 
receptors (Husnjak et al. 2008). It is also worthy to note that in this particular study 
(Husnjak et al. 2008), the strain of yeast that was used for the rpn10∆rpn13∆ double 
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deletion, did not express the three known UBA-UBL domain proteins; Rad23, Dsk2 and 
Ddi1. This was done to factor out the role UBA-UBL domain proteins may have in 
delivering ubiquitinated substrates to the proteasome. A double deletion of just Rpn10 and 
Rpn13 alone with Rad23, Dsk2 and Ddi1 still intact was not studied. 
There are several lines of evidence which suggest that Rpn10 and Rpn13 cooperate with 
UBA-UBL domain proteins in their role as intrinsic ubiquitin receptors of the 26S 
proteasome. Firstly, it was found that the double deletion of Rpn10 together with the UBA-
UBL domain protein, Rad23, was sufficient to show accumulation of multi-ubiquitinated 
proteins and the stabilisation of proteolytic substrates (Lambertson et al. 1999). 
Additionally, a triple deletion yeast strain for Rpn10 and two UBA-UBL domain proteins, 
Rad23 and Dsk2, showed a greater accumulation of multi-ubiquitinated proteins than any 
combination of either single or double deletion strains (Saeki et al. 2002). The finding that 
the deletion of either Rpn10 or Rpn13 alone did not totally perturb ubiquitin-recognition at 
the proteasome compared to Rpn10/Rpn13/UBA-UBL deletion may indicate a more 
prominent role for UBA-UBL domain proteins in delivering ubiquitinated substrates to the 
proteasome. Interestingly, the mutant yeast strain with deletion of the five known ubiquitin 
receptors; rpn10∆rpn13∆rad23∆dsk2∆ddi1∆, still showed a modest capacity of the 
proteasome to bind ubiquitin chains (Husnjak et al. 2008), suggesting there they may still 
be unidentified ubiquitin receptors present. However, the vast difference in the ubiquitin 
binding capacity at the proteasome level of the rpn10∆rpn13∆rad23∆dsk2∆ddi1∆ strain 
compared to wild-type seems to suggest that Rpn10, Rpn13, Rad23, Dsk2 and Ddi1 act 
cohesively as the main ubiquitin receptors in yeast (Husnjak et al. 2008). 
Through studies presented in this chapter, we have established that hDDI2 can indeed be 
associated with the proteasome. We have shown through various techniques that hDDI2 
can interact with the proteasome, particularly, through an intrinsic subunit of the 
proteasome, hRPN13. To begin our investigation, we chose a more directed approach to 
study the link between hDDI2 and the proteasome. Given the broad literature available on 
the proteasome and its interaction with UBL domain proteins, we chose to study an 
association with hRPN13, as hRPN13 has been shown to interact with both ubiquitin and 
UBL domain proteins (Husnjak et al. 2008). Although the analysis of the primary sequence 
of Rpn13 did not reveal any homology to any previously known ubiquitin receptors, 
structural studies found that the N-terminus of Rpn13 contains a pleckstrin-homology 
domain (PHD) fold which gives it its ubiquitin binding properties (Schreiner et al. 2008). 
Because of this, the N-terminal domain of Rpn13 was named the ‘pleckstrin-like receptor 
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for ubiquitin’ or PRU domain. We also noted that this novel ubiquitin domain on Rpn13 was 
found to show high affinity to K48 linked diubiquitin and that binding to ubiquitin was shown 
to be stronger than other known ubiquitin receptors (Husnjak et al. 2008). This further 
substantiated our direct approach of investigating hRPN13 as a potential binding partner 
for hDDI2. 
Through in vitro binding assays, we have also determined that the N-terminal UBL domain 
of hDDI2 is sufficient for it to interact with hRPN13. Additionally, the PRU domain of 
hRPN13 can directly bind to the UBL domain of hDDI2. Our findings here are therefore 
consistent with a previous report by Husjnak et al (2008) which showed that the novel PRU 
domain of hRPN13 could interact directly with the UBL domains of other UBA-UBL 
proteins, hHR23A and hPLIC2. Our findings here are also the first to demonstrate a 
functional interaction of the hDDI2 UBL domain. 
 
4.3.2 hDDI2 associates with ubiquitinated proteins 
In yeast, Ddi1 has been shown to interact with both the proteasome and ubiquitinated 
proteins through its UBL and UBA domains respectively (Bertolaet et al. 2001; Saeki et al. 
2002; Kaplun et al. 2005). Our sequence analysis using bioinformatic software did not 
detect any putative UBA domain in the sequence of hDDI2 or hDDI1. However, a putative 
UIM domain which is another ubiquitin binding domain functionally similar to the UBA 
domain was detected at the C-terminus of hDDI2 (refer to chapter 3). Here, we tested 
whether hDDI2 with a putative UIM domain could show functionality by interacting with 
ubiquitin. An in vivo assay was employed using HA-epitope tagged ubiquitin. We showed 
that HA-tagged ubiquitin conjugates of high molecular weight could be co-
immunoprecipitated with Myc-hDDI2 indicating an association of Myc-hDDI2 with 
ubiquitinated proteins. Although we cannot rule out that the interaction between Myc-
hDDI2 and ubiquitin is an indirect interaction, based on our current findings, we can only 
postulate that the UIM domain of hDDI2 functions in recognising ubiquitinated proteins. 
Future studies employing mutational analysis of the UIM domain of hDDI2 would be 
needed to confirm the functionality of this putative UIM domain. Despite this, we have 
shown that hDDI2 can indeed be associated with ubiquitinated proteins, similar to what 
has been shown for its yeast counterpart. 
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4.3.3 Deletion of UBL domain affects the stability and localisation of hDDI2 
Lastly, we investigated the significance of the UBL domain of hDDI2 in maintaining the 
stability and localisation of hDDI2. Our observation during the generation of stable cell 
lines expressing either full length Myc-hDDI2 or its truncated form Myc-hDDI2∆UBL 
prompted this investigation. We observed that when the full length form is over-expressed 
in U2OS cells, its intra-cellular localisation differed from that of endogenous hDDI2. Myc-
hDDI2 FL showed a more perinuclear staining pattern as opposed to the nuclear staining 
observed for endogenous hDDI2. On the contrary, the truncated form, Myc-hDDI2∆UBL 
showed strong nuclear staining. Studies of yeast Ddi1 have revealed that the UBL as well 
as the UBA domains are required for nuclear localisation, where mutant Ddi1 lacking either 
the UBL or UBA domain had only minor accumulation in the nucleus (Gabriely et al. 2008). 
We have shown here that the UBL domain of human DDI2 is not necessary for nuclear 
localisation. However, it was surprising that full length Myc-hDDI2FL did not localise to the 
nucleus in the same way as endogenous hDDI2. It may be that the over-expression of 
Myc-hDDI2 causes it to mislocalise. From our observation, however, we could speculate 
that the UBL domain might be required for nuclear export of hDDI2, explaining why in 
mutant truncated Myc-hDDI2∆UBL expressing cells, an accumulation in the nucleus was 
observed. This, however, is yet to be proven and is pending further investigation.  
In our studies, we have not ruled out that the N-terminal epitope tag present on both Myc-
hDDI2FL and Myc-hDDI2∆UBL may be interfering with the proper localisation of the 
protein. However, it must also be noted that both forms of the hDDI2 proteins (Myc-
hDDI2FL and Myc-hDDI2∆UBL) were Myc-tagged at their N-terminal and therefore the 
position of the tag could not explain the differences in localisation between the two forms. 
Another significant difference that we observed between the full length Myc-hDDI2 and the 
truncated form, Myc-hDDI2∆UBL, was their protein stability. We have shown that full 
length Myc-hDDI2FL when expressed in U2OS cells displayed a remarkably short half life 
compared to endogenous hDDI2 which is a considerably stable protein. On the other 
hand, the truncated form, Myc-hDDI2∆UBL, displayed a significantly longer half life 
compared to the full length form. From this observation, we can conclude that the absence 
of the N-terminal UBL domain of hDDI2 renders the protein more stable. The difference in 
half life between the over-expressed full length Myc-hDDI2FL and the more stable 
truncated form, Myc-hDDI2∆UBL, may have been brought about by a couple of factors. 
Firstly, it may be possible that the UBL domain of hDDI2 harbours the ubiquitination site 
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for ubiquitin conjugation and hence acts as a protein degradation signal for the 
proteasome. There exist several lysine residues in the UBL domain that could potentially 
serve as a target by the ubiquitination machinery. Although our studies have not 
determined whether hDDI2 itself is ubiquitinated, it is tempting to speculate that hDDI2 can 
be ubiquitinated considering that; 1) other UBL-UBA proteins, eg. Rad23 and hHR23A can 
be ubiquitinated and 2) hDDI2 has lysine residues that can potentially be ubiquitinated. 
Research investigating the specificity of the lysine residues that are ubiquitinated in any 
particular protein has led to mixed findings. In some cases distinct lysine residues are 
required (Kornitzer et al. 1994; Scherer et al. 1995), while in others, ubiquitination is 
independent of any particular lysine residue (Hou et al. 1994; Treier et al. 1994). Studies 
on the Rad23 protein have also shown that the introduction of mutations to all the lysine 
residues present on the UBL domain of Rad23 had no effect on its multi-ubiquitination 
(Watkins et al. 1993), indicating that none of the lysine residues on the UBL domain are 
utilised for its multi-ubiquitination. Our data, however, seem to suggest that should hDDI2 
be ubiquitinated, the UBL domain on hDDI2 would prove vital to its ubiquitination and 
therefore its degradation by the proteasome. 
A second possible explanation for the difference in stability between the full length and 
truncated forms of hDDI2 may be their ability to localise to the proteasome. Evidence from 
previous studies has shown that the localisation of a protein to the proteasome on its own 
is sufficient for it to be degraded, whereby the ubiquitination of a protein may not be strictly 
necessary (Janse et al. 2004). Based on this, it may be the case that when full length Myc-
hDDI2 is over-expressed, much of it localises to the proteasome, which is then sufficient 
for it to be degraded. In the absence of the UBL domain, the truncated Myc-hDDI2∆UBL 
may not be able to localise to the proteasome, therefore allowing it to accumulate, making 
it a more stable protein. 
 
4.3.4 Summary 
In conclusion, we have shown that hDDI2 is a novel proteasomal associated protein. 
Through our studies, we have assigned a function to the UBL domain of hDDI2. We 
presented evidence that the UBL domain of hDDI2 is sufficient to allow an interaction with 
the proteasome. Additionally, we have found that hDDI2 can indeed associate with 
ubiquitinated proteins, a function possibly brought about through its putative UIM domain. 
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Lastly, we showed that the N-terminal UBL domain of hDDI2 plays a role in the stability 
and localisation of the protein, suggesting that this region of hDDI2 may be vital in its 
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Chapter 5 hDDI2 plays a functional role in the ubiquitin-proteasome 
pathway 
5.1 Introduction 
The ubiquitin-proteasome pathway plays an integral role in regulating the turnover of 
important components of cellular processes. There is, however, a lack of understanding on 
how the ubiquitin-proteasome pathway recognises specific substrates and how it regulates 
degradation in a timely and spatial manner. Although the proteasome by itself, through 
specific subunits, is able to bind ubiquitinated substrates directly, numerous studies have 
shown a role for extrinsic factors in the delivery of ubiquitinated substrates to the 
proteasome for degradation (Elsasser et al. 2002; Saeki et al. 2002; Hartmann-Petersen 
and Gordon 2004; Husnjak et al. 2008).  
A class of proteins known as the UBA-UBL domain proteins, which bear two functional 
domains related to ubiquitin, the ubiquitin-like (UBL) and ubiquitin associated (UBA) 
domains, have been the subject of much research because of their fundamental role in 
proteasomal degradation. Members of this family in yeast include Ddi1, Rad23 and Dsk2. 
Due to their ability to interact with the proteasome through their UBL domain and poly-
ubiquitinated substrates via their UBA domain, UBA-UBL domain proteins have been 
hypothesised to act as “shuttle factors”, bridging ubiquitinated substrates to the 
proteasome for degradation (Schauber et al. 1998; Bertolaet et al. 2001; Wilkinson et al. 
2001; Elsasser et al. 2002).   
This chapter will provide an insight into the role hDDI2 plays in the ubiquitin-proteasome 
pathway. We studied how hDDI2 regulates a known substrate of the ubiquitin-proteasome 
pathway, the tumour suppressor protein, p53. Firstly, a review of the current literature 
relevant to the biology of known UBA-UBL proteins and their link to the ubiquitin-
proteasome pathway will be presented. 
 
5.1.1 Ubiquitin receptors – intrinsic vs. extrinsic receptors 
There are currently two known proteasomal subunits that can act as ubiquitin receptors. 
The proteasomal subunit S5a/Rpn10 was the first protein identified capable of interacting 
with poly-ubiquitin chains (Deveraux et al. 1994). S5a binds ubiquitin through a motif called 
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the ubiquitin-interacting motif (UIM) (Young et al. 1998). Mutated yeast strains lacking the 
rpn10 gene, however, showed no notable phenotype and the degradation of the majority of 
proteasomal substrates remained unperturbed (van Nocker et al. 1996). Additionally, 
proteasomes lacking Rpn10 can still bind ubiquitinated substrates (Elsasser et al. 2002), 
indicating the presence of either additional subunits with parallel functions to Rpn10 or 
alternative mechanisms that take place contributing to the recognition of ubiquitinated 
substrates by the proteasome for degradation. 
A second proteasomal subunit that is able to bind ubiquitin is Rpn13 (Husnjak et al. 2008). 
Rpn13 binds to ubiquitin through the PRU (pleckstrin-like receptor for ubiquitin) domain 
with similar binding properties to that of the Rpn10 protein (Husnjak et al. 2008; Schreiner 
et al. 2008). The presence of two ubiquitin receptors on the proteasome suggests an 
overlapping and redundant role for ubiquitin binding at the proteasome. This is exemplified 
by the fact that only the double deletion of rpn10 and rpn13 in mutant yeast strains 
resulted in the complete abrogation of ubiquitin chain recognition by the proteasome 
(Husnjak et al. 2008).   
Even though intrinsic proteasomal ubiquitin receptors exist, various studies have 
presented compelling evidence to show that extrinsic ubiquitin receptors act equally, and 
are perhaps more important in ubiquitin recognition by the proteasome. A study performed 
by Lambertson et al (1999) showed that Rpn10 functions in collaboration with the UBA-
UBL domain protein, Rad23, in proteasomal degradation. Double deletion of the rpn10 and 
rad23 genes in yeast resulted in the accumulation of multi-ubiquitinated proteins and the 
stabilisation of proteolytic substrates, none of which were observed in the single deletion 
strains of either gene. Furthermore, it was shown that the introduction of mutant Rad23, 
lacking the UBL domain failed to rescue the phenotype of the double deletion strain, 
indicating that the interaction between Rad23 and the proteasome is of significant 
importance (Lambertson et al. 1999). The importance of extrinsic factors have been further 
substantiated by the fact that co-purification of ubiquitin chains with the proteasome are 
primarily dependent on the presence of UBA-UBL domain proteins (Elsasser et al. 2004). 
Additionally, it was shown that proteasomes from yeast strains lacking both Rad23 and 
Dsk2 presented a far greater defect in ubiquitin conjugation than what was observed in 
yeast strains lacking Rpn10 alone (Elsasser et al. 2004). In another study, triple deletion of  
Rad23, Dsk2 and Rpn10 showed a greater accumulation of ubiquitin conjugates than did 
any single or double deletion of the Rad23, Dsk2 and Rpn10 proteins, indicating a 
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collaborative role by all three proteins in ubiquitin recognition by the proteasome (Saeki et 
al. 2002).  
 
5.1.2 Regulatory role for UBA-UBL domain proteins in proteasomal degradation 
The significance of the UBA-ubiquitin and UBL-proteasome interactions of UBA-UBL 
domain proteins has been studied by numerous groups. There are various lines of 
evidence to show that UBA-UBL domain proteins function to regulate the degradation of 
ubiqutinated substrates by the proteasome.  
In yeast, the overexpression of the Rad23 protein led to an accumulation of ubiquitinated 
proteins, with an even greater accumulation observed when Rad23 containing a defective 
UBL domain was overexpressed (Hwang et al. 2005), suggesting a functional significance 
of the UBL domain. Interestingly, a loss of Rad23 function also led to similar findings 
(Lambertson et al. 1999). In a more detailed study, it was shown that overexpression of 
Rad23 led to a decrease in the ubiquitination of Rad4 (a Rad23 interacting protein), which 
subsequently resulted in an increase in Rad4 protein stability (Ortolan et al. 2004). In a 
similar manner, the overexpression of another UBA-UBL domain protein, Dsk2, has also 
been shown to result in the accumulation of ubiquitinated proteins (Funakoshi et al. 2002; 
Matiuhin et al. 2008). These findings therefore implicate a role for UBA-UBL domain 
proteins in regulating the degradation of ubiquitinated proteins. 
 
5.1.2.1 Human homologues of Rad23 and Dsk2 are involved in p53 degradation 
Human homologues of the yeast Rad23 protein, hHR23A and hHR23B (for Human 
Homologue of Rad23 A and B) were first identified in an attempt to isolate interacting 
proteins of the DNA repair factor, xeroderma pigmentosum-complementation group C (XP-
C, homologous to yeast Rad4) (Masutani et al. 1994). Initially, much of the research into 
hHR23A and hHR23B was on their role in the nucleotide excision repair (NER) pathway, 
through their interaction with the XP-C protein (Sugasawa et al. 1996; van der Spek et al. 
1996; Sugasawa et al. 1997). However, a search of the literature reveals an increasing 
interest, in the ubiquitin-associated aspect of the hHR23 proteins. A study by Kumar et al 
(1997) was the first to implicate the hHR23 proteins in the ubiquitin-mediated protein 
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degradation of a substrate protein, in this case, the tumor suppressor protein, p53. Using 
the yeast two-hybrid system, one of the human homologues of Rad23, hHR23A, was 
isolated as an interacting substrate to the E6-associated protein (E6AP) (Kumar et al. 
1997). E6AP functions as an E3-ubiquitin protein ligase in association with the E6 
oncoprotein of human papilloma virus type 16 (HPV) in the ubiquitination of p53 (Scheffner 
et al. 1990). Subsequent studies then showed that both hHR23A and hHR23B are able to 
interact with E6AP and are factors for the E6AP-mediated ubiquitination and consequent 
degradation of p53, a process that was found to be dependent on the UBL-domain of the 
proteins (Kumar et al. 1999).  In a similar manner, hPLIC-1 and hPLIC-2 (human protein 
linking IAP with cytoskeleton-1 and -2, human homologues of the yeast Dsk2) have also 
been identified as interacting proteins of E6AP (Kleijnen et al. 2000). 
A regulatory role for hHR23 and hPLIC proteins in the proteasomal degradation of p53 has 
been proposed (Kleijnen et al. 2000; Glockzin et al. 2003). In two independent reports, the 
over-expression of hHR23 proteins led to an increase in abundance of p53 caused by the 
accumulation of ubiquitinated p53 species (Glockzin et al. 2003; Brignone et al. 2004). The 
UBA domain of hHR23 proteins (hHR23A and hHR23B) was shown to be required for p53 
to be stabilised in hHR23A and hHR23B over-expressing cells (Brignone et al. 2004). On 
the other hand, siRNA-mediated depletion of hHR23A and hHR23B led to an acceleration 
of p53 degradation by the proteasome (Brignone et al. 2004). In another report, however, it 
has been shown that down-regulation of hHR23A led to an accumulation of p53 (Glockzin 
et al. 2003). Despite the contradicting reports from different groups, a regulatory role for 
hHR23 in p53 degradation by the proteasome is evident. 
Based on these studies, a model for p53 regulation by hHR23 has been proposed. It was 
proposed that hHR23 binds to the proteasome through its UBL domain and aids in 
targetting ubiquitinated p53 for degradation. hHR23 that is not bound to the proteasome 
might then sequester and protect ubiquitinated p53 from degradation.  
The over-expression of both hPLIC-1 and hPLIC-2 can also result in the accumulation of 
p53 and an increase in its protein stability (Kleijnen et al. 2000). The same study also 
showed that other substrates of the ubiquitin-proteasome pathway can be stabilised in 
hPLIC overexpressing cell lines. The substrate IΚBα (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha), which is ubiquitinated by the SCF 
(Skp-Cullin-F-box containing complex) E3 ubiquitin ligase, undergoes rapid degradation 
by the proteasome (Yaron et al. 1998). Overexpression of hPLIC1 and hPLIC2 proteins 
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led to an increase in its stability which resulted in an accumulation of IΚBα (Kleijnen et al. 
2000). 
Through numerous studies, it is clear that UBA-UBL domain proteins, hHR23 and hPLIC 
are involved in the regulation of substrates targetted to the proteasome, through their 
associations with the ubiquitin-proteasome pathway. These major findings therefore 
suggest an additional means of regulation of the ubiquitin-proteasome pathway by UBA-
UBL domain proteins.  
 
5.1.3 UBA-UBL domain proteins – The “shuttle factor” hypothesis 
Bringing together a number of different factors: 1) the need for alternate ubiquitin receptors 
other than the proteasomal subunits Rpn10 and Rpn13, 2) the regulatory roles of UBA-
UBL domain proteins through their interaction with ubiquitin and the proteasome, and 3) 
the ability for UBA-UBL domain proteins to interact with ubiquitin and the proteasome, it 
has been hypothesised that UBA-UBL domain proteins act as “shuttle factors” regulating 
the translocation of poly-ubiquitinated substrates to the proteasome for degradation. This 
model proposes that UBA-UBL domain proteins provide an intermediary scaffold between 




We hypothesised that hDDI2 plays a regulatory role in the ubiquitin-proteasome pathway 
by acting as an intermediate factor between the ubiquitination machinery and the 
proteasome. In order to investigate this, we have employed siRNA–mediated knockdown 
of hDDI2 in cells and studied the effect on the ubiquitin-proteasome pathway, while also 
investigating growth and viability in knockdown cells. The specific aims are: 
1. To investigate the role of hDDI2 in cell proliferation and survival after DNA 
damage. We studied cell growth and proliferation in hDDI2 knockdown cells and 
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compared them to controls using growth assays under normal conditions as well as 
DNA damaging conditions. 
2. To establish a role for hDDI2 in the ubiquitin-proteasome pathway. The effect on 
the expression levels of the tumour suppressor protein, p53, was studied in hDDI2 
knockdown cells. We also studied the effect on DNA-damage induced p53 stability in 
hDDI2 knockdown cells. 
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5.2 Results 
5.2.1 hDDI2 protein expression is not induced by DNA damage 
In yeast, the expression of Ddi1 is regulated under DNA damaging conditions (Liu et al. 
1997). The Ddi1 gene in yeast was found to be divergently transcribed along side another 
DNA damage inducible gene, Mag1, a 3-methyladenine DNA glycosylase, which functions 
to protect cells from killing by methylmethanesulfonate (MMS)-induced DNA replication 
blocks (Liu and Xiao 1997). Ddi1 and Mag1 were found to be induced by the same set of 
damaging agents such as MMS, ultraviolet (UV) radiation, 4-Nitroquinoline 1-oxide (4NQO) 
and hydroxyurea (HU) (Liu and Xiao 1997). 
Although the exact function of Ddi1 during DNA damage is not yet known, it has been 
suggested that it may be involved in the DNA damage signalling and repair pathway (Liu 
and Xiao 1997). To determine if the expression of hDDI2 is regulated by DNA damage, we 
examined expression levels of hDDI2 in cells after treatment with various DNA damaging 
agents. For this study, Neonatal Foreskin Fibroblast (NFF) cells were used because these 
are primary cells with less occurrence of endogenous DNA damage. To study hDDI2 
expression in DNA damage, NFF cells were subjected to ionising radiation (IR), ultraviolet 
radiation (UV) and hydroxyurea (HU), and cells were harvested at various time points after 
treatment. Cell lysates were then analysed by SDS-PAGE followed by western blotting 
using anti-DDI2 antibodies. Although our western blot analysis revealed a slight change in 
expression levels of hDDI2 protein after treatment with DNA damaging agents, we are not 
convinced, at this stage, that this is a significant change in expression levels (Figure 5.1). 
The expression of p53 was also examined using anti-p53 antibodies as a positive control 
marker for DNA damage. Our results for hDDI2 are in contrast to that shown for yeast 
Ddi1. From our study, it appears that hDDI2 and yeast Ddi1 may not share common 
factors that regulate their expression. The function of yeast Ddi1 in the context of DNA 
damage has yet to be determined. It is therefore premature to state whether Ddi1 in yeast 
or in mammals play a part in DNA damage and repair pathways. 
 




Figure 5.1 hDDI2 expression is not induced by DNA damage. 
Neonatal foreskin fibroblast cells were treated with ionising radiation (IR), ultraviolet (UV) 
rays and hydroxyurea (HU) at the indicated doses and cells were harvested at various time 
points post treatment. Cell extracts were then subjected to western blotting analysis using 
anti-DDI2. Levels of p53, a marker for DNA damage, were detected using anti-p53 
antibodies. GAPDH was used as a loading control.Values shown below the respective 
hDDI2 blot indicates hDDI2 levels as quantitated by densitometry (normalised to GAPDH; 
Values are in relative amount where band intensity at t=0 has been set to 1.00. The figure 
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5.2.2 Knockdown of hDDI2 leads to cell growth retardation and decreased cell 
survivability after DNA damage 
The use of RNA interference (RNAi) technology has emerged as a powerful molecular tool 
to study the function of a gene. To induce RNAi in our system, we employed specific 
siRNA against hDDI2 mRNA (refer to Materials and Methods and Chapter 3). Ddi1 in yeast 
has been shown to be involved in multiple cellular roles including cell cycle control and 
SNARE complex formation (Gabriely et al. 2008). In our studies, we used the 
xCELLigence system (Roche) to assess the phenotype of cells depleted of hDDI2. The 
xCELLigence platform provides a realtime system that assays for cell growth without the 
use of invasive labels in a 96 well plate format (refer to Methods and Materials). We 
assayed for overall cell growth in U2OS cells transfected with hDDI2 siRNA and compared 
them to control cells. In addition, we also looked at U2OS cells transfected with hHR23B 
siRNA as a control. hHR23B was chosen as a control because of its similarity to hDDI2 as 
a UBA-UBL domain protein. Additionally, there are reports on hHR23B depletion in cells 
and the effect on cell growth and survival after DNA damage treatment (Hsieh et al. 2005). 
Our studies showed that cells depleted of either hDDI2 and hHR23B showed a reduction 
in cell index, observed at approximately 40 hrs post-siRNA transfection which may 
correspond to a decrease in cell growth (Figure 5.2). 
Utilising the same system, we also investigated the effect of DNA damage on the 
knockdown of hDDI2. U2OS cells were transfected with siRNA against hDDI2, hHR23B 
and control siRNA. At 48 hrs post-transfection, cells were treated with a single dose of UV 
(10J/m2) and assayed for cell growth using the xCELLigence platform. We found that, 
following UV treatment, cells that were knocked down for hDDI2 and hHR23B had 
baseline cell indexes, which corresponded to either negative cell growth or total inhibition 
of overall cell growth (Blue and red lines, Figure 5.3). Control cells, on the other hand 
showed a baseline cell index for approximately 36 hrs post-UV treatment before showing a 
linear increase in cell index, indicating normal cell proliferation and division (Red line, 
Figure 5.3).    
 
  







Figure 5.2 hDDI2 depletion leads to decreased cell growth. 
U2OS cells were plated onto a 96 well E-plate and allowed to grow overnight. siRNA for 
hDDI2, hHR23B and control siRNA were transfected directly onto the E-plate and cells 
were incubated at 37°C in a tissue culture incubator. Cell growth as calculated by the cell 
index was measured in real-time using the xCELLigence platform. Cell indexes were 
normalised to the time point when transfection of siRNA was performed (0 hr). The graph 
shows the average of three wells, error bars indicate standard deviation. The experiment 
was repeated 3 times showing a consistent trend in decreased cell growth in knockdown 
cells compared to negative controls. 
  









Figure 5.3 hDDI2 is essential for cell growth after UV treatment. 
U2OS cells grown in 6 well plates were transfected with control, hDDI2 or hHR23B siRNA. 
Twenty-four hrs post-transfection, cells were trypsinised and re-plated (in triplicate) into 96 
well E-plates in equal numbers and allowed to attach and grow overnight. The next day, 
cells were treated with UV (10J/m2). Cell growth as calculated by the cell index was 
measured in real-time using the xCELLigence platform. Cell indexes were normalised to 
the time point of UV treatment (0 hr, approx 48hrs post-siRNA transfection). The graph 
shows the average of three wells, error bars indicate standard deviation. The experiment 
was repeated 3 times showing a consistent trend in decreased cell growth in knockdown 
cells compared to negative controls. 
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To further assess the ability to survive for hDDI2 knockdown cells after DNA damage, we 
performed colony survival assays. Colony survival assays determine the ability of cells to 
proliferate and replicate resulting in the formation of colonies. U2OS cells were transfected 
with hDDI2, hHR23B and control siRNA. At 24 hrs post transfection, cells were counted 
and seeded at low density into individual wells in a 6-well plate format. Cells were then 
treated with increasing doses of UV (0 to 20J/m2) and were left to grow over a period of 10 
days to allow for colony formation (refer to Methods and Materials). Colonies for each cell 
type were counted and plotted as a graph (Figure 5.4). We found that survival rates were 
up to 90% lower in hDDI2 and hHR23B knockdown cells when compared to control cells 
indicating that the absence of hDDI2 or hHR23B renders cells more sensitive to DNA 
damage.  
Taken together, our results provide evidence that hDDI2 may be an important factor in the 
DNA damage pathway. The decrease in the ability of hDDI2 knockdown cells to survive 
also suggests that DNA repair activity may be hindered in the absence of hDDI2.   
  




Figure 5.4 hDDI2 is essential in cell colony forming assays 
hDDI2, hHR23B and control knockdown cells were plated in triplicate at low density onto 6 
well plates. Cells were allowed to attach and grow on plates overnight before treating with 
different doses of UV (0-20J/m2). After UV treatment, cells were left to grow for 10 days to 
allow for colony formation. Colonies (≥50cells) were then stained with Coomassie stain 
and counted. The percentage of survival was calculated and plotted on a log scale graph 
against the dose given (Upper panel). Error bars indicate standard deviation across the 
triplicate wells. A representation of colonies formed on the 6-well plate for each cell type 
and dose given is shown (Lower panel). 
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5.2.3 Knockdown of hDDI2 decreases p53 abundance and stability 
We investigated the role of hDDI2 in the ubiquitin-proteasome pathway by studying a well 
known proteasomal substrate, the tumour suppressor protein, p53. Our studies were 
performed in U2OS cells, because they express wild-type p53 that is effectively 
ubiquitinated and degraded through known components of the ubiquitin-proteasome 
pathway (Florenes et al. 1994). In assessing the role of hDDI2 in the ubiquitin-proteasome 
pathway, we employed siRNA-mediated knockdown of endogenous hDDI2 in U2OS cells 
and studied the effect on the level of p53 protein. U2OS cells were transfected in triplicate 
with either control siRNA or hDDI2 siRNA and harvested 72 hrs post-transfection. 
Additionally, we also transfected siRNA against another UBA-UBL domain protein, 
hHR23B, which has previously been shown to be implicated in p53 regulation through the 
ubiquitin-proteasome pathway (Glockzin et al. 2003; Brignone et al. 2004). From our 
studies, we found that in hDDI2 knockdown cells, levels of p53 were observed to be 49% 
lower compared to control cells (Figure 5.5). This trend could also be observed in hHR23B 
knockdown cells which showed a 63% decrease in p53 levels, corroborating earlier reports 
(Brignone et al. 2004). A double knockdown of hDDI2 and hHR23B in U2OS cells led to 
similar levels of p53 as in either knockdown alone, showing a 50% decrease in p53 levels 
compared to control cells. The differences between the groups did not reach statistical 
significance, possibly due to the small sample size. 
To further examine the mechanism of p53 accumulation in hDDI2 knockdown cells, the 
half-life of p53 was measured. We performed cycloheximide chase experiments on U2OS 
cells transfected with hDDI2 siRNA and compared them to control cells. Here, we show 
that knockdown of hDDI2 in U2OS cells led to a decrease in p53 half-life compared to 
control cells (Figure 5.6).  It was observed that as early as 30mins, hDDI2 knockdown cells 
showed an 88% decrease in p53 levels when compared to control cells. Taken with the 
finding that knockdown of hDDI2 led to a decrease in p53 protein levels, the accelerated 
half-life of p53 in hDDI2 knockdown cells further implicates a possible role of hDDI2 in the 
stability and therefore the degradation of p53. 
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Figure 5.5 Knockdown of hDDI2 leads to decreased levels of p53 expression in 
U2OS cells. 
A. U2OS cells were treated with negative control, hDDI2, hHR23B and a combination 
of hDDI2 and hHR23B siRNAs. Cells were harvested 72 hrs post-transfection and 
analysed for p53 protein levels by western blotting using anti-p53 antibodies. Cells 
were transfected in triplicate in separate wells. The Western blot shown is that of a 
representative experiment, similar results were obtained in at least 3 independent 
experiments. 
B. Levels of p53 were quantitated by densitometry and normalised to GAPDH. Data 
are shown as the mean and error bars represent standard deviation. Statistical 
comparisons performed using the Student t test did not show any significant 
statistical differences between the groups (p>0.05).  
A 
B 





Figure 5.6 hDDI2 depleted cells show accelerated p53 degradation. 
A. U2OS cells transfected with hDDI2 siRNA for 48 hrs were treated with 100µg/mL 
cycloheximide and cells were harvested at different timepoints to investigate the 
half life of p53. Cell extracts were then analysed for p53 levels. Western blot 
analysis showed that hDDI2 depleted cells had a shortened p53 half life 
compared to controls. GAPDH was used as a loading control. Western blot 
shown is that of a representative experiment, similar results were obtained in 2 
independent experiments. 
 
B. p53 blots were quantitated and normalised to GAPDH. p53 for each timepoint 
was expressed as a percentage of p53 level at the start of the experiment 
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5.2.4 UBL domain of hDDI2 is required for hDDI2 stabilisation 
We previously showed that the N-terminal UBL domain of hDDI2 is necessary for its 
interaction with the proteasome (refer to Chapter 4). We have also shown that hDDI2 is 
implicated in the preservation of p53 from degradation. To determine the significance of 
the UBL domain in this context, we overexpressed full length Myc-hDDI2FL and truncated 
Myc-hDDI2∆UBL in U2OS cells and analysed p53 expression levels. Cells were harvested 
48 hrs post-transfection and the expression of p53 protein was analysed by western 
blotting. Our results showed that p53 accumulates only when full length Myc-hDDI2FL and 
not when the truncated Myc-hDDI2∆UBL protein is expressed (Figure 5.7). Statistical 
comparisons using the Student t test almost reached significant statistical difference 
between the two groups (p=0.06).  
We also compared the half-life of p53 in both full length Myc-hDDI2 and truncated Myc-
hDDI2∆UBL expressing cells in a cycloheximide chase experiment. Here, we 
demonstrated that in full length Myc-hDDI2FL expressing cells, p53 showed a longer half-
life compared to the truncated Myc-hDDI2∆UBL expressing cells (Figure 5.8). At 4hrs post-
cycloheximide treatment, p53 in Myc-hDDI2FL expressing cells only decreased to 
approximately 40% of the original level compared to 80% in Myc-hDDI2∆UBL expressing 
cells. Given the ability of the UBL domain to interact with the proteasome, our results 
suggest that the UBL-proteasome interaction of hDDI2 may be required for the regulation 
of p53. 
  





Figure 5.7 Over-expression of full length Myc-hDDI2 and not the truncated Myc-
hDDI2UBL led to accumulation of p53. 
A. U2OS cells were transfected in triplicate with plasmids expressing Myc-hDDI2FL 
and Myc-hDDI2∆UBL. Cells were harvested 48 hrs post-transfection and analysed 
for p53 protein levels by western blotting using anti-p53 antibodies. Western blot 
shown is that of a representative experiment, similar results were obtained in 2 
independent experiments. 
B. p53 blots were quantitated and normalised to GAPDH. Data are shown as the 
mean; error bars represent standard deviation. Statistical comparisons were 
performed using the Student t-test and the difference in p53 between the two 









Figure 5.8 Overexpression of full length hDDI2 stabilises p53 expression. 
A. U2OS cells were transfected with plasmids expressing Myc-hDDI2FL or Myc-
hDDI2∆UBL for 48 hrs before being treated with cycloheximide. Cells were 
harvested at different timepoints to investigate the half life of p53. Cell extracts 
were then analysed for p53 levels by Western blotting. Western blot shown is 
that of a representative experiment, similar results were obtained in 2 
independent experiments. 
 
B. p53 blots were quantitated and normalised to GAPDH. p53 for each timepoint 
was expressed as a percentage of p53 levels at the start of the experiment 
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5.2.5 hDDI2 co-immunoprecipitates with p53 
Unlike other UBA-UBL domain proteins like hHR23A/B and hPLIC1/2, hDDI2 does not 
contain a C-terminal UBA domain (refer to chapter 3). It has been reported previously that 
both hHR23 and hPLIC proteins are able to interact with ubiquitinated substrates through 
their UBA domains (Kleijnen et al. 2000; Glockzin et al. 2003; Brignone et al. 2004; Ko et 
al. 2004). We showed in the previous chapter that hDDI2 has a putative UIM domain (refer 
to chapter 4). We also showed that hDDI2 is able to interact with ubiquitinated substrates 
possibly through its putative UIM domain. To follow up on the role hDDI2 plays in the 
regulation of p53 through the ubiquitin-proteasome pathway and to better understand the 
mechanism, we investigated the ability of hDDI2 to interact with p53. We performed co-
immunoprecipitation experiments to capture hDDI2 protein complexes in U2OS cells. As 
protein-protein interactions may be weak or transient, we inhibited proteasomal activity by 
treating cells with the proteasomal inhibitor, MG132. Western blot analysis of 
immunoprecipitated (IP) proteins revealed that endogenous p53 could be detected in the 
hDDI2 IP but not in the control IgG IP (p53 blot, lanes 3/4 and 7/8, Figure 5.9). 
Furthermore, the p53-hDDI2 interaction seemed to be stronger when U2OS cells were 
treated with MG132 (p53 blot, lanes 3 and 4, Figure 5.9). We also performed an IP with 
antibodies against the proteasomal subunit, hRPN13 as a positive control. As expected, 
p53 was detected in the hRPN13 IP (p53 blot, lanes 5 and 6, Figure 5.9), and this 
interaction was stabilised when cells were treated with MG132. Our findings showed that 
hDDI2 can interact with p53. We, however, note that the interaction between hDDI2 and 
hRPN13 in this experiment could only be visualised in the DDI2 blot through an RPN13 IP. 
No detectable hRPN13 bands were observed in the DDI2 IP lanes contrary to what was 
shown previously (Chapter 4.2.2). In this regard, we speculate that the interaction between 
hDDI2 and hRPN13 may only be transient. It is also possible that in the DDI2 IP, only a 
small proportion of the immunoprecipitated hDDI2 protein interacted with hRPN13, and 
therefore, any interacting hRPN13 could not easily be detected through Western blotting. 
Nevertheless, our findings taken together, implicate the existence of hDDI2, p53 and 
hRPN13 in the same complex. This may suggest that the interaction between hDDI2 and 
p53 takes place at the site of the proteasome. 
  








Figure 5.9 hDDI2 interacts with p53 in U2OS cells 
U2OS cells that were treated with either vehicle or MG132 were lysed and  
immunoprecipitated with anti-DDI2, anti-RPN13 and non-specific IgG. Western blot 
analysis using anti-DDI2, anti-RPN13 and anti-p53 antibodies showed that p53 can be co-
immunoprecipiated by anti-DDI2 and anti-RPN13. The interactions appear stronger in 
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5.2.6 Knockdown of hDDI2 abrogates p53 stabilisation during DNA damage 
p53 functions as a transcription factor activating downstream genes in the pathway in 
response to cellular stress (Prives and Hall 1999; Appella and Anderson 2001). In the 
event of cellular stress such as DNA damage, p53 is stabilised which allows the activation 
of downstream genes such as p21 and Bax, which signal for cell cycle arrest or apoptosis, 
respectively. We have shown that hDDI2 regulates p53 stability in unstressed cells. Here, 
we investigated a role for hDDI2 in the regulation of p53 after DNA damage. U2OS cells 
transfected with either control or hDDI2 siRNA, were treated with 50J/m2 ultraviolet (UV) 
radiation, 48 hrs post-transfection and cells were harvested at set time-points after UV 
treatment. Cells at each time-point were then analysed by western blotting and assessed 
for p53 expression in order to determine the kinetics of p53 activation after DNA damage. 
Western blot analysis of p53 showed that when compared to control cells, hDDI2 
knockdown cells showed a marked decrease in p53 stabilisation across the time-points 
after UV treatment (Figure 5.10). This suggests an important role for hDDI2 in maintaining 









Figure 5.10 p53 induction after UV treatment is abrogated in hDDI2 depleted cells 
A. U2OS cells were transfected with control and hDDI2 siRNA. Cells were treated with 
a dose of UV (50J/m2)72 hrs post siRNA transfection, and harvested at various 
time-points (0-8 hrs) after UV treatment. Cell lysates were analysed by western blot 
analysis for p53, hDDI2 and GAPDH as a loading control. Western blot shown is 
that of a representative experiment, similar results were obtained in >3  
independent experiments. 
B. p53 levels were normalised to GAPDH and plotted on a graph against time after UV 
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5.3 Discussion 
5.3.1 hDDI2 plays an important role in cell proliferation and survival 
The yeast homologue Ddi1 was first identified as a DNA damage inducible gene (Liu and 
Xiao 1997). In this chapter, we analysed the response of hDDI2 to various DNA damaging 
conditions. Although the yeast and human homologues share significant sequence 
similarities, our studies have shown that their expression in response to DNA damaging 
conditions differs. Genetic studies in yeast have revealed the promoter region upstream of 
the yeast Ddi1 gene that is involved in its DNA damage responsiveness together with 
another known gene induced by DNA damage, Mag1 (Liu and Xiao 1997). Extensive 
research has shown that although there is a strong conservation in the genetic makeup of 
yeast and human, the regulatory mechanism of DNA damage induction in humans has 
evolved significantly to take into account the more complex biology present in humans 
(Bergmann et al. 2004). In our studies, however, we show that the expression of human 
DDI2 protein does not respond to the same set of stimuli (IR, UV or HU) that induces the 
expression of its yeast counterpart. To study hDDI2 expression in the context of DNA 
damage, a more thorough investigation looking at the promoter region of hDDI2 would be 
needed.  
In our quest to understand the function of hDDI2, we took a loss-of-function approach and 
studied the effect of hDDI2 knockdown. First, we investigated the ability of hDDI2 
knockdown cells to proliferate under normal and DNA damaging conditions. Using two 
separate assays: a clonogenic assay and a real time cell analyser assay, we found that 
hDDI2 knockdown cells showed a decrease in overall cell growth and a reduced survival 
rate after DNA damage. As a control we also performed knockdown of a similar protein 
from the UBA-UBL protein family, hHR23B. A similar effect on cell growth and survival was 
also observed in hHR23B knockdown cells. Although further investigation is still required, 
our preliminary findings implicate both hDDI2 and hHR23B in the control and regulation of 
the cell cycle.  
In yeast studies, there are several lines of evidence that support a role for Ddi1 together 
with Rad23p to function in cell cycle progression. The progression of the cell cycle from 
metaphase to anaphase is dependent on the efficient degradation of its inhibitor Pds1p 
(Cohen-Fix et al. 1996; Cohen-Fix and Koshland 1997; Cohen-Fix and Koshland 1997). 
Before the onset of anaphase, Pds1p is bound to another protein, Esp1p, and this 
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interaction inhibits the anaphase-promoting activity of Esp1p (Ciosk et al. 1998). For 
anaphase to occur, Pds1p has to firstly be ubiquitinated by the E3 ubiquitin-protein ligase, 
APC. This then leads to the recognition and subsequent degradation of Pds1p by the 26S 
proteasome which relieves and frees Esp1p, allowing for it to function in the onset of 
anaphase. A role for Ddi1 and Rad23p in the regulation of Pds1p has been previously 
reported (Clarke et al. 2001). As was discussed earlier in chapter 3, both Ddi1 and Rad23p 
were found to be dosage suppressors to the temperature sensitive mutant pds1-128 and 
that their C-terminal UBA domains play a crucial role in the stabilisation of Pds1p (Clarke 
et al. 2001). It was suggested that Ddi1 and Rad23p, through their UBA domains, play a 
regulatory role in the control of anaphase progression by being able to recognise 
ubiquitinated Pds1p and thereby preventing it from being targeted for degradation by the 
proteasome. In agreement with this, it was further demonstrated that yeast strains 
expressing Rad23p and Ddi1 with mutations in their UBA domains, are partially defective 
in the S-phase control checkpoint, as mutant strains showed increased sensitivity to HU 
treatment (which induces early S-phase replication block). A deregulation of Pds1p 
proteolysis during anaphase may have been the underlying cause of the HU sensitivity as 
rad23∆Uba2 ddi1∆uba did not show sensitivity to nocodazole or gamma irradiation, neither of 
which activates S phase checkpoint control. 
A novel role for Ddi1 in the regulation of the SCF complex has also been established 
(Ivantsiv et al. 2006). SCF complexes (made up of Skp1-Cul1-F-box protein + Roc1/Rbx1) 
are E3 ubiquitin-protein ligases that are involved in the ubiquitination and proteolysis of 
many core components of the cell cycle machinery (Skaar and Pagano 2009). Ivantsiv et 
al. (2006) provided evidence that Ddi1 exerts its function in the regulation of SCF 
complexes through its interaction with the F-box protein, Ufo1. Ddi1 interacts with the UIM 
domain of Ufo1 which is required for its regulation by Ddi1 (Ivantsiv et al. 2006). A 
truncation of the Ufo1 protein at the UIM domain renders the protein highly stable (Ivantsiv 
et al. 2006).  Concurrently, the same study also found that wildtype Ufo1 can be stabilised 
in the absence of Ddi1. F-box proteins, such as Ufo1, are recruited to SCF complexes and 
are specific in their recruitment of substrates for ubiquitination and subsequent 
degradation by the proteasome (Cardozo and Pagano 2004). The SCFUfo1 specifically 
ubiquitinates the Ho endonuclease and promotes its degradation (Kaplun et al. 2005; 
Kaplun et al. 2006). It was further shown that mutation in the UIM domain of Ufo1 does not 
hinder the ubiquitination of Ho nor does it affect its degradation by the proteasome, 
indicating that the function of SCFUfo1 is maintained even in the absence of its UIM domain 
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(Ivantsiv et al. 2006).  In retrospect, however, the highly stable Ufo1∆UIM fails to be 
recognised by Ddi1 and thus its turnover cannot be regulated by Ddi1. Ubiquitination 
through the SCF pathway is a highly regulated process. Core components of the SCF 
complex (Skp1 and Cul1) are constantly being recruited together with other 
interchangeable F-box proteins to ubiquitinate and facilitate the degradation of specific 
substrates. In the highly stable SCFUfo1∆UIM, where Ufo1∆UIM cannot be regulated, the 
ability of the core components of the SCF complex (Skp1 and Cul1) to form complexes 
with other F box proteins is therefore compromised. This cumulative effect can be 
observed in Ufo1∆UIM expressing cells, where substrates of other SCF complexes have 
been shown to accumulate; such as Cln2 (ubiquitinated by SCFGrr1) and Sic1 
(ubiquitinated by SCFCdc4) (Ivantsiv et al. 2006). This demonstrated that the turnover of 
Ufo1 is therefore, critical in the proper functioning of the SCF ubiquitination pathway, as 
core components of the SCF complex (Skp1 and Cul1) are tightly regulated and recruited 
to form SCF complexes with other interchangeable F-box proteins.  
Another interesting phenotype presented in Ufo1∆UIM expressing cells was the 
interference of cell cycle progression (Ivantsiv et al. 2006).  When Ufo1 was 
overexpressed in ∆ddi1 cells, cell cycle arrest could be observed (Ivantsiv et al. 2006).  A 
common denominator in both instances was the dysregulation of Ufo1, which in turn led to 
the inhibition of the SCF pathway of substrate degradation. Through these studies, it is 
apparent that Ddi1 plays an indirect role in maintaining the function of SCF machinery 
through its ability to regulate the turnover of Ufo1. 
In yeast, the collaborative role for Ddi1 and Rad23p in cell cycle progression is evident. 
The rad23∆ddi1∆ double deletion strain showed accumulation of cells in the G2/M cell 
cycle phase while single deletion strains showed no significant difference in cell cycle 
distribution (Diaz-Martinez et al. 2006). It was also observed that while Ddi1 works 
collaboratively with Rad23p, no evidence could be found for a functional role for Ddi1 with 
another UBA-UBL protein, Dsk2p. 
Based on our findings, hDDI2 plays a crucial role in cell survival after DNA damage. A role 
for hHR23B in the nucleotide excision repair (NER) pathway has already been established 
(Sugasawa et al. 1998; Hsieh et al. 2005). It acts primarily through its interaction and 
regulation of the NER repair factor, XPC (van der Spek et al. 1996; Li et al. 1997; Ortolan 
et al. 2004). In our studies, we used hHR23B knockdown cells as a positive control, mainly 
because of hHR23B’s similarity to hDDI2 as a UBA-UBL domain protein, but also because 
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a link to the DNA damage pathway has already been shown. Whether or not hDDI2 can 
functionally interact with hHR23B is yet to be established. Future work will investigate 
whether hDDI2 and hHR23B play similar roles in DNA damage repair.  
 
5.3.2 hDDI2 regulates post-translational p53 expression through the ubiquitin-
proteasome pathway 
The interaction of hDDI2 with both the proteasome and ubiquitinated proteins provides an 
attractive proposition for a role in the ubiquitin-proteasome pathway. In line with this 
hypothesis, we studied the effect of knocking down hDDI2 on a known substrate of the 
ubiquitin-proteasome pathway, p53. We found that knocking down hDDI2 consistently led 
to a dysregulation of p53 levels and that the destabilisation of p53 was caused by its rapid 
degradation. In our studies, hHR23B knockdown cells were used as positive controls. This 
was based this on findings that have been previously reported in the literature for hHR23B 
(Glockzin et al. 2003; Brignone et al. 2004; Kaur et al. 2007). Glockzin et al. (2003) and 
Brignone et al. (2004) proposed that hHR23 proteins (both hHR23A and hHR23B) can act 
as bridges between ubiquitinated p53 and the proteasome, depending on the levels of 
cellular hHR23 proteins. Evidence from both studies showed that during events where 
hHR23 proteins are in abundance, there is an excess binding of hHR23 proteins to the 
proteasome through their UBL domain. Likewise, separate hHR23 molecules also bind 
ubiquitinated p53 through their UBA domains. Since, the complex of p53-hHR23-26S 
proteasome is broken up by the excess hHR23 proteins, ubiquitinated p53 is sequestered 
from docking the proteasome for degradation, causing it to be stabilised. On the other 
hand, when hHR23 proteins are in low abundance, hHR23 proteins, through both their 
UBA and UBL domains can simultaneously interact with ubiquitinated p53 and the 
proteasome, thus facilitating the docking of ubiquitinated p53 to the proteasome and 
allowing for degradation.  
Based on our experiments, we believe that hDDI2 can function at the same level as 
hHR23 proteins in the regulation of p53 degradation. In the absence of endogenous 
hDDI2, the rate of p53 degradation is accelerated, which may be due to the absence of an 
hDDI2 inhibitory effect possibly caused by the sequestration of p53 docking sites on the 
proteasome. In studies concerning the knockdown of hHR23 proteins, there has been 
mixed results reported for its effect on p53 levels. While Glockzin et al (2003) reported that 
the downregulation of hHR23 in primary cells resulted in the accumulation of p53, 
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Brignone et al. (2004) showed that the depletion of hHR23 proteins led to the 
destabilisation of p53. Going by the hypothesis of a dual role for hHR23, results from both 
groups may actually corroborate each other, and that the regulation of p53 in cells may 
well depend on the cellular levels of hHR23 proteins in comparison to other components of 
the degradation pathway.  
In our studies, we performed a double knockdown of hDDI2 and hHR23B, which did not 
further reduce the levels of p53 as compared to hDDI2 or hHR23B knockdown alone. We 
took this as an indication that hDDI2 and hHR23 may act on p53 at the same level of 
regulation and not up or downstream of one another. It may well be that hDDI2 and 
hHR23B act in a redundant manner with each other in the regulation of p53 degradation. A 
collaborative role for both hDDI2 and hHR23B, however, cannot be ruled out. The study 
performed by Brignone et al. (2004), however, showed that double knockdown of hHR23A 
and hHR23B was more potent in the reduction of p53 levels compared to either 
knockdown alone. Unfortunately, whether this effect was statistically significant was not 
addressed by the study. Instead, the study took to the notion that hHR23A and hHR23B 
may both act interchangeably in the regulation of p53. 
Given our results, it is of interest to determine how hDDI2 fits into the pathway with other 
UBA-UBL proteins. Another UBA-UBL protein, hPLIC, has also been shown to play a 
regulatory role in p53 degradation (Kleijnen et al. 2000). In the study, Kleijnen et al (2000) 
showed that the overexpression of hPLIC proteins resulted in the stability of p53. 
Moreover, it was shown that it was the association between hPLIC and p53 that inhibited 
the degradation of p53 rather than the association between hPLIC and the proteasome as 
overexpression of the N-terminal fragment of the hPLIC protein (containing the UBL 
domain but lacking the UBA domain) did not interfere with the degradation of p53.  
In contrast to the hPLIC study by Kleijnen et al (2000), our studies showed that the UBL 
domain of hDDI2 is important in event leading to the stability of p53. p53 levels 
accumulated and showed an increase in half-life only when full length Myc-hDDI2 was 
over-expressed and not when the truncated form, Myc-hDDI2∆UBL, was over-expressed. 
Based on this, it can be concluded that an interaction with the proteasome (which is 
governed by the UBL domain) may be essential for an inhibitory role played by over-
expressed hDDI2. The inability of the truncated Myc-hDDI2∆UBL to interact with the 
proteasome may be a factor that led to our observation. It could be due to its 
incompetency to sequester ubiquitinated p53 from being localised to the proteasome for 
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degradation. Taking our findings into account, it would also be of interest to investigate the 
complimentary roles hDDI2 and other UBA-UBL domain proteins may have in the 
regulation of p53. 
 
5.3.3 hDDI2 is present in the same complex as p53  
To further strengthen our case, we also showed that using co-immunoprecipitation 
techniques, hDDI2 can be present in the same complex as p53. To regulate p53 
degradation, hDDI2 would need to interact with p53. We propose that hDDI2, through its 
putative UIM domain, interacts with ubiquitinated p53. On the same note, we showed in 
the previous chapter that hDDI2 can interact with ubiquitinated proteins (refer to Chapter 
4). Our finding that hDDI2 and p53 can exist in the same complex is in agreement with a 
functional role for hDDI2 in the regulation of p53 degradation. Furthermore, we showed 
that hDDI2 may exist in the same complex as hRPN13 and p53. Also of interest is the fact 
that in our co-immunoprecipitation experiments, treatment of the cells with the proteasomal 
inhibitor MG132 prior to carrying out the immunoprecipitation experiment strengthens the 
interaction between hDDI2, p53 and hRPN13. This is indicative that inhibition of 
proteasomal activity may be important to the interaction between these three proteins.. 
Taken together, this suggests that the p53-hDDI2 interaction takes place at the site of the 
proteasome which strengthens the notion of hDDI2 as a “shuttle factor”. Future studies to 
look at the exact domains involved in these interactions may prove useful. 
 
5.3.4 p53 response to UV is abrogated in hDDI2 knockdown cells 
In addition to showing that hDDI2 regulates the degradation of p53, we also showed that 
hDDI2 is important in maintaining its stability after DNA damage. In the absence of hDDI2 
and upon DNA damage induction, we found that the cellular response to p53 was 
abrogated. Normal wildtype cells responds to DNA damage by stabilizing p53 and 
inhibiting its degradation. Activated p53 would then signal for the induction of downstream 
genes such as p21 and Bax, which would induce for cell cycle arrest or apoptosis, 
respectively. In the absence of hDDI2, however, the stabilization of p53 is affected. In 
other words, when hDDI2 is absent, p53 continues to be degraded instead of being 
stabilized due to DNA damage. We reason that this is caused by the absence of hDDI2. 
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This is in line with what we have shown in section 5.2.3 that silencing of hDDI2 leads to an 
increase in p53 degradation.  
Earlier, we proposed that hDDI2 and hHR23B act in a similar manner in the regulation of 
p53 degradation. Our results here further emphasise this idea. Our results also 
substantiate findings from another report by Kaur et al (2007). In that study, it was found 
that treatment of hHR23B knockdown cells with DNA damage attenuated p53 stabilisation, 
similar to what we observed in hDDI2 knockdown cells.  
Although it cannot be ruled out that other substrates may also be regulated by hDDI2 and 
its related proteins, our findings in this chapter corroborates well with the notion that the 




Through work in this chapter, we have established a novel regulatory role for hDDI2 in the 
ubiquitin-proteasome pathway.  In addition, we also showed that hDDI2 is essential for cell 
proliferation and survival after DNA damage. Specifically, we looked at the regulation of 
p53 by the ubiquitin-proteasome pathway. Indeed we found that hDDI2 functions as a 
mediator between the ubiquitination machinery and the proteasome, and acts either to 
inhibit or promote its degradation, depending on the cellular levels of hDDI2 compared to 







   139 
 
  
   140 
 
Chapter 6 Identification of hDDI2 interacting proteins 
6.1 Introduction 
In the previous chapter, we showed a role for hDDI2 in the regulation of the tumour 
suppressor protein, p53, through the ubiquitin-proteasome pathway. hDDI2 shares much 
homology with its yeast counterpart Ddi1, particularly in the UBL and RVP domain regions 
(refer to chapter 3 and 4), indicating the functional importance of these regions. Although 
there has been limited literature on Ddi1 compared to other similar proteins such as Rad23 
and Dsk2, it has been suggested that Ddi1 functions in a similar way to other known UBA-
UBL domain proteins, as a proteasomal “shuttle factor” involved in translocating 
ubiquitinated proteins to the proteasome for degradation (Clarke et al. 2001; Saeki et al. 
2002; Diaz-Martinez et al. 2006). Ddi1, through its multiple domains has been implicated in 
a variety of cellular roles (Gabriely et al. 2008). Amongst the other known UBA-UBL 
domain proteins, Dsk2 and Rad23, Ddi1 has been the least studied. Based on its similar 
homology with Ddi1, hDDI2 is hypothesised to be involved in similar cellular roles.  
The function of a novel protein can be studied through assigning it into the functional 
context of its interacting proteins or “molecular environment” (Bauer and Kuster 2003). The 
study of protein complexes at the proteomic level has been greatly advanced in recent 
times by the new technological platforms which have become available.  
One common approach used by researchers in identifying protein complexes is the use of 
affinity chromatography using immunoprecipitation techniques to isolate protein complexes 
followed by western blotting or mass spectrometry to identify novel interacting partners. 
Once a protein complex is isolated, proteins that have been captured can then be 
identified through mass spectrometry. Mass spectrometry has proven to be an important 
tool for protein identification, due to advances in the speed and sensitivity in sequencing 
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6.1.1 Aims 
In order to elucidate the function of hDDI2, we investigated the interacting partners of 
hDDI2. These may provide an insight into the pathways that hDDI2 is involved in, and 
ultimately its role and function within these pathways.  The specific aims are: 
1. To isolate DDI2 complexes from U2OS cell lysates and mouse liver 
homogenates. Large scale IPs were performed using anti-DDI2 on U2OS cell 
lysates and mouse liver homogenates to isolate DDI2 complexes. The presence of 
immunoprecipitated proteins was confirmed by SDS-PAGE gel analysis.  
 
2. To identify DDI2 interacting proteins through mass spectrometry. Using Liquid 
Chromatography – tandem mass spectrometry (LC-MS/MS), protein bands from IP 
gels were identified. Peptides were then matched against protein databases to 
identify proteins that are potential novel DDI2 interacting partners. From the list of 
identified proteins, highly probable proteins were picked and validated through 





   142 
 
6.2 Results 
6.2.1 Identification of novel DDI2 interacting proteins 
To identify novel hDDI2 interacting proteins, hDDI2 complexes were isolated from U2OS 
cells stably expressing Myc-tagged hDDI2 by immunoprecipitation using anti-DDI2 
antibodies that were cross-linked to protein G Sepharose beads. Additionally, we also 
investigated the interacting proteins of the mouse homologue, mDdi2, through a DDI2 IP 
from mouse liver tissue. Before DDI2 IPs were performed, mouse liver homogenates 
obtained from a normal C57BL6 mouse were fractionated into nuclear and cytoplasmic 
fractions. Western blotting using anti-DDI2 antibodies confirmed the expression of mDdi2 
in both the nuclear and cytoplasmic fractions (Figure 6.1A). For each DDI2 IP, a parallel IP 
using non-specific IgG was also performed as a negative control. 
DDI2 and IgG IPs from mouse nuclear fractions, mouse cytoplasmic fractions and U2OS 
cells were then separated by SDS-PAGE, followed by Coomassie Blue staining to 
visualise protein bands (Figure 6.2). In all three DDI2 IPs, a band of approximately 50kDa 
in size (marked by asterix in Figure 6.2) could be visualised that was not present in any of 
the IgG IPs. This band is presumably the DDI2 protein pulled down through the DDI2 IPs. 
To confirm this, we performed western blotting using anti-DDI2 antibodies on all three sets 
of IPs (Figure 6.1B). 
In our DDI2 IPs, we observed bands of high and low molecular weight that appeared to be 
specifically in the DDI2 IPs (indicated by arrows, Figure 6.2) and not in any of the IgG IPs. 
These observed bands are therefore potential DDI2 interacting proteins pulled down in 
complexes by the DDI2 antibody. To identify these putative DDI2 interacting proteins, each 
IP lane (DDI2 IPs and IgG IPs) were excised into 15 fragments, excluding the IgG heavy 
chain and light chain (as indicated in Figure 6.2), trypsin digested and analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
 
  






Figure 6.1 Western blotting of mouse liver fractions and IPs  
A. Mouse liver homogenates were fractionated into the cytoplasmic, nuclear 
and insoluble fractions. Equal amounts of each fraction were loaded onto a 
gel and western blotted with anti-DDI2. 
B. DDI2 and IgG IPs performed on mouse liver nuclear and cytoplasmic 
fractions and U2OS Myc-hDDI2 cell lysates were loaded onto a gel and 
DDI2 protein detected by western blot analysis using anti-DDI2. 
A 
B 




Figure 6.2. DDI2 IPs to identify interacting proteins in U2OS Myc-hDDI2 cells and 
mouse liver nuclear and cytoplasmic homogenates. 
U2OS Myc-hDDI2 lysates and mouse liver nuclear and cytoplasmic homogenates were 
immunoprecipitated using anti-DDI2 and non-specific IgG (as a negative control) cross-
linked to Protein G Sepharose beads. Immunoprecipitated proteins were then loaded onto 
an SDS-PAGE gel and stained with SimplyBlue Safe Stain (Invitrogen) to visualise protein 
bands. Arrows marked with an asterix are predicted DDI2 bands. Unmarked arrows 
indicate bands present in DDI2 IPs but not IgG IPs. The heavy chain and light chain of IgG 
are indicated.  
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6.2.2 Mass spectrometry identification of proteins 
The mass spectra obtained were analysed by three algorithms: SEQUEST 
(BioworksBrowser 3.3.1 SP1, Thermo Finnigan), MASCOT (Matric Science) and X! 
tandem (Scaffold, proteomeScience). Sequenced peptides were then matched against the 
human and mouse International Protein Index (IPI) database. Fixed modification of 
carbamidomethylation at C (Cysteine) and variable modification of oxidation at M 
(Methionine) and phosphorylation at ST (Serine, Threonine) were also taken into account. 
Identified proteins were considered to be significant when represented in all the three 
algorithms. Proteins that were identified through the non-specific IgG IPs were treated as 
non-specific pull downs and disregarded from our analysis.  
Through LC-MS/MS we have confirmed the identification of the DDI2 protein in all three 
DDI2 IPs with sequence coverage of 72%, 64% and 84% in mouse liver nuclear fraction, 
cytoplasmic fraction and U2OS Myc-hDDI2 cells, respectively. In our analysis, we 
identified a list of potential interacting proteins for DDI2. The data in tables 6.1, 6.2 and 6.3 
shows a summary of details of proteins identified through mass spectrometry for all three 
DDI2 IPs.  
In all three DDI2 IPs, subunits of the 19S RP proteasomal complex were identified as 
interacting proteins, strengthening our notion of DDI2 as a proteasome interacting protein. 
Specifically, four proteins were positively identified in all three DDI2 IPs (Table 6.4), two of 
them being proteasomal subunits, Rpn2 and Rpn7 while the other two being the ubiquitin 
precursor, UBA52, and a less well characterised protein, Ahnak2. The identification of the 
same proteins across different DDI2 IPs indicates that these proteins are consistently 
pulled down in complex with DDI2, and are therefore more likely to be interacting proteins.  
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Ddi2 - DNA damage inducible 
protein 2 
63003917 45 kDa 28 34 
Uba52 - Ubiquitin-60S ribosomal 
protein L40 
9845265 15 kDa 2 20 
Ahnak2 - Nucleoprotein 2 309272904 183 kDa 6 2 
Nudt21 - Cleavage and 
polyadenylation specificity factor 
subunit 5 
13386106 26 kDa 8 33 
Decr2 - 2,4-dienoyl-CoA reductase 
(NADPH) activity 
6753622 31 kDa 7 33 
Mettl7b - Methyltransferase activity 27229118 28 kDa 2 13 
Psmd7 - 26S Proteasome non-
ATPase regulatory subunit 7 
(Rpn7) 
6754724 37 kDa 1 4 
Psmd2 - 26S Proteasome non-
ATPase regulatory subunit 2 
(Rpn2) 
19882201 100 kDa 2 5 
Psmd3 - 26S  Proteasome non-
ATPase regulatory subunit 3 
(Rpn3) 
19705424 61 kDa 3 6 
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Table 6.2 Summary of mass spectrometry data from DDI2 IP performed in the 














Ddi2, DNA damage inducible 
protein 2 
63003917 45 kDa 22 64 
Atp5b, ATP synthase subunit beta, 
mitochondrial precursor 
31980648 56 kDa 25 63 
Dbt, Lipoamide acyltransferase 
component of branched-chain 
alpha-keto acid dehydrogenase 
complex, mitochondrial precursor 
170172520 53 kDa 24 49 
Hsd17b4, Peroxisomal 
multifunctional enzyme type 2 
31982273 79 kDa 28 53 
Ahnak2, AHNAK nucleoprotein 2 309272904 341 kDa 10 6 
Bckdha, 2-oxoisovalerate 
dehydrogenase subunit alpha, 
mitochondrial 
183396774 51 kDa 21 59 
Psmd1, 26S Proteasome non-
ATPase regulatory subunit 1 
(Rpn1) 
74315975 106 kDa 1 2 
Bckdhb, Isoform 2 of 2- 
oxoisovalerate  dehydrogenase  
subunit beta, mitochondrial 
40353220 36 kDa 16 54 
Hnrnpul1, Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 
21450323 96 kDa 19 30 
Uba52,  Ubiquitin-60S ribosomal 
protein L40 
9845265 15 kDa 3 27 
Adarb1, Isoform 2 of double-
stranded RNA-specific editase 1 




118403322 45 kDa 12 38 
Znfx1 - Zinc finger, NFX1-type 
containing 1 
123240391 119 kDa 2 2 
Psmc2 -  26S Proteasome ATPase 
subunit 2 (Rpn2) 
33859604 53 kDa 1 2 
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Table 6.3 Summary of mass spectrometry data from DDI2 IP performed in the 













Ddi2 - DNA damage inducible 
protein 2 
63003917 45 kDa 35 72 
Atp5b - ATP synthase subunit beta, 
mitochondrial precursor 
31980648 56 kDa 13 36 
Dbt -Lipoamide acyltransferase 
component of branched-chain 
alpha-keto acid dehydrogenase 
complex, mitochondrial precursor 
170172520 53 kDa 13 34 
Hsd17b4 - Peroxisomal 
multifunctional enzyme type 2 
31982273 79 kDa 29 54 
Ahnak2 - AHNAK nucleoprotein 2 309272904 341 kDa 11 6 
Bckdha - 2-oxoisovalerate 
dehydrogenase subunit alpha, 
mitochondrial 
183396774 51 kDa 0.04 15 
Psmd1 - 26S Proteasome non-
ATPase regulatory subunit 1 (Rpn1) 
74315975 106 kDa 11 18 
Pzp - Alpha-2-macroglobulin 
precursor 
110347469 167 kDa 38 36 
Bckdhb - Isoform 2 of 2-
oxoisovalerate dehydrogenase 
subunit beta, mitochondrial 
precursor 
40353220 36 kDa 3 14 
Uba52 -  Ubiquitin-60S ribosomal 
protein L40 
9845265 15 kDa 4 34 
Psmd2 - 26S proteasome non-
ATPase regulatory subunit 2 (Rpn2) 
19882201 100 kDa 16 24 
Znfx1 -  Zinc finger, NFX1-type 
containing 1 
123240391 119 kDa 4 5 
Ndrg2 - Isoform 1 of protein NDRG2 7305305 41 kDa 7 37 
Ddb1 - DNA damage-binding 
protein 1 
 
7657011 127 kDa 4 6 
Psmc6 - 26S Protease regulatory 
subunit 10B Rpt4 
 
27754103 44 kDa 3 10 








Psmd11 - 26S proteasome non-
ATPase regulatory subunit 11 
(Rpn11) 
134053905 47 kDa 3 9 
Psmc2 -  26S Proteasome ATPase 
subunit 2 (Rpt2) 
33859604 53 kDa 2 4 
Psmd6 - 26S Proteasome non-
ATPase regulatory subunit 6 (Rpn6) 
46049022 46 kDa 4 9 
Vps26a - Isoform 2 of vacuolar 
protein sorting-associated protein 
26A 
164518904 42 kDa 2 7 
Psmd7 - 26S Proteasome non-
ATPase regulatory subunit 7 (Rpn7) 
6754724 37 kDa 2 8 












Table 6.4 Common proteins identified by all three independent DDI2 IPs.  
 
Name of protein Description 
Ahnak2 AHNAK nucleoprotein 2 
Uba52 Ubiquitin-60S ribosomal protein L40 
Psmd2 (Rpn2) 26S proteasome non-ATPase regulatory subunit 2 (Rpn2) 
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6.2.3 Confirmation of interaction by specific antibodies 
To validate the data that was obtained from the mass spectrometry analysis, we performed 
co-immunoprecipitation experiments using specific antibodies against the potential DDI2 
interacting proteins. Due to the extensive list of proteins identified by mass spectrometry 
from all three datasets and for the purpose of this thesis, we focussed on only a handful of 
proteins that were of considerable significance based on their ranked probability in the 
proteomics analysis and also based our current knowledge of DDI2 biology. In our studies 
we chose to validate subunits of the 19S complex of the 26S proteasome: Rpn1, Rpn6, 
Rpn7, Rpn2 and Rpt4. Because of the close association of proteasomal subunits with 
each other (Coux 2003), we analysed other 19S proteasomal subunits that were not 
positively identified in our mass spectrometry analysis, Rpn8 and Rpn10. Other proteins of 
interest such as the NDRG2 and DDB1 were also investigated in our validation. NDRG2 is 
a protein found to be induced by the tumour suppressor protein, p53 (Liu et al. 2008) and 
implicated in the regulation of cell differentiation and proliferation (Kim et al. 2009) while 
DDB2 is a DNA damage response protein which also acts as an E3 ubiquitin-ligase (Iovine 
et al. 2011). Due to certain limitations such as time constraints and unreliable antibodies, 
only Rpn1, Rpn6, Rpt4, Rpn8 and NDRG2 are shown (Figure 6.3) while other antibodies 
tested did not show bands of the correct size. 
For the purpose of validation, we performed DDI2 IPs in mouse liver homogenates. A 
parallel IP using non-specific IgG was also performed. DDI2 and IgG IPs were then loaded 
on gels and probed with specific antibodies by western blotting (Figure 6.3). In our 
validation experiment, only the proteasomal subunit, Rpt4, could co-IP with mDdi2. Rpn1, 
Rpn6, Rpn8 and NDRG2, on the other hand, did not successfully co-IP with mDdi2.  
  




Figure 6.3 Western blot analysis of DDI2 and IgG IPs using specific 
antibodies against Rpn1, Rpn6, NDRG2, Rpt4 and Rpn8. 
Mouse liver homogenates were immunoprecipitated using anti-DDI2 and 
non-specific IgG as a control. IPs were then loaded onto a gel and 
interacting proteins detected by western blot analysis using antibodies 
against Rpn1, Rpn6, NDRG2, Rpt4 and Rpn8. SM indicates starting 
material which is 10% of materials used in each IPs. 
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6.3 Discussion 
In an attempt to elucidate the function of hDDI2, we took an open ended approach by 
using a combination of immunoprecipitation to retrieve DDI2 complexes and mass 
spectrometry to identify proteins associated with DDI2. In our studies, we isolated DDI2 
complexes in three different cellular samples: U2OS cells expressing Myc-hDDI2, and the 
cytoplasmic and nuclear fractions of mouse liver.  
Our choice of cell line to use in our proteomic studies was the U2OS cell line because 
most of our studies investigating hDDI2 involved the use of U2OS cells. hDDI2 protein 
yield from cell lines, however, were found to be relatively low (data not shown). Taking this 
into consideration, we opted for cells that were stably expressing Myc-hDDI2. Although the 
physiological effect of hDDI2 overexpression and the presence of an N-terminal epitope 
tag have yet to be determined, the use of overexpressed, tagged proteins in proteomics 
experiments has been broadly accepted (Zachariae et al. 1998; Ikura et al. 2000). In 
performing DDI2 immunoprecipitation, we also chose to use anti-DDI2 antibodies instead 
of the monoclonal anti-Myc antibody for the reason that the anti-DDI2 antibody will 
immunoprecipitate both exogenously expressed Myc-hDDI2 and endogenously expressed 
hDDI2. Furthermore, our anti-DDI2 antibody has been shown to be specific in 
immunoprecipitation and western blotting experiments (Chapter 3). We also performed 
DDI2 immunoprecipitation on mouse liver homogenates that were fractionated into nuclear 
and cytoplasmic fractions. Our rationale to investigate mDdi2 in mouse liver, were that: 1) 
mDdi2 is expressed highly in mouse liver (Chapter 3), which may indicate a functional role 
for mDdi2 in the liver: 2) previous work done in the laboratory investigating the expression 
of mDdi2 in mouse liver sections has shown that mDdi2 is expressed in both the nucleus 
and cytoplasm of hepatocytes (data not shown). It would therefore be of interest to study 
its interacting profile in an exclusive context for both the nucleus and cytoplasm. Any 
finding from this, however, has to be viewed as a vague indication of its interacting profile 
in the two subcellular compartments, as our cell fractionation preparation was not tested 
for cross contamination between the nuclear and cytoplasmic fractions. Data that were 
obtained would therefore need to be validated in future studies.  
In all three DDI2 IPs, mass spectrometry analysis identified various proteasomal subunits 
as DDI2 interacting proteins. Ddi1 in yeast has been shown to interact with the 
proteasome, in particular the 19S RP, through its UBL domain (Kaplun et al. 2005). Our 
data here further strengthens the notion of DDI proteins as proteasome interacting 
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proteins. This is also in agreement with data presented in chapter 4, where hRPN13 was 
found to interact with hDDI2. The finding that various proteasomal subunits were identified 
as DDI2 interacting proteins may also indicate that the DDI2 IP pulled down a complex 
made up of DDI2 together with the proteasome as a complex. Furthermore, all the 
proteasomal subunits that were identified were subunits of the 19S RP complex. Although 
our IPs did not identify any interaction with the 20S CP subunits, the possibility of DDI2 
interacting with the 26S proteasome complex as a whole is still plausible. We take note 
that the IP conditions that were used may not have been optimised to maintain a stable 
association of the 19S RP and the 20S CP as a complex. Previous studies have shown 
that factors such as the depletion of ATP and moderate salt concentrations may cause the 
dissociation of the 26S proteasome complex (Glickman et al. 1998). In an ideal IP 
condition, the isolation of the 19S RP subunits through a DDI2 IP would also pulldown the 
20S CP subunits in a complex. We reason that the 20S CP may have dissociated itself 
because of non-favourable conditions in our experiments.  
The UBA52 protein was identified through mass spectrometry in all three DDI2 IPs as a 
DDI2 interacting protein. In the genome of eukaryotes, the ubiquitin protein is expressed 
by genes encoding for either tandem ubiquitin repeats or as a fusion protein (Wiborg et al. 
1985; Ozkaynak et al. 1987). The UBA52 protein is a 128 amino acid fusion protein made 
up of a 76 amino acid ubiquitin peptide fused to a C-terminal ribosomal protein of 52 amino 
acids (Baker and Board 1991). Free ubiquitin is obtained through the action of 
deubiquitinating enzymes (DUBs) which liberate ubiquitin from its ribosomal extension 
protein (Komander et al. 2009). The finding that UBA52 could IP with DDI2 strengthens 
what was shown in a previous chapter where hDDI2 showed an interaction with 
ubiquitinated proteins (chapter 4). The interaction of DDI2 with the ubiquitin precursor also 
led us to speculate that DDI2 may be involved in the proteolytic cleavage of the ubiquitin 
precursor into free ubiquitin. The retroviral protease (RVP) domain present on DDI proteins 
is highly conserved across species (Krylov and Koonin 2001; Sirkis et al. 2006). The 
function of the RVP domain as a functional protease is an attractive notion. Its structure in 
yeast has already been solved and has been shown to be similar to the HIV protease 
(Sirkis et al. 2006). There is also evidence that the dimerisation of Ddi1 through the RVP 
domain is important for protein secretion (White et al. 2011). Protein secretion in yeast 
cells involves exocytosis, a role mediated by Ddi1 as a negative regulator of SNARE 
complex formation in membrane trafficking (Lustgarten and Gerst 1999). The RVP domain, 
like aspartic proteases are thought to be catalytically active only when in dimer form, which 
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would allow for the hydrolysis of the water molecule needed for peptide bond breaking 
(Lapatto et al. 1989). In this regard, it is therefore tempting to propose a proteolytic 
function for DDI2 through its RVP domain. As for UBA52, we could speculate that DDI2 
proteins interact with the N-terminal ubiquitin region of UBA52 and through their active 
protease site function to catalytically cleave off the C-terminal tail. 
 Another protein that was identified by mass spectrometry in all three DDI2 IPs was the 
Ahnak2 protein. Without any proper validation of the interaction, it may be premature to 
consider the Ahnak2 protein as a true DDI2 interacting protein. Ahnak2, a large 
multidomain protein, has been described as a scaffold protein involved in different 
signalling pathways (Haase et al. 1999; Sekiya et al. 1999; Gentil et al. 2001; Sussman et 
al. 2001). If real, the relevance of this interaction is not currently known and there is 
insufficient information available to suggest a possible link between Ahnak2 and DDI2.  
We attempted to validate our findings from the proteomic studies by performing western 
blotting on mouse liver DDI2 IPs. Unfortunately, our western blotting analysis only showed 
a positive interaction for the Rpt4 subunit of the proteasome and not any of the other 
proteins that were examined. One possible explanation for the negative results in our 
western blot analysis maybe due to the limited sensitivity that western blotting can provide, 
as the level of protein present in the small scale DDI2 IP may be below a detectable 
threshold. It may also be possible that the interaction present was too weak and therefore 
could not be captured and detected through our methods. In any case, further studies are 
needed for the full validation of the mass spectrometry findings. The interactions with the 
different proteasomal subunits, in particular, are of much interest, and it would be useful to 
determine whether the interactions between them are direct.  
In our validation western blots, we also looked at NDRG2. NDRG2 was identified as a 
DDI2 interacting protein by mass spectrometry only in the DDI2 IP from the mouse liver 
nuclear fraction. Although our coIP did not show any interaction, NDRG2 was regarded as 
an interesting protein because of its link with p53 (Liu et al. 2008). It was shown that 
NDRG2 expression is induced by p53 through an identified p53 binding site upstream of 
the NDRG2 gene (Liu et al. 2008). Furthermore, NDRG2 has been shown to be required 
for the initiation of p53-mediated apoptosis in cells (Liu et al. 2008). A role for NDRG2 in 
tumour suppression has also been reported by several groups (Deng et al. 2003; Lusis et 
al. 2005; Choi et al. 2007; Lorentzen et al. 2007). We have proposed a regulatory role for 
hDDI2 in the expression of p53 (Chapter 5). It is therefore tempting to associate hDDI2 
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with downstream partners of p53 such as NDRG2. The first obvious question to address in 
future studies is to verify whether this interaction is real and whether a direct interaction 
exists. If a direct interaction does exist, then it is possible that hDDI2 may also regulate 
NDRG2 expression. 
Findings from this chapter have identified an extensive list of DDI2 interacting proteins. 
Although most are yet to be validated, based on the known role of hDDI2 in regulating 
proteasomal substrates, we can be inclined to regard these interactors as probable factors 
regulated by DDI2 through the ubiquitin-proteasome pathway. Without any additional 
information on the individual interactions, however, it is difficult to predict their relevance to 
DDI2 function. Nonetheless, data from our investigation here will prove useful and could 
pave the way for a more targetted approach to studying DDI2 interacting proteins and 
ultimately DDI2 function. 
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Chapter 7 Final discussion and future directions 
The regulation of the ubiquitin-proteasome pathway, from its early days of discovery in the 
1970s (Goldberg and St John 1976; Etlinger and Goldberg 1977) until present, remains to 
be fully understood. What was initially thought to be a simple linear pathway to 
degradation has now emerged as a complex, multi-faceted pathway with a growing 
number of factor proteins surrounding it. In light of this, there is a large body of evidence 
that a group of proteins called the UBA-UBL domain proteins play a fundamental role in 
the regulation of the ubiquitin-proteasome pathway. These proteins act through their ability 
to interact with both the proteasome via their UBL domains and ubiquitinated substrates 
via their UBA domains (Schauber et al. 1998; Bertolaet et al. 2001; Wilkinson et al. 2001; 
Elsasser et al. 2002). The aim of this project was to characterise two novel proteins called 
hDDI1 and hDDI2. These proteins were initially identified through a database search of 
mammalian orthologues to the yeast protein Ddi1, a known member of the UBA-UBL 
domain protein family.  Work from this thesis has thus provided a framework to 
understanding of the role hDDI proteins play in the function of the ubiquitin-proteasome 
pathway. 
 
7.1 Summary of findings 
In chapter 3, the basic characterisation of these novel proteins was undertaken. hDDI1 
and hDDI2 proteins showed significant sequence similarities to the yeast Ddi1 protein and 
are valid orthologues of the yeast Ddi1 protein. Similar to the yeast protein, we described 
hDDI1 and hDDI2 as ubiquitin-like (UBL) domain proteins, containing N-terminal UBL 
domains. hDDI1 and hDDI2, however, do not contain  ubiquitin associated (UBA) domains 
at their C-terminal ends, a property possibly unique to the yeast protein. However, 
bioinformatic analysis showed a putative ubiquitin-interacting motif (UIM) present at the C-
terminus of hDDI2. A database search of DDI orthologues revealed its conservation in the 
genomes from simple organisms through to higher and more complex organisms. 
Interestingly, we observed that the genomes of higher organisms encode for at least two 
copies of the Ddi1 gene. The presence of evolutionary conserved gene duplication has 
been well documented since the 1930s (Bridges 1936). The recent availability of 
sequenced genomic data has provided further evidence of the high occurrence of gene 
duplication. Despite being nearly identical to each other, our expression studies have 
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shown that unlike hDDI2, which showed expression in all tissues, hDDI1 is expressed 
specifically in the testis. The difference in their tissue expression suggests a redundant 
role for two very similar proteins. The high level of expression in the testis may however, 
suggest a specialised role for hDDI1 in the testis. 
In the subsequent chapters, we chose to focus solely on hDDI2 and not hDDI1 due to the 
restricted expression of hDDI1 in the testis. Furthermore, our cell line models did not 
express hDDI1 at a detectable level. Chapter 4 investigated the significance of the UBL 
domain of hDDI2 and its association with the proteasome. Using techniques such as 
colocalisation immunoflourescence microscopy, co-immunoprecipitation and in vitro 
binding assays, it was established that hDDI2 through its UBL domain can interact directly 
with the hRPN13 subunit of the 19S lid complex of the 26S proteasome. The yeast Ddi1 
protein interacts with ubiquitin through its UBA domain (Bertolaet et al. 2001). Even though 
hDDI2 does not contain a UBA domain, we explored the possibility that hDDI2 may 
interact with ubiquitin through its putative UIM domain. Our studies showed that HA-Ub 
can be co-immunoprecipitated with hDDI2. Thus, we hypothesise that hDDI2 interacts with 
ubiquitin through its putative UIM domain. The significance of the UBL domain was also 
explored. We showed that the UBL domain of hDDI2 is important in regulating its protein 
stability and localisation. In our experiments, truncated hDDI2 proteins lacking the UBL 
domain showed a marked decrease in stability compare to wildtype proteins (Chapter 4). 
Furthermore Myc-hDDI2FL and Myc-hDDI2∆UBL showed difference in their subcellular 
localisation when expressed in U2OS cells (Chapter 4). 
Chapter 5 of this thesis looked at the functional role of hDDI2. We found that the 
expression of hDDI2, unlike its yeast homologue, was not induced by DNA damage. 
Through various assays, hDDI2 was shown to be essential for cell proliferation under 
normal conditions and cell survival after exposure to UV radiation. A role for hDDI2 in the 
ubiquitin-proteasome pathway has also been demonstrated. We studied the effect of 
hDDI2 siRNA knockdown on a known substrate of the ubiquitin-proteasome pathway, p53. 
Knockdown of hDDI2 led to the destabilisation of p53. In addition, the UBL domain of 
hDDI2 was shown to be required for p53 stabilistion in hDDI2 overexpressing cells. In the 
presence of DNA damage, we showed that hDDI2 is essential for p53 stabilisation.  
Lastly, in chapter 6, we sought to identify novel hDDI2 interacting proteins. Using mass 
spectrometry analysis, we identified novel proteins present in DDI2 complexes from three 
separate DDI2 populations: U2OS expressing Myc-hDDI2, mouse liver cytoplasmic 
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fraction and mouse liver nuclear fraction. Our analysis has revealed novel interacting 
proteins that were consistent in all three datasets. To confirm interaction, we used 
antibodies specific for these novel proteins in a Western blotting experiment of DDI2 IP 
performed in mouse liver homogenates. For the purpose of this thesis, however, we chose 
to only focus on a handful of highly probable proteins. In our experiments, we were only 
able to confirm the interaction between hDDI2 and Rpt4. 
The emergence of the UBL-UBA class of proteins and their important role in regulation of 
the ubiquitin-proteasome pathway is clearly well appreciated in the ubiquitin-proteasome 
field. Here, our results have identified hDDI1 and hDDI2 as novel proteins with emerging 
roles in the ubiquitin-proteasome pathway. Below we will discuss the potential significance, 
implication and possibilities for future investigations. 
 
7.1.1 General discussion  
hDDI1 and hDDI2 are differentially expressed across tissues. Work in the laboratory (data 
not shown) has indicated the expression of hDDI1 in Sertoli cells of the testis. Sertoli cells 
are specialised cells in the testis involved in sperm cell formation (Griswold 1998). The 
expression of hDDI1 in these cells therefore suggests that it may be involved in the 
process of spermatogenesis. Although our studies did not investigate the role of hDDI1 in 
testiscular function, owing to its high sequence similarities with hDDI2, hDDI1 may also 
play a role in the ubiquitin-proteasome pathway. Like many other important cellular 
processes, the ubiquitin-proteasome pathway plays an active role in spermatogenesis, as 
has been reported (Sutovsky 2003). Components of the ubiquitin-proteasome pathway are 
highly expressed during gonad and germ cell differentiation by Sertoli cells, indicating its 
importance (Pusch et al. 1998; Kon et al. 1999; Baarends et al. 2000). The expression of 
hDDI1 in Sertoli cells during embryogenesis and also the different stages of development 
could be of interest and would come from future studies. We speculate that if indeed, 
hDDI1 plays an important role in Sertoli cells, its level of expression throughout the 
different stages of development may reflect upon this.  
Interestingly, hDDI1 contains no intron and was initially thought to be a pseudogene 
bearing no true protein coding region. Our studies have, however, shown otherwise. 
Intronless genes have also reported to be evolutionally conserved across species and a 
substantial proportion of them are involved in important housekeeping functions 
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(Sakharkar et al. 2006). Moreover, intronless genes do not undergo alternative splicing, 
reported to be the cause of many disease causing variation in gene expression (Venables 
2004). We therefore propose that hDDI1 through its role with the ubiquitin-proteasome 
pathway is an essential component of testicular function. The exact role and function of 
hDDI1 in the testis will come from future studies. An investigation to look at the effect on 
the inactivation of the mDdi1 gene in mouse would prove useful to determining its function. 
Although mHr23A and mHr23B have been shown to be expressed in all tisues, the 
expression of both mHr23A and mHr23B in mouse has been shown to be highly elevated 
in the testis (van der Spek et al. 1996). Backed up by yeast studies which showed an 
induction of Rad23 mRNA during meiotic prophase and DNA recombination (Madura and 
Prakash 1990), it has been hypothesises that mHr23A and mHr23B may also play an 
importance role in meiotic recombination. Furthermore, the importance of mHr23A and 
mHr23B in development has been shown through knockout mouse studies (Ng et al. 2002; 
Ng et al. 2003). The inactivation of the mHr23B gene in mouse led to an impairment in 
embryonic development (Ng et al. 2002) while the mHR23A-/- mHR23B-/- double knockout 
caused embryonic lethality (Ng et al. 2003). Although both hDDI1 and hDDI2 are 
expressed in the testis, the high expression and exclusiveness of hDDI1 in the testis may 
imply a crucial role for hDDI1 in development. Based on findings presented in this thesis, 
we hypothesise that hDDI1 in an important factor in the ubiquitin-proteasome pathway. 
The importance of the ubiquitin-proteasome pathway in the functioning of a cell has been 
well defined and the inhibition of this pathway often results in a rapid dysregulation of 
multiple cellular processes and subsequently apoptosis. Additionally, the ubiquitin-
proteasome pathway plays a crucial role in gametogenesis (Grootegoed et al. 1998) and 
knockdown mouse models with impairment in this process suggest a strong role for the 
ubiquitin-proteasome pathway. Moreover, level of protein expression fluctuates during the 
different phases of spermatogenesis and this heavily relies on the ubiqutin-proteasome 
pathway, further emphasising the significance of the ubiquitin-proteasome pathway in 
mammalian development (Baarends et al. 2000). The differential tissue expression of 
hDDI1 and hDDI2 may suggest that both proteins have mutually exclusive roles within the 
mammalian system. As was mentioned earlier, hDDI1 and hDDI2 may have evolved from 
the process of gene duplication. While we speculate that the role of hDDI1 is exclusive to 
its function in the testis, the identity conservation between the two proteins may imply a 
common and well defined role for these two proteins within the context of the ubiquitin-
proteasome pathway. A broader role outside this pathway, however, cannot be ruled out. 
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hDDI2 can be associated with both the proteasome and ubiquitinated  proteins. We have 
presented evidence that hDDI2 can interact with the proteasomal subunit, hRPN13, 
possibly through the N-terminal UBL domain of hDDI2. hRPN13 is one of the few subunits 
of the proteasome that has been shown to bind UBL domains (Husnjak et al. 2008). 
Furthermore, the same study also showed an in vitro binding of hDDI1 UBL domain with 
hRPN13. In our studies, we have only investigated the interaction of hDDI2 with hRPN13. 
The possibility that hDDI2 can also interact with other subunits, however, cannot be ruled 
out. Indeed, in our proteomic analysis of DDI2 interacting proteins, several subunits of the 
proteasome were seen to be able to interact with DDI2. Other subunits of the proteasome 
that have been shown to interact with UBL domains are the S5a domain through its 
ubiquitin-interacting motif (UIM) (Hiyama et al. 1999; Walters et al. 2002) and Rpn1 
through its leucine-rich-repeat-like (LLR) domain (Elsasser et al. 2002). Suprisingly 
however, Rpn13 was not identified in our proteomic analysis. In any case, our proteomic 
analysis of DDI2 immunoprecipitates would still require further validation. We also showed 
that hDDI2 can immunoprecipitate ubiqutinated proteins, possibly through a putative UIM 
domain present on the C-terminal end of hDDI2.  
Through its interaction with the proteasome and ubiquitinated proteins, we hypothesise 
that hDDI2 acts as a regulator of the degradation of ubiquitinated substrates. In the case of 
p53, which under normal conditions is constitutively degraded by the proteasome, we 
propose that hDDI2 facilitates in bridging the delivery of ubiquitinated p53 to the 
proteasome for degradation (Figure 7.1A). Having hDDI2 as a facilitator would allow for an 
added layer of regulation in p53 degradation. 
Being able to bind to both ubiquitinated p53 and the proteasome, however, it is possible 
that hDDI2 acts in the opposite manner, as a negative regulator, when overexpressed. 
This has been observed in studies concerning other UBA-UBL domain proteins, hHR23A 
and hHR23B, where overexpression of the proteins acted to inhibit the degradation of p53 
(Glockzin et al. 2003; Brignone et al. 2004). These findings suggest that the intracellular 
level of proteins such as hDDI2 and hHR23A/B are important in determining the fate of 
ubiquitinated p53. We propose a model that when hDDI2/hHR23A/hHR23B proteins are 
absent or low in abundance, ubiquitinated p53 is constitutively degraded, as the 
proteasome can easily recognise ubiquitinated substrates (Figure 7.1A). A positive role for 
hDDI2/hHR23A/hHR23B in facilitating the degradation of ubiquitinated p53 may take place 
when the molecular ratio of these proteins to p53 is at par with each other. Our knockdown 
studies are in agreement with this hypothesis, in which the absence of hDDI2 led to a 
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decrease in p53 levels, possibly through an increase in p53 degradation. We propose that 
when hDDI2 is not present, there is a dysregulation of p53. Having hDDI2, therefore, 
regulates the degradation of p53, should there be a need for its downstream function. 
hDDI2/hHR23A/hHR23B may also sequester and inhibit ubiquitinated proteins from 
translocating to the proteasome for degradation. This may be the case when these 
proteins are overexpressed. The excess molar concentration of these proteins would 
cause them to bind the proteasome through their UBL domains and ubiquitinated proteins 
through their UBA/UIM domains sequestering the translocation of ubiquitinated p53 to the 
proteasome for degradation (Figure 7.1B). 
hDDI2 is essential for p53 stability in the event of DNA damage. We showed that in the 
absence of hDDI2, p53 failed to be stabilised, as in control cells. Again, this finding agrees 
with our hypothesis of hDDI2 being a regulator of p53 degradation and it further 
emphasises the need for hDDI2 in maintaining p53 stability. Another group has also shown 
a similar role for hHR23B in p53 stabilisation in stressful events (Kaur et al. 2007). The 
role of p53 as a tumour suppressor has been well defined (Prives and Hall 1999; Appella 
and Anderson 2001; Bartel et al. 2002). It is estimated that in half of all cancers, the p53 
gene is either mutated or is functionally inactive (Haupt et al. 1997; Blandino et al. 1999). 
In this context, the ubiquitin-proteasome pathway plays a pro-active role in the regulation 
of the p53 protein. Our finding that hDDI2 can be implicated in the regulation of p53 
through the ubiquitin-proteasome pathway therefore brings forth an avenue for further 
study in the cancer research arena. The role of hDDI2 in various types of cancer will come 
from future studies. Specifically, the expression of hDDI2, as well as hDDI1, should be 
investigated in the different types of cancer cells.  
From this work, it is also evident that hDDI2 shares common roles with UBA-UBL domain 
proteins such as hHR23A and hHR23B. In yeast a collaborative role for Rad23 and Ddi1 
has been shown (Bertolaet et al. 2001; Diaz-Martinez et al. 2006; Auesukaree et al. 2008). 
Whether hDDI2 acts in collaboration in the same pathway or in parallel pathways with 
hHR23A and hHR23B is yet to be determined and will be a subject of future studies. 
Another attractive proposition to be explored in further studies is the function of the RVP 
domain on hDDI2 as an active aspartyl protease. Multiple alignment analysis of the yeast 
Ddi1 RVP domain with known retroviral aspartyl proteases showed strict conservation of 
signature residues and secondary structure elements in the RVP domain of Ddi1 proteins 
(Krylov and Koonin 2001).  Studies have also shown that Ddi1 homodimerises through its 
   164 
 
RVP domain (Gabriely et al. 2008), a known characteristic of aspartyl proteases to allow 
for the activation of water molecule in peptide bond hydrolysis (Davies 1990). To date, no 
substrate to the RVP as an active aspartyl protease has been identified. The importance of 
its homodimerisation, and presumably its action as a protease, however, has been shown 
(White et al. 2011). It is therefore possible that DDI proteins, through their RVP domain, 
operate as deubiquitinating (DUB) enzymes. If so, this hypothesis would also agree with 
our current data on the regulation of p53 by hDDI2. It may be possible that hDDI2 
deubiquitinates p53, therefore preventing its degradation by the proteasome. 
Overexpression of full length Myc-hDDI2 showed an accumulation of p53 when compared 
to the truncated Myc-hDDI2∆UBL form. However, if hDDI2 did possess DUB properties, 
then Myc-hDDI2∆UBL would also be expected to stabilise p53, through its RVP domain 
function. Therefore, as attractive of a proposition it may be, further studies are still needed 
to delineate the mechanism by which hDDI2 stabilises p53. Perhaps, the UBL domain also 
plays an active role in parallel to the RVP domain of hDDI2. The prospect of hDDI2 or 
even hDDI1 as DUBs is an interesting prospect to further study.  
 
7.2 Summary 
Findings from this project have implicated hDDI1 and hDDI2 in the ubiquitin-proteasome 
pathway. A functional role for hDDI2 in the degradation of p53 through the ubiquitin-
proteasome pathway has also been established. The presence of other similar proteins 
with similar roles, like hHR23A/B and hPLIC-1/2, suggest a central and fundamental role 
played by these proteins in the ubiquitin-proteasome pathway. The functioning of these 
proteins in the ubiquitin-proteasome pathway may also provide for potential therapeutic 
targets as aberrations to the pathway lead to many forms of health complications. Seeing 
that hDDI2 is also important in cell viability and survival after DNA damage may also pave 
way for future research into the role hDDI2 play in tumour and cancer cells. 
  






A – Normal hDDI2 levels 
B – Excess hDDI2 levels 
Figure 7.1 Schematic representation on the role of hDDI2 in p53 degradation. 
A. hDDI2 can interact with the 26S proteasome through its UBL and ubiquitinated p53 
through its UIM domain. At normal levels, hDDI2 acts as a positive facilitator to 
ubiquitinated p53, allowing it to be translocated to the proteasome for recognition 
and subsequent degradation. 
B. When overexpressed, an excess of hDDI2 molecules bind to the proteasome and 
ubiquitinated p53. Binding sites are occupied by separate hDDI2 molecules thus 
sequestering the translocation of ubiquitinated p53 to the proteasome leading to its 
accumulation. 
   166 
 
References 
Appella, E. and C. W. Anderson (2001). "Post-translational modifications and activation of p53 by 
genotoxic stresses." Eur J Biochem 268(10): 2764-2772. 
Auesukaree, C., I. Fuchigami, et al. (2008). "Ddi1p and Rad23p play a cooperative role as negative 
regulators in the PHO pathway in Saccharomyces cerevisiae." Biochem Biophys Res 
Commun 365(4): 821-825. 
Baarends, W. M., R. van der Laan, et al. (2000). "Specific aspects of the ubiquitin system in 
spermatogenesis." J Endocrinol Invest 23(9): 597-604. 
Bai, C., P. Sen, et al. (1996). "SKP1 connects cell cycle regulators to the ubiquitin proteolysis 
machinery through a novel motif, the F-box." Cell 86(2): 263-274. 
Bailly, V., S. Lauder, et al. (1997). "Yeast DNA repair proteins Rad6 and Rad18 form a 
heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities." J 
Biol Chem 272(37): 23360-23365. 
Baker, R. T. and P. G. Board (1991). "The human ubiquitin-52 amino acid fusion protein gene 
shares several structural features with mammalian ribosomal protein genes." Nucleic Acids 
Res 19(5): 1035-1040. 
Bakhrat, A., M. S. Jurica, et al. (2004). "Homology modeling and mutational analysis of Ho 
endonuclease of yeast." Genetics 166(2): 721-728. 
Banerji, J., J. Sands, et al. (1990). "A gene pair from the human major histocompatibility complex 
encodes large proline-rich proteins with multiple repeated motifs and a single ubiquitin-like 
domain." Proc Natl Acad Sci U S A 87(6): 2374-2378. 
Bartel, F., H. Taubert, et al. (2002). "Alternative and aberrant splicing of MDM2 mRNA in human 
cancer." Cancer Cell 2(1): 9-15. 
Bauer, A. and B. Kuster (2003). "Affinity purification-mass spectrometry. Powerful tools for the 
characterization of protein complexes." Eur J Biochem 270(4): 570-578. 
Bergmann, S., J. Ihmels, et al. (2004). "Similarities and differences in genome-wide expression data 
of six organisms." PLoS Biol 2(1): E9. 
Bertolaet, B. L., D. J. Clarke, et al. (2001). "UBA domains mediate protein-protein interactions 
between two DNA damage-inducible proteins." J Mol Biol 313(5): 955-963. 
Bertolaet, B. L., D. J. Clarke, et al. (2001). "UBA domains of DNA damage-inducible proteins 
interact with ubiquitin." Nat Struct Biol 8(5): 417-422. 
Blandino, G., A. J. Levine, et al. (1999). "Mutant p53 gain of function: differential effects of 
different p53 mutants on resistance of cultured cells to chemotherapy." Oncogene 18(2): 
477-485. 
Bochtler, M., L. Ditzel, et al. (1999). "The proteasome." Annu Rev Biophys Biomol Struct 28: 295-
317. 
   167 
 
Borden, K. L. (2000). "RING domains: master builders of molecular scaffolds?" J Mol Biol 295(5): 
1103-1112. 
Boyd, S. D., K. Y. Tsai, et al. (2000). "An intact HDM2 RING-finger domain is required for 
nuclear exclusion of p53." Nat Cell Biol 2(9): 563-568. 
Bridges, C. B. (1936). "The Bar "Gene" a Duplication." Science 83(2148): 210-211. 
Brignone, C., K. E. Bradley, et al. (2004). "A post-ubiquitination role for MDM2 and hHR23A in 
the p53 degradation pathway." Oncogene 23(23): 4121-4129. 
Brzovic, P. S., J. R. Keeffe, et al. (2003). "Binding and recognition in the assembly of an active 
BRCA1/BARD1 ubiquitin-ligase complex." Proc Natl Acad Sci U S A 100(10): 5646-5651. 
Cardozo, T. and M. Pagano (2004). "The SCF ubiquitin ligase: insights into a molecular machine." 
Nat Rev Mol Cell Biol 5(9): 739-751. 
Castro, A., C. Bernis, et al. (2005). "The anaphase-promoting complex: a key factor in the 
regulation of cell cycle." Oncogene 24(3): 314-325. 
Chau, V., J. W. Tobias, et al. (1989). "A multiubiquitin chain is confined to specific lysine in a 
targeted short-lived protein." Science 243(4898): 1576-1583. 
Chen, Y. W., T. Tajima, et al. (2011). "The crystal structure of the ubiquitin-like (UbL) domain of 
human homologue A of Rad23 (hHR23A) protein." Protein Eng Des Sel 24(1-2): 131-138. 
Choi, S. C., S. R. Yoon, et al. (2007). "Expression of NDRG2 is related to tumor progression and 
survival of gastric cancer patients through Fas-mediated cell death." Exp Mol Med 39(6): 
705-714. 
Ciechanover, A. (2003). "The ubiquitin proteolytic system and pathogenesis of human diseases: a 
novel platform for mechanism-based drug targeting." Biochem Soc Trans 31(2): 474-481. 
Ciechanover, A., S. Elias, et al. (1980). "Characterization of the heat-stable polypeptide of the ATP-
dependent proteolytic system from reticulocytes." J Biol Chem 255(16): 7525-7528. 
Ciechanover, A., H. Heller, et al. (1981). "Activation of the heat-stable polypeptide of the ATP-
dependent proteolytic system." Proc Natl Acad Sci U S A 78(2): 761-765. 
Ciosk, R., W. Zachariae, et al. (1998). "An ESP1/PDS1 complex regulates loss of sister chromatid 
cohesion at the metaphase to anaphase transition in yeast." Cell 93(6): 1067-1076. 
Clarke, D. J., G. Mondesert, et al. (2001). "Dosage suppressors of pds1 implicate ubiquitin-
associated domains in checkpoint control." Mol Cell Biol 21(6): 1997-2007. 
Cohen-Fix, O. and D. Koshland (1997). "The anaphase inhibitor of Saccharomyces cerevisiae 
Pds1p is a target of the DNA damage checkpoint pathway." Proc Natl Acad Sci U S A 
94(26): 14361-14366. 
Cohen-Fix, O. and D. Koshland (1997). "The metaphase-to-anaphase transition: avoiding a mid-life 
crisis." Curr Opin Cell Biol 9(6): 800-806. 
Cohen-Fix, O., J. M. Peters, et al. (1996). "Anaphase initiation in Saccharomyces cerevisiae is 
controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p." Genes Dev 
10(24): 3081-3093. 
   168 
 
Cook, J. C. and P. B. Chock (1992). "Isoforms of mammalian ubiquitin-activating enzyme." J Biol 
Chem 267(34): 24315-24321. 
Coux, O. (2003). "An interaction map of proteasome subunits." Biochem Soc Trans 31(2): 465-469. 
Davies, D. R. (1990). "The structure and function of the aspartic proteinases." Annu Rev Biophys 
Biophys Chem 19: 189-215. 
DeMartino, G. N., C. R. Moomaw, et al. (1994). "PA700, an ATP-dependent activator of the 20 S 
proteasome, is an ATPase containing multiple members of a nucleotide-binding protein 
family." J Biol Chem 269(33): 20878-20884. 
Deng, L., C. Wang, et al. (2000). "Activation of the IkappaB kinase complex by TRAF6 requires a 
dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain." Cell 
103(2): 351-361. 
Deng, Y., L. Yao, et al. (2003). "N-Myc downstream-regulated gene 2 (NDRG2) inhibits 
glioblastoma cell proliferation." Int J Cancer 106(3): 342-347. 
Deshaies, R. J. and C. A. Joazeiro (2009). "RING domain E3 ubiquitin ligases." Annu Rev Biochem 
78: 399-434. 
Deveraux, Q., V. Ustrell, et al. (1994). "A 26 S protease subunit that binds ubiquitin conjugates." J 
Biol Chem 269(10): 7059-7061. 
Diaz-Martinez, L. A., Y. Kang, et al. (2006). "Yeast UBL-UBA proteins have partially redundant 
functions in cell cycle control." Cell Div 1: 28. 
Dieckmann, T., E. S. Withers-Ward, et al. (1998). "Structure of a human DNA repair protein UBA 
domain that interacts with HIV-1 Vpr." Nat Struct Biol 5(12): 1042-1047. 
Dikic, I., S. Wakatsuki, et al. (2009). "Ubiquitin-binding domains - from structures to functions." 
Nat Rev Mol Cell Biol 10(10): 659-671. 
Dominguez, C., A. M. Bonvin, et al. (2004). "Structural model of the UbcH5B/CNOT4 complex 
revealed by combining NMR, mutagenesis, and docking approaches." Structure 12(4): 633-
644. 
Elsasser, S., D. Chandler-Militello, et al. (2004). "Rad23 and Rpn10 serve as alternative ubiquitin 
receptors for the proteasome." J Biol Chem 279(26): 26817-26822. 
Elsasser, S., R. R. Gali, et al. (2002). "Proteasome subunit Rpn1 binds ubiquitin-like protein 
domains." Nat Cell Biol 4(9): 725-730. 
Etlinger, J. D. and A. L. Goldberg (1977). "A soluble ATP-dependent proteolytic system 
responsible for the degradation of abnormal proteins in reticulocytes." Proc Natl Acad Sci U 
S A 74(1): 54-58. 
Finley, D. (2009). "Recognition and processing of ubiquitin-protein conjugates by the proteasome." 
Annu Rev Biochem 78: 477-513. 
Finley, D. and V. Chau (1991). "Ubiquitination." Annu Rev Cell Biol 7: 25-69. 
Finley, D., A. Ciechanover, et al. (1984). "Thermolability of ubiquitin-activating enzyme from the 
mammalian cell cycle mutant ts85." Cell 37(1): 43-55. 
   169 
 
Finley, D., S. Sadis, et al. (1994). "Inhibition of proteolysis and cell cycle progression in a 
multiubiquitination-deficient yeast mutant." Mol Cell Biol 14(8): 5501-5509. 
Florenes, V. A., G. M. Maelandsmo, et al. (1994). "MDM2 gene amplification and transcript levels 
in human sarcomas: relationship to TP53 gene status." J Natl Cancer Inst 86(17): 1297-
1302. 
Funakoshi, M., T. Sasaki, et al. (2002). "Budding yeast Dsk2p is a polyubiquitin-binding protein 
that can interact with the proteasome." Proc Natl Acad Sci U S A 99(2): 745-750. 
Gabriely, G., R. Kama, et al. (2008). "Different domains of the UBL-UBA ubiquitin receptor, 
Ddi1/Vsm1, are involved in its multiple cellular roles." Mol Biol Cell 19(9): 3625-3637. 
Gentil, B. J., C. Delphin, et al. (2001). "The giant protein AHNAK is a specific target for the 
calcium- and zinc-binding S100B protein: potential implications for Ca2+ homeostasis 
regulation by S100B." J Biol Chem 276(26): 23253-23261. 
Gillette, T. G., B. Kumar, et al. (2008). "Differential roles of the COOH termini of AAA subunits of 
PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome." J 
Biol Chem 283(46): 31813-31822. 
Girdwood, D. W., M. H. Tatham, et al. (2004). "SUMO and transcriptional regulation." Semin Cell 
Dev Biol 15(2): 201-210. 
Glickman, M. H. and A. Ciechanover (2002). "The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction." Physiol Rev 82(2): 373-428. 
Glickman, M. H., D. M. Rubin, et al. (1998). "A subcomplex of the proteasome regulatory particle 
required for ubiquitin-conjugate degradation and related to the COP9-signalosome and 
eIF3." Cell 94(5): 615-623. 
Glickman, M. H., D. M. Rubin, et al. (1998). "The regulatory particle of the Saccharomyces 
cerevisiae proteasome." Mol Cell Biol 18(6): 3149-3162. 
Glockzin, S., F. X. Ogi, et al. (2003). "Involvement of the DNA repair protein hHR23 in p53 
degradation." Mol Cell Biol 23(24): 8960-8969. 
Goldberg, A. L. and A. C. St John (1976). "Intracellular protein degradation in mammalian and 
bacterial cells: Part 2." Annu Rev Biochem 45: 747-803. 
Griswold, M. D. (1998). "The central role of Sertoli cells in spermatogenesis." Semin Cell Dev Biol 
9(4): 411-416. 
Groll, M., M. Bajorek, et al. (2000). "A gated channel into the proteasome core particle." Nat Struct 
Biol 7(11): 1062-1067. 
Groll, M., L. Ditzel, et al. (1997). "Structure of 20S proteasome from yeast at 2.4 A resolution." 
Nature 386(6624): 463-471. 
Grootegoed, J. A., W. M. Baarends, et al. (1998). "Knockout mouse model and gametogenic 
failure." Mol Cell Endocrinol 145(1-2): 161-166. 
   170 
 
Guzder, S. N., V. Bailly, et al. (1995). "Yeast DNA repair protein RAD23 promotes complex 
formation between transcription factor TFIIH and DNA damage recognition factor RAD14." 
J Biol Chem 270(15): 8385-8388. 
Haas, A. L. and I. A. Rose (1982). "The mechanism of ubiquitin activating enzyme. A kinetic and 
equilibrium analysis." J Biol Chem 257(17): 10329-10337. 
Haas, A. L. and T. J. Siepmann (1997). "Pathways of ubiquitin conjugation." FASEB J 11(14): 
1257-1268. 
Haase, H., T. Podzuweit, et al. (1999). "Signaling from beta-adrenoceptor to L-type calcium 
channel: identification of a novel cardiac protein kinase A target possessing similarities to 
AHNAK." FASEB J 13(15): 2161-2172. 
Hartmann-Petersen, R. and C. Gordon (2004). "Integral UBL domain proteins: a family of 
proteasome interacting proteins." Semin Cell Dev Biol 15(2): 247-259. 
Hartmann-Petersen, R. and C. Gordon (2004). "Protein degradation: recognition of ubiquitinylated 
substrates." Curr Biol 14(18): R754-756. 
Haupt, Y., R. Maya, et al. (1997). "Mdm2 promotes the rapid degradation of p53." Nature 
387(6630): 296-299. 
Heinemeyer, W., M. Fischer, et al. (1997). "The active sites of the eukaryotic 20 S proteasome and 
their involvement in subunit precursor processing." J Biol Chem 272(40): 25200-25209. 
Hershko, A., H. Heller, et al. (1983). "Components of ubiquitin-protein ligase system. Resolution, 
affinity purification, and role in protein breakdown." J Biol Chem 258(13): 8206-8214. 
Hicke, L. (1997). "Ubiquitin-dependent internalization and down-regulation of plasma membrane 
proteins." FASEB J 11(14): 1215-1226. 
Hirano, S., M. Kawasaki, et al. (2006). "Double-sided ubiquitin binding of Hrs-UIM in endosomal 
protein sorting." Nat Struct Mol Biol 13(3): 272-277. 
Hiyama, H., M. Yokoi, et al. (1999). "Interaction of hHR23 with S5a. The ubiquitin-like domain of 
hHR23 mediates interaction with S5a subunit of 26 S proteasome." J Biol Chem 274(39): 
28019-28025. 
Hofmann, K. and P. Bucher (1996). "The UBA domain: a sequence motif present in multiple 
enzyme classes of the ubiquitination pathway." Trends Biochem Sci 21(5): 172-173. 
Hofmann, K. and L. Falquet (2001). "A ubiquitin-interacting motif conserved in components of the 
proteasomal and lysosomal protein degradation systems." Trends Biochem Sci 26(6): 347-
350. 
Hou, D., C. Cenciarelli, et al. (1994). "Activation-dependent ubiquitination of a T cell antigen 
receptor subunit on multiple intracellular lysines." J Biol Chem 269(19): 14244-14247. 
Hsieh, H. C., Y. H. Hsieh, et al. (2005). "HHR23A, a human homolog of Saccharomyces cerevisiae 
Rad23, regulates xeroderma pigmentosum C protein and is required for nucleotide excision 
repair." Biochem Biophys Res Commun 335(1): 181-187. 
   171 
 
Huang, F., D. Kirkpatrick, et al. (2006). "Differential regulation of EGF receptor internalization and 
degradation by multiubiquitination within the kinase domain." Mol Cell 21(6): 737-748. 
Huibregtse, J. M., M. Scheffner, et al. (1995). "A family of proteins structurally and functionally 
related to the E6-AP ubiquitin-protein ligase." Proc Natl Acad Sci U S A 92(11): 5249. 
Huibregtse, J. M., M. Scheffner, et al. (1991). "A cellular protein mediates association of p53 with 
the E6 oncoprotein of human papillomavirus types 16 or 18." EMBO J 10(13): 4129-4135. 
Huibregtse, J. M., M. Scheffner, et al. (1993). "Cloning and expression of the cDNA for E6-AP, a 
protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53." 
Mol Cell Biol 13(2): 775-784. 
Husnjak, K., S. Elsasser, et al. (2008). "Proteasome subunit Rpn13 is a novel ubiquitin receptor." 
Nature 453(7194): 481-488. 
Hwang, G. W., D. Sasaki, et al. (2005). "Overexpression of Rad23 confers resistance to 
methylmercury in saccharomyces cerevisiae via inhibition of the degradation of 
ubiquitinated proteins." Mol Pharmacol 68(4): 1074-1078. 
Ikura, T., V. V. Ogryzko, et al. (2000). "Involvement of the TIP60 histone acetylase complex in 
DNA repair and apoptosis." Cell 102(4): 463-473. 
Ingley, E. and B. A. Hemmings (1994). "Pleckstrin homology (PH) domains in signal transduction." 
J Cell Biochem 56(4): 436-443. 
Iovine, B., M. L. Iannella, et al. (2011). "Damage-specific DNA binding protein 1 (DDB1): A 
protein with a wide range of functions." Int J Biochem Cell Biol. 
Ivantsiv, Y., L. Kaplun, et al. (2006). "Unique role for the UbL-UbA protein Ddi1 in turnover of 
SCFUfo1 complexes." Mol Cell Biol 26(5): 1579-1588. 
Janse, D. M., B. Crosas, et al. (2004). "Localization to the proteasome is sufficient for degradation." 
J Biol Chem 279(20): 21415-21420. 
Jensen, T. J., M. A. Loo, et al. (1995). "Multiple proteolytic systems, including the proteasome, 
contribute to CFTR processing." Cell 83(1): 129-135. 
Jentsch, S. and G. Pyrowolakis (2000). "Ubiquitin and its kin: how close are the family ties?" 
Trends Cell Biol 10(8): 335-342. 
Johnson, E. S., B. Bartel, et al. (1992). "Ubiquitin as a degradation signal." Embo J 11(2): 497-505. 
Kamura, T., S. Sato, et al. (1998). "The Elongin BC complex interacts with the conserved SOCS-
box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat 
families." Genes Dev 12(24): 3872-3881. 
Kang, Y., N. Zhang, et al. (2007). "Ubiquitin receptor proteins hHR23a and hPLIC2 interact." J 
Mol Biol 365(4): 1093-1101. 
Kaplun, L., Y. Ivantsiv, et al. (2006). "The F-box protein, Ufo1, maintains genome stability by 
recruiting the yeast mating switch endonuclease, Ho, for rapid proteasome degradation." Isr 
Med Assoc J 8(4): 246-248. 
   172 
 
Kaplun, L., R. Tzirkin, et al. (2005). "The DNA damage-inducible UbL-UbA protein Ddi1 
participates in Mec1-mediated degradation of Ho endonuclease." Mol Cell Biol 25(13): 
5355-5362. 
Kaur, M., M. Pop, et al. (2007). "hHR23B is required for genotoxic-specific activation of p53 and 
apoptosis." Oncogene 26(8): 1231-1237. 
Kim, H. T., K. P. Kim, et al. (2007). "Certain pairs of ubiquitin-conjugating enzymes (E2s) and 
ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing 
all possible isopeptide linkages." J Biol Chem 282(24): 17375-17386. 
Kim, Y. J., S. Y. Yoon, et al. (2009). "NDRG2 expression decreases with tumor stages and 
regulates TCF/beta-catenin signaling in human colon carcinoma." Carcinogenesis 30(4): 
598-605. 
Kirkin, V., D. G. McEwan, et al. (2009). "A role for ubiquitin in selective autophagy." Mol Cell 
34(3): 259-269. 
Kleijnen, M. F., A. H. Shih, et al. (2000). "The hPLIC proteins may provide a link between the 
ubiquitination machinery and the proteasome." Mol Cell 6(2): 409-419. 
Ko, H. S., T. Uehara, et al. (2004). "Ubiquilin interacts with ubiquitylated proteins and proteasome 
through its ubiquitin-associated and ubiquitin-like domains." FEBS Lett 566(1-3): 110-114. 
Komander, D., M. J. Clague, et al. (2009). "Breaking the chains: structure and function of the 
deubiquitinases." Nat Rev Mol Cell Biol 10(8): 550-563. 
Kon, Y., D. Endoh, et al. (1999). "Expression of protein gene product 9.5, a neuronal ubiquitin C-
terminal hydrolase, and its developing change in sertoli cells of mouse testis." Mol Reprod 
Dev 54(4): 333-341. 
Kornitzer, D., B. Raboy, et al. (1994). "Regulated degradation of the transcription factor Gcn4." 
EMBO J 13(24): 6021-6030. 
Krylov, D. M. and E. V. Koonin (2001). "A novel family of predicted retroviral-like aspartyl 
proteases with a possible key role in eukaryotic cell cycle control." Curr Biol 11(15): R584-
587. 
Kumar, S., W. H. Kao, et al. (1997). "Physical interaction between specific E2 and Hect E3 
enzymes determines functional cooperativity." J Biol Chem 272(21): 13548-13554. 
Kumar, S., A. L. Talis, et al. (1999). "Identification of HHR23A as a substrate for E6-associated 
protein-mediated ubiquitination." J Biol Chem 274(26): 18785-18792. 
Kwon, Y. T., Y. Reiss, et al. (1998). "The mouse and human genes encoding the recognition 
component of the N-end rule pathway." Proc Natl Acad Sci U S A 95(14): 7898-7903. 
Lambertson, D., L. Chen, et al. (1999). "Pleiotropic defects caused by loss of the proteasome-
interacting factors Rad23 and Rpn10 of Saccharomyces cerevisiae." Genetics 153(1): 69-79. 
Lapatto, R., T. Blundell, et al. (1989). "X-ray analysis of HIV-1 proteinase at 2.7 A resolution 
confirms structural homology among retroviral enzymes." Nature 342(6247): 299-302. 
   173 
 
Li, L., X. Lu, et al. (1997). "XPC interacts with both HHR23B and HHR23A in vivo." Mutat Res 
383(3): 197-203. 
Li, W., M. H. Bengtson, et al. (2008). "Genome-wide and functional annotation of human E3 
ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's 
dynamics and signaling." PLoS One 3(1): e1487. 
Lin, R. C. and R. H. Scheller (2000). "Mechanisms of synaptic vesicle exocytosis." Annu Rev Cell 
Dev Biol 16: 19-49. 
Lisztwan, J., G. Imbert, et al. (1999). "The von Hippel-Lindau tumor suppressor protein is a 
component of an E3 ubiquitin-protein ligase activity." Genes Dev 13(14): 1822-1833. 
Liu, N., L. Wang, et al. (2008). "N-Myc downstream-regulated gene 2 is involved in p53-mediated 
apoptosis." Nucleic Acids Res 36(16): 5335-5349. 
Liu, Y., H. Dai, et al. (1997). "UAS(MAG1), a yeast cis-acting element that regulates the 
expression of MAG1, is located within the protein coding region of DDI1." Mol Gen Genet 
255(5): 533-542. 
Liu, Y. and W. Xiao (1997). "Bidirectional regulation of two DNA-damage-inducible genes, MAG1 
and DDI1, from Saccharomyces cerevisiae." Mol Microbiol 23(4): 777-789. 
Lorentzen, A., L. K. Vogel, et al. (2007). "Expression of NDRG2 is down-regulated in high-risk 
adenomas and colorectal carcinoma." BMC Cancer 7: 192. 
Lovering, R., I. M. Hanson, et al. (1993). "Identification and preliminary characterization of a 
protein motif related to the zinc finger." Proc Natl Acad Sci U S A 90(6): 2112-2116. 
Lowe, E. D., N. Hasan, et al. (2006). "Structures of the Dsk2 UBL and UBA domains and their 
complex." Acta Crystallogr D Biol Crystallogr 62(Pt 2): 177-188. 
Lusis, E. A., M. A. Watson, et al. (2005). "Integrative genomic analysis identifies NDRG2 as a 
candidate tumor suppressor gene frequently inactivated in clinically aggressive 
meningioma." Cancer Res 65(16): 7121-7126. 
Lustgarten, V. and J. E. Gerst (1999). "Yeast VSM1 encodes a v-SNARE binding protein that may 
act as a negative regulator of constitutive exocytosis." Mol Cell Biol 19(6): 4480-4494. 
Madura, K. and S. Prakash (1990). "Transcript levels of the Saccharomyes cerevisiae DNA repair 
gene RAD23 increase in response to UV light and in meiosis but remain constant in the 
mitotic cell cycle." Nucleic Acids Res 18(16): 4737-4742. 
Marash, M. and J. E. Gerst (2003). "Phosphorylation of the autoinhibitory domain of the Sso t-
SNAREs promotes binding of the Vsm1 SNARE regulator in yeast." Mol Biol Cell 14(8): 
3114-3125. 
Masutani, C., K. Sugasawa, et al. (1994). "Purification and cloning of a nucleotide excision repair 
complex involving the xeroderma pigmentosum group C protein and a human homologue of 
yeast RAD23." Embo J 13(8): 1831-1843. 
Mathias, N., C. N. Steussy, et al. (1998). "An essential domain within Cdc34p is required for 
binding to a complex containing Cdc4p and Cdc53p in Saccharomyces cerevisiae." J Biol 
Chem 273(7): 4040-4045. 
   174 
 
Matiuhin, Y., D. S. Kirkpatrick, et al. (2008). "Extraproteasomal Rpn10 restricts access of the 
polyubiquitin-binding protein Dsk2 to proteasome." Mol Cell 32(3): 415-425. 
McGrath, J. P., S. Jentsch, et al. (1991). "UBA 1: an essential yeast gene encoding ubiquitin-
activating enzyme." EMBO J 10(1): 227-236. 
McKnight, G. L., T. S. Cardillo, et al. (1981). "An extensive deletion causing overproduction of 
yeast iso-2-cytochrome c." Cell 25(2): 409-419. 
Miller, R. D., L. Prakash, et al. (1982). "Defective excision of pyrimidine dimers and interstrand 
DNA crosslinks in rad7 and rad23 mutants of Saccharomyces cerevisiae." Mol Gen Genet 
188(2): 235-239. 
Monia, B. P., D. J. Ecker, et al. (1989). "Gene synthesis, expression, and processing of human 
ubiquitin carboxyl extension proteins." J Biol Chem 264(7): 4093-4103. 
Mueller, T. D. and J. Feigon (2002). "Solution structures of UBA domains reveal a conserved 
hydrophobic surface for protein-protein interactions." J Mol Biol 319(5): 1243-1255. 
Mueller, T. D. and J. Feigon (2003). "Structural determinants for the binding of ubiquitin-like 
domains to the proteasome." EMBO J 22(18): 4634-4645. 
Nandi, D., P. Tahiliani, et al. (2006). "The ubiquitin-proteasome system." J Biosci 31(1): 137-155. 
Navon, A. and A. L. Goldberg (2001). "Proteins are unfolded on the surface of the ATPase ring 
before transport into the proteasome." Mol Cell 8(6): 1339-1349. 
Ng, J. M., W. Vermeulen, et al. (2003). "A novel regulation mechanism of DNA repair by damage-
induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein." 
Genes Dev 17(13): 1630-1645. 
Ng, J. M., H. Vrieling, et al. (2002). "Developmental defects and male sterility in mice lacking the 
ubiquitin-like DNA repair gene mHR23B." Mol Cell Biol 22(4): 1233-1245. 
Ohsumi, Y. and N. Mizushima (2004). "Two ubiquitin-like conjugation systems essential for 
autophagy." Semin Cell Dev Biol 15(2): 231-236. 
Ohta, T. (1989). "Role of gene duplication in evolution." Genome 31(1): 304-310. 
Ortolan, T. G., L. Chen, et al. (2004). "Rad23 stabilizes Rad4 from degradation by the 
Ub/proteasome pathway." Nucleic Acids Res 32(22): 6490-6500. 
Ozkaynak, E., D. Finley, et al. (1987). "The yeast ubiquitin genes: a family of natural gene fusions." 
EMBO J 6(5): 1429-1439. 
Page, A. M. and P. Hieter (1999). "The anaphase-promoting complex: new subunits and 
regulators." Annu Rev Biochem 68: 583-609. 
Pelzer, C., I. Kassner, et al. (2007). "UBE1L2, a novel E1 enzyme specific for ubiquitin." J Biol 
Chem 282(32): 23010-23014. 
Peng, J., D. Schwartz, et al. (2003). "A proteomics approach to understanding protein 
ubiquitination." Nat Biotechnol 21(8): 921-926. 
   175 
 
Peters, J. M., W. W. Franke, et al. (1994). "Distinct 19 S and 20 S subcomplexes of the 26 S 
proteasome and their distribution in the nucleus and the cytoplasm." J Biol Chem 269(10): 
7709-7718. 
Potuschak, T., S. Stary, et al. (1998). "PRT1 of Arabidopsis thaliana encodes a component of the 
plant N-end rule pathway." Proc Natl Acad Sci U S A 95(14): 7904-7908. 
Prives, C. and P. A. Hall (1999). "The p53 pathway." J Pathol 187(1): 112-126. 
Pusch, W., D. Jahner, et al. (1998). "Molecular cloning and testicular expression of the gene 
transcripts encoding the murine multiubiquitin-chain-binding protein (Mcb1)." Gene 207(1): 
19-24. 
Raasi, S. and C. M. Pickart (2003). "Rad23 ubiquitin-associated domains (UBA) inhibit 26 S 
proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains." J 
Biol Chem 278(11): 8951-8959. 
Rabl, J., D. M. Smith, et al. (2008). "Mechanism of gate opening in the 20S proteasome by the 
proteasomal ATPases." Mol Cell 30(3): 360-368. 
Raiborg, C. and H. Stenmark (2009). "The ESCRT machinery in endosomal sorting of ubiquitylated 
membrane proteins." Nature 458(7237): 445-452. 
Reddy, M. K., J. D. Etlinger, et al. (1975). "Removal of Z-lines and alpha-actinin from isolated 
myofibrils by a calcium-activated neutral protease." J Biol Chem 250(11): 4278-4284. 
Robzyk, K., J. Recht, et al. (2000). "Rad6-dependent ubiquitination of histone H2B in yeast." 
Science 287(5452): 501-504. 
Rothman, J. E. and G. Warren (1994). "Implications of the SNARE hypothesis for intracellular 
membrane topology and dynamics." Curr Biol 4(3): 220-233. 
Rotin, D. and S. Kumar (2009). "Physiological functions of the HECT family of ubiquitin ligases." 
Nat Rev Mol Cell Biol 10(6): 398-409. 
Russell, S. J., K. A. Steger, et al. (1999). "Subcellular localization, stoichiometry, and protein levels 
of 26 S proteasome subunits in yeast." J Biol Chem 274(31): 21943-21952. 
Saeki, Y., A. Saitoh, et al. (2002). "Ubiquitin-like proteins and Rpn10 play cooperative roles in 
ubiquitin-dependent proteolysis." Biochem Biophys Res Commun 293(3): 986-992. 
Saeki, Y., T. Sone, et al. (2002). "Identification of ubiquitin-like protein-binding subunits of the 26S 
proteasome." Biochem Biophys Res Commun 296(4): 813-819. 
Saeki, Y. and K. Tanaka (2008). "Cell biology: two hands for degradation." Nature 453(7194): 460-
461. 
Sakharkar, K. R., M. K. Sakharkar, et al. (2006). "Functional and evolutionary analyses on 
expressed intronless genes in the mouse genome." FEBS Lett 580(5): 1472-1478. 
Saraste, M. and M. Hyvonen (1995). "Pleckstrin homology domains: a fact file." Curr Opin Struct 
Biol 5(3): 403-408. 
Schauber, C., L. Chen, et al. (1998). "Rad23 links DNA repair to the ubiquitin/proteasome 
pathway." Nature 391(6668): 715-718. 
   176 
 
Scheffner, M., J. M. Huibregtse, et al. (1993). "The HPV-16 E6 and E6-AP complex functions as a 
ubiquitin-protein ligase in the ubiquitination of p53." Cell 75(3): 495-505. 
Scheffner, M., B. A. Werness, et al. (1990). "The E6 oncoprotein encoded by human papillomavirus 
types 16 and 18 promotes the degradation of p53." Cell 63(6): 1129-1136. 
Scherer, D. C., J. A. Brockman, et al. (1995). "Signal-induced degradation of I kappa B alpha 
requires site-specific ubiquitination." Proc Natl Acad Sci U S A 92(24): 11259-11263. 
Schreiner, P., X. Chen, et al. (2008). "Ubiquitin docking at the proteasome through a novel 
pleckstrin-homology domain interaction." Nature 453(7194): 548-552. 
Schwartz, A. L. and A. Ciechanover (1999). "The ubiquitin-proteasome pathway and pathogenesis 
of human diseases." Annu Rev Med 50: 57-74. 
Sekiya, F., Y. S. Bae, et al. (1999). "AHNAK, a protein that binds and activates phospholipase C-
gamma1 in the presence of arachidonic acid." J Biol Chem 274(20): 13900-13907. 
Shih, S. C., K. E. Sloper-Mould, et al. (2000). "Monoubiquitin carries a novel internalization signal 
that is appended to activated receptors." EMBO J 19(2): 187-198. 
Shimura, H., N. Hattori, et al. (2000). "Familial Parkinson disease gene product, parkin, is a 
ubiquitin-protein ligase." Nat Genet 25(3): 302-305. 
Sirkis, R., J. E. Gerst, et al. (2006). "Ddi1, a eukaryotic protein with the retroviral protease fold." J 
Mol Biol 364(3): 376-387. 
Skaar, J. R. and M. Pagano (2009). "Control of cell growth by the SCF and APC/C ubiquitin 
ligases." Curr Opin Cell Biol 21(6): 816-824. 
Smith, D. M., S. C. Chang, et al. (2007). "Docking of the proteasomal ATPases' carboxyl termini in 
the 20S proteasome's alpha ring opens the gate for substrate entry." Mol Cell 27(5): 731-
744. 
Sobhian, B., G. Shao, et al. (2007). "RAP80 targets BRCA1 to specific ubiquitin structures at DNA 
damage sites." Science 316(5828): 1198-1202. 
Spence, J., S. Sadis, et al. (1995). "A ubiquitin mutant with specific defects in DNA repair and 
multiubiquitination." Mol Cell Biol 15(3): 1265-1273. 
Staub, O., S. Dho, et al. (1996). "WW domains of Nedd4 bind to the proline-rich PY motifs in the 
epithelial Na+ channel deleted in Liddle's syndrome." EMBO J 15(10): 2371-2380. 
Staub, O., I. Gautschi, et al. (1997). "Regulation of stability and function of the epithelial Na+ 
channel (ENaC) by ubiquitination." EMBO J 16(21): 6325-6336. 
Sturm, A. and S. Lienhard (1998). "Two isoforms of plant RAD23 complement a UV-sensitive 
rad23 mutant in yeast." Plant J 13(6): 815-821. 
Sugasawa, K., C. Masutani, et al. (1996). "HHR23B, a human Rad23 homolog, stimulates XPC 
protein in nucleotide excision repair in vitro." Mol Cell Biol 16(9): 4852-4861. 
Sugasawa, K., J. M. Ng, et al. (1998). "Xeroderma pigmentosum group C protein complex is the 
initiator of global genome nucleotide excision repair." Mol Cell 2(2): 223-232. 
   177 
 
Sugasawa, K., J. M. Ng, et al. (1997). "Two human homologs of Rad23 are functionally 
interchangeable in complex formation and stimulation of XPC repair activity." Mol Cell 
Biol 17(12): 6924-6931. 
Sussman, J., D. Stokoe, et al. (2001). "Protein kinase B phosphorylates AHNAK and regulates its 
subcellular localization." J Cell Biol 154(5): 1019-1030. 
Sutovsky, P. (2003). "Ubiquitin-dependent proteolysis in mammalian spermatogenesis, fertilization, 
and sperm quality control: killing three birds with one stone." Microsc Res Tech 61(1): 88-
102. 
Swanson, K. A., R. S. Kang, et al. (2003). "Solution structure of Vps27 UIM-ubiquitin complex 
important for endosomal sorting and receptor downregulation." EMBO J 22(18): 4597-4606. 
Tanaka, K., M. Funakoshi, et al. (2006). "Identification of two isoforms of Dsk2-related protein 
XDRP1 in Xenopus eggs." Biochem Biophys Res Commun 350(3): 768-773. 
Terrell, J., S. Shih, et al. (1998). "A function for monoubiquitination in the internalization of a G 
protein-coupled receptor." Mol Cell 1(2): 193-202. 
Thrower, J. S., L. Hoffman, et al. (2000). "Recognition of the polyubiquitin proteolytic signal." 
Embo J 19(1): 94-102. 
Toniolo, D., M. Persico, et al. (1988). "A "housekeeping" gene on the X chromosome encodes a 
protein similar to ubiquitin." Proc Natl Acad Sci U S A 85(3): 851-855. 
Treier, M., L. M. Staszewski, et al. (1994). "Ubiquitin-dependent c-Jun degradation in vivo is 
mediated by the delta domain." Cell 78(5): 787-798. 
Ulrich, H. D. and H. Walden (2010). "Ubiquitin signalling in DNA replication and repair." Nat Rev 
Mol Cell Biol 11(7): 479-489. 
van der Spek, P. J., A. Eker, et al. (1996). "XPC and human homologs of RAD23: intracellular 
localization and relationship to other nucleotide excision repair complexes." Nucleic Acids 
Res 24(13): 2551-2559. 
van der Spek, P. J., C. E. Visser, et al. (1996). "Cloning, comparative mapping, and RNA 
expression of the mouse homologues of the Saccharomyces cerevisiae nucleotide excision 
repair gene RAD23." Genomics 31(1): 20-27. 
van Nocker, S., S. Sadis, et al. (1996). "The multiubiquitin-chain-binding protein Mcb1 is a 
component of the 26S proteasome in Saccharomyces cerevisiae and plays a nonessential, 
substrate-specific role in protein turnover." Mol Cell Biol 16(11): 6020-6028. 
Venables, J. P. (2004). "Aberrant and alternative splicing in cancer." Cancer Res 64(21): 7647-
7654. 
Verma, R., L. Aravind, et al. (2002). "Role of Rpn11 metalloprotease in deubiquitination and 
degradation by the 26S proteasome." Science 298(5593): 611-615. 
Walters, K. J., M. F. Kleijnen, et al. (2002). "Structural studies of the interaction between ubiquitin 
family proteins and proteasome subunit S5a." Biochemistry 41(6): 1767-1777. 
   178 
 
Walters, K. J., P. J. Lech, et al. (2003). "DNA-repair protein hHR23a alters its protein structure 
upon binding proteasomal subunit S5a." Proc Natl Acad Sci U S A 100(22): 12694-12699. 
Wang, Q., P. Young, et al. (2005). "Structure of S5a bound to monoubiquitin provides a model for 
polyubiquitin recognition." J Mol Biol 348(3): 727-739. 
Ward, C. L., S. Omura, et al. (1995). "Degradation of CFTR by the ubiquitin-proteasome pathway." 
Cell 83(1): 121-127. 
Watkins, J. F., P. Sung, et al. (1993). "The Saccharomyces cerevisiae DNA repair gene RAD23 
encodes a nuclear protein containing a ubiquitin-like domain required for biological 
function." Mol Cell Biol 13(12): 7757-7765. 
Weissman, A. M. (2001). "Themes and variations on ubiquitylation." Nat Rev Mol Cell Biol 2(3): 
169-178. 
White, R. E., J. R. Dickinson, et al. (2011). "The retroviral proteinase active site and the N-terminus 
of Ddi1 are required for repression of protein secretion." FEBS Lett 585(1): 139-142. 
Wiborg, O., M. S. Pedersen, et al. (1985). "The human ubiquitin multigene family: some genes 
contain multiple directly repeated ubiquitin coding sequences." EMBO J 4(3): 755-759. 
Wilkinson, C. R., M. Seeger, et al. (2001). "Proteins containing the UBA domain are able to bind to 
multi-ubiquitin chains." Nat Cell Biol 3(10): 939-943. 
Winget, J. M. and T. Mayor (2010). "The diversity of ubiquitin recognition: hot spots and varied 
specificity." Mol Cell 38(5): 627-635. 
Xie, Y. (2010). "Structure, assembly and homeostatic regulation of the 26S proteasome." J Mol Cell 
Biol 2(6): 308-317. 
Xie, Y. and A. Varshavsky (1999). "The E2-E3 interaction in the N-end rule pathway: the RING-
H2 finger of E3 is required for the synthesis of multiubiquitin chain." EMBO J 18(23): 
6832-6844. 
Xing, J. Z., L. Zhu, et al. (2005). "Dynamic monitoring of cytotoxicity on microelectronic sensors." 
Chem Res Toxicol 18(2): 154-161. 
Xu, P., D. M. Duong, et al. (2009). "Quantitative proteomics reveals the function of unconventional 
ubiquitin chains in proteasomal degradation." Cell 137(1): 133-145. 
Yao, T. and R. E. Cohen (2002). "A cryptic protease couples deubiquitination and degradation by 
the proteasome." Nature 419(6905): 403-407. 
Yaron, A., A. Hatzubai, et al. (1998). "Identification of the receptor component of the 
IkappaBalpha-ubiquitin ligase." Nature 396(6711): 590-594. 
Ye, Y. and M. Rape (2009). "Building ubiquitin chains: E2 enzymes at work." Nat Rev Mol Cell 
Biol 10(11): 755-764. 
Yoshimura, T., K. Kameyama, et al. (1993). "Molecular characterization of the "26S" proteasome 
complex from rat liver." J Struct Biol 111(3): 200-211. 
Young, P., Q. Deveraux, et al. (1998). "Characterization of two polyubiquitin binding sites in the 26 
S protease subunit 5a." J Biol Chem 273(10): 5461-5467. 
   179 
 
Zachariae, W., A. Shevchenko, et al. (1998). "Mass spectrometric analysis of the anaphase-
promoting complex from yeast: identification of a subunit related to cullins." Science 
279(5354): 1216-1219. 
Zheng, N., P. Wang, et al. (2000). "Structure of a c-Cbl-UbcH7 complex: RING domain function in 
ubiquitin-protein ligases." Cell 102(4): 533-539. 
 
   180 
 
Appendix 






















           
Ddi2 - DNA 
damage inducible 
protein 2 
63003917 45 kDa (K)AFVDSGAQmTIMSQAcAER(C) 697.6905 2,090.05 249 267 95% 28 34 
(R)ALcELESGIPAAESQIVYAERPLTDNHR(S) 1,047.90 3,140.68 32 59 95%     
(K)DGDVVILR(Q) 443.3456 884.6766 68 75 95%     
(R)DLSEVTFSLQVDADFELHNFR(A) 828.3881 2,482.14 11 31 95%     
(R)DmLLANPHELSLLK(E) 806.4767 1,610.94 140 153 95%     
(R)EDIRPEEIADQELAEAIQK(S) 734.2205 2,199.64 371 389 95%     
(K)ERNPPLAEALLSGDLEK(F) 928.4631 1,854.91 154 170 95%     
(R)HQCSIDLK(K) 501.2536 1,000.49 330 337 95%     
(R)IDFSSIAVPGTSNPQ(Q) 768.0256 1,534.04 94 108 95%     
(R)IDFSSIAVPGTSNPQQR(Q) 909.0137 1,816.01 94 110 95%     
(K)KNVLVIGTTGSQTTFLPEGELPEcAR(L) 940.1979 2,817.57 338 363 95%     
(R)LFSADPFDLEAQAK(I) 776.6027 1,551.19 192 205 95%     
(-)mLLTVYcVR(R) 586.2347 1,170.45 1 9 95%     
(R)NPPLAEALLSGDLEK(F) 523.5121 1,567.51 156 170 95%     
(K)NVLVIGTTGSQTTFLPEGELPEcAR(L) 897.8588 2,690.55 339 363 95%     
(P)PLAEALLSGDLEK(F) 678.7872 1,355.56 158 170 95%     
(D)PRPAVQFSNLPR(I) 692.4496 1,382.88 82 93 95%     
(A)qHSSPGEMASSPQGLDNPALLR(D) 759.5292 2,275.57 118 139 95%     
(R)QKENADPRPAVQFSNLPR(I) 689.9611 2,066.86 76 93 95%     
(R)QQNIEENmTIAMEEAPESFGQVAmLYINcR(V) 1,184.14 3,549.40 212 241 95%     
(R)SLASYGLK(D) 420.2471 838.4796 60 67 95%     
(H)SSPGEMASSPQGLDNPALLR(D) 1,013.92 2,025.82 120 139 95%     
(A)SSPQGLDNPALLR(D) 684.4547 1,366.89 127 139 95%     
(R)TQAQHSSPGEmASSPQGLDNPALLR(D) 870.8612 2,609.56 115 139 95%     
(R)VHLAQVQIEGDFLAcSF(S) 968.2672 1,934.52 294 310 95%     
(R)VHLAQVQIEGDFLAcSFSILEEQPmDmLLGLDmLK(R) 1,348.12 4,041.34 294 328 95%     
(R)VLVEQQQDR(A) 558.2577 1,114.50 174 182 95%     
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(R)WAGIAKGVGTQK(I) 608.3932 1,214.77 278 289 95%     









9845265 15 kDa (K)ESTLHLVLR(L) 534.4557 1,066.90 64 72 95% 2 20% 
(K)TITLEVEPSDTIENVK(A) 895.1722 1,788.33 12 27 95%     
   
        AHNAK2 
nucleoprotein 2 
309272904 183 kDa (K)VEADVAPPQVQGDLK(T) 783.4822 1,564.95 650 664 95% 6 2% 
(K)LEGELALADKDVAAK(D) 772.2322 1,542.45 774 788 95%     
(K)LPEGQLPEAELPAAQAAAAAGAGLK(G) 782.4075 2,344.20 688 712 95%     
(K)VEADVAPPQVQGDLK(T) 783.5361 1,565.06 650 664 95%     
(K)LPEGQLPEAELPAAQAAAAAGAGLK(G) 782.3725 2,344.10 688 712 95%     
(K)LEGELALADKDVAAK(D) 772.1526 1,542.29 774 788 95%     
   





13386106 26 kDa (K)LFLVQLQEK(A) 559.3672 1,116.72 174 182 95% 8 33 
(R)LMTEILGR(Q) 475.4106 948.8066 124 131 95%     
(K)LPGGELNPGEDEVEGLKR(L) 637.3655 1,909.07 106 123 95%     
(K)LPGGELNPGEDEVEGLKR(L) 637.6035 1,909.79 106 123 95%     
(R)TVEGVLIVHEHR(L) 694.8687 1,387.72 79 90 95%     
(K)LVAAPLFELYDNAPGYGPIISSLPQLLSR(F) 1,039.34 3,114.99 193 221 95%     
(K)LPGGELNPGEDEVEGLKR(L) 955.2977 1,908.58 106 123 95%     
(K)LPGGELNPGEDEVEGLK(R) 877.1522 1,752.29 106 122 95%     
   




6753622 31 kDa (K)LFLVQLQEK(A) 559.3672 1,116.72 174 182 95% 7 33 
(R)LMTEILGR(Q) 475.4106 948.8066 124 131 95%     
(K)LPGGELNPGEDEVEGLKR(L) 637.3655 1,909.07 106 123 95%     
(R)TVEGVLIVHEHR(L) 694.8687 1,387.72 79 90 95%     
(R)TVEGVLIVHEHR(L) 694.8687 1,387.72 79 90 95%     
(K)LVAAPLFELYDNAPGYGPIISSLPQLLSR(F) 1,039.34 3,114.99 193 221 95%     
(K)LPGGELNPGEDEVEGLKR(L) 955.2977 1,908.58 106 123 95%     
(K)LPGGELNPGEDEVEGLK(R) 877.1522 1,752.29 106 122 95%     
   
        Mettl7b - 
methyltransferase 
activity 
27229118 28 kDa (R)FIVAYGENMK(Q) 594.6697 1,187.32 122 131 95% 2 13 
(R)VLRPGGLLFFWEHVAEPQGSR(A) 799.4789 2,395.41 163 183 95%     
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6754724 37 kDa (R)SVVALHNLINNK(I) 661.3832 1,320.75 268 279 95% 1 4 
           






19882201 100 kDa (K)AIQLEYSEAR(R) 590.6642 1,179.31 293 302 95% 2 5 
   






19705424 61 kDa (R)LNILDTLSK(F) 509.1616 1,016.31 704 712 95% 3 6 
(R)NEcDPALALLSDYVLHNSNTmR(L) 850.7335 2,549.18 457 478 95%     
(K)TITGFQTHTTPVLLAHGER(A) 694.0618 2,079.16 861 879 95%     
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           Ddi2 - DNA damage 
inducible protein 2 
63003917 45 kDa (K)AFVDSGAQMTImSQAcAER(C) 1,698.07 2,091.19 249 267 95% 22 64 
(R)ALcELESGIPAAESQIVYAER(P) 1,153.82 2,305.63 32 52 95%     
(R)ALcELESGIPAAESQIVYAERPLTDNHR(S) 1,048.15 3,141.42 32 59 95%     
(K)DGDVVILR(Q) 886.6256 885.6183 68 75 95%     
(R)DMLLANPHELSLLK(E) 798.5842 1,595.15 140 153 95%     
(R)EDIRPEEIADQELAEAIQK(S) 733.4832 2,197.43 371 389 95%     
(K)ERNPPLAEALLSGDLEK(F) 618.5752 1,852.70 154 170 95%     
(R)IDFSSIAVPGTSNPQQR(Q) 909.4165 1,816.82 94 110 95%     
(K)KNVLVIGTTGSQTTFLPEGELPEcAR(L) 940.3682 2,818.08 338 363 95%     
(R)LFSADPFDLEAQAK(I) 778.3648 1,554.72 192 205 95%     
(-)MLLTVYcVR(R) 578.2561 1,154.50 1 9 95%     
(R)NPPLAEALLSGDLEK(F) 784.9847 1,567.95 156 170 95%     
(K)NVLVIGTTGSQTTFLPEGELPEcAR(L) 897.9587 2,690.85 339 363 95%     
(R)PAVQFSNLPR(I) 564.3184 1,126.62 84 93 95%     
(N)PPLAEALLSGDLEK(F) 727.3339 1,452.65 157 170 95%     
(A)QHSSPGEMASSPQGLDNPALLR(D) 764.9255 2,291.75 118 139 95%     
(R)QKENADPRPAVQFSNLPR(I) 690.1232 2,067.35 76 93 95%     
(R)SLASYGLK(D) 420.4274 838.8402 60 67 95%     
(R)TQAQHsSPGEmASSPQGLDNPALLR(D) 897.3158 2,688.93 115 139 95%     
(R)VHLAQVQIEGDFLAcSF(S) 968.3947 1,934.77 294 310 95%     
(R)VLVEQQQDR(A) 1,114.55 1,113.54 174 182 95%     
(R)WAGIAK(G) 645.5352 644.5279 278 283 95%     




31980648 56 kDa (K)ADKLAEEHGS(-) 529.5219 1,057.03 520 529 95% 25 63 
(K)AHGGYSVFAGVGER(T) 704.2245 1,406.43 226 239 95%     
(R)AIAELGIYPAVDPLDSTSR(I) 995.8477 1,989.68 388 406 95%     
(R)DQEGQDVLLFIDNIFR(F) 961.6056 1,921.20 295 310 95%     
(R)EGNDLYHEMIESGVINLK(D) 688.117 2,061.33 242 259 95%     
(R)FLSQPFQVAEVFTGHMGK(L) 1,012.40 2,022.79 463 480 95%     
(R)FTQAGSEVSALLGR(I) 719.1022 1,436.19 311 324 95%     
(K)GFQQILAGEYDHLPEQAFYMVGPIEEAVAK 1,118.06 3,351.16 490 519 95%     
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(A) 
(K)IGLFGGAGVGK(T) 489.2301 976.4457 202 212 95%     
(R)IMNVIGEPIDER(G) 694.2857 1,386.56 144 155 95%     
(R)IPSAVGYQPTLATDMGTMQER(I) 1,133.68 2,265.35 325 345 95%     
(K)IPVGPETLGR(I) 520.8138 1,039.61 134 143 95%     
(R)LVLEVAQHLGESTVR(T) 825.9395 1,649.86 95 109 95%     
(Y)MVGPIEEAVAK(A) 573.1008 1,144.19 509 519 95%     
(K)QFAPIHAEAPEFIEMSVEQEILVTGIK(V) 1,010.35 3,028.02 162 188 95%     
(K)SLQDIIAILGMDELSEEDK(L) 1,060.97 2,119.93 433 451 95%     
(K)SLQDIIAILGMDELSEEDKLTVSR(A) 893.13 2,676.37 433 456 95%     
(R)TIAMDGTEGLVR(G) 632.7816 1,263.55 110 121 95%     
(R)TREGNDLYHEMIESGVINLK(D) 774.0273 2,319.06 240 259 95%     
(K)TVLIMELINNVAK(A) 730.1769 1,458.34 213 225 95%     
(R)VALTGLTVAEYFR(D) 721.2916 1,440.57 282 294 95%     
(K)VALVYGQMNEPPGAR(A) 801.5459 1,601.08 265 279 95%     
(K)VLDSGAPIK(I) 450.5769 899.1393 125 133 95%     
(K)VLDSGAPIKIPVGPETLGR(I) 641.3453 1,921.01 125 143 95%     
(K)VVDLLAPYAK(G) 545.0536 1,088.09 189 198 95%     









170172520 53 kDa (K)AQIMNVSWSADHR(V) 758.9209 1,515.83 441 453 95% 24 49 
(K)DRTEPVTGFQK(A) 639.3469 1,276.68 251 261 95%     
(K)DRTFPTPIAKPPVFTGK(D) 625.2919 1,872.85 234 250 95%     
(K)DSEEDVVETPAVSHDEHTHQEIK(G) 878.3528 2,632.04 145 167 95%     
(K)EDILSFLEK(Q) 548.0388 1,094.06 203 211 95%     
(R)EELKPVALAR(G) 563.5911 1,125.17 292 301 95%     
(R)ILKEDILSFLEK(Q) 725.2795 1,448.54 200 211 95%     
(R)LAMENNIK(L) 467.5469 933.0792 180 187 95%     
(K)LGSSGQLGTTDLTGGTFTLSNIGSIGGTYA
K(P) 992.1195 2,973.34 380 410 95%     
(K)LREELKPVALAR(G) 466.0432 1,395.11 290 301 95%     
(K)LSDIGEGIR(E) 959.486 958.4787 69 77 95%     
(K)LSEVVGSGK(D) 438.6112 875.2078 188 196 95%     
(K)LSEVVGSGKDGR(I) 602.7032 1,203.39 188 199 95%     
(R)LYYNLDDIAYVGK(P) 774.8677 1,547.72 121 133 95%     
(R)LYYNLDDIAYVGKPLIDIETEALK(D) 924.179 2,769.52 121 144 95%     
(K)PLIDIETEALK(D) 621.89 1,241.77 134 144 95%     
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(K)PVILPPEVAIGALGAIK(A) 553.8816 1,658.62 411 427 95%     
(K)QTGAILPPSPK(S) 555.0642 1,108.11 212 222 95%     
(R)RLAMENNIK(L) 545.3259 1,088.64 179 187 95%     
(K)SEITPPPPQPK(D) 596.2476 1,190.48 223 233 95%     
(K)SYLENPAFMLLDLK(-) 828.5388 1,655.06 469 482 95%     
(R)TEPVTGFQK(A) 504.3875 1,006.76 253 261 95%     
(R)TFPTPIAKPPVFTGK(D) 801.6519 1,601.29 236 250 95%     
(R)VIDGATMSR(F) 475.8932 949.7718 454 462 95%     
           Hsd17b4, 
Peroxisomal 
multifunctional 
enzyme type 2 
31982273 79 kDa (K)AAVAVPNRPPDAVLR(D) 774.2426 1,546.47 479 493 95% 28 53 
(R)AAWDHMK(K) 430.2036 858.3926 133 139 95%     
(K)ALHGEQYLELYKPLPR(S) 643.5873 1,927.74 403 418 95%     
(K)ANAVFEWHITK(G) 658.8061 1,315.60 645 655 95%     
(K)AVANYDSVEAGEK(L) 677.5391 1,353.06 69 81 95%     
(R)AYALAFAER(G) 507.0262 1,012.04 24 32 95%     
(K)cEAVIADILDK(G) 624.332 1,246.65 424 434 95%     
(R)DATSLNQAALYR(L) 662.3386 1,322.66 494 505 95%     
(R)FAKPVYPGQTLQTEMWK(E) 1,012.51 2,023.01 562 578 95%     
(K)FVYEGSADFScLPTFGVIVAQK(S) 813.0669 2,436.18 362 383 95%     
(R)GALVIVNDLGGDFK(G) 710.5265 1,419.04 33 46 95%     
(R)GNImLSQK(L) 454.3453 906.6761 717 724 95%     
(K)GSGVVIVmDVYSYSGK(E) 839.2698 1,676.53 435 450 95%     
(R)HVLQQFADNDVSR(F) 765.6329 1,529.25 542 554 95%     
(K)IcDFSNASKPQTIQESTGGIVEVLHK(V) 953.999 2,858.98 276 301 95%     
(R)IDVVVNNAGILR(D) 642.6417 1,283.27 93 104 95%     
(R)ILMTSSASGIYGNFGQANYSAAK(L) 785.3569 2,353.05 146 168 95%     
(R)ISDEDWDIIHR(V) 700.5079 1,399.00 111 121 95%     
(K)LGILGLcNTLAIEGR(K) 800.8665 1,599.72 169 183 95%     
(K)LPSFSSSYTELQSIMYALGVGASVK(N) 1,318.75 2,635.48 331 355 95%     
(R)NQPmTPEAVR(D) 580.1921 1,158.37 261 270 95%     
(K)PQTIQESTGGIVEVLHK(V) 613.2645 1,836.77 285 301 95%     
(K)SGSGEVYQGPAK(G) 590.8414 1,179.67 669 680 95%     
(K)SmMNGGLAEVPGLSFNFAK(A) 994.3489 1,986.68 384 402 95%     
(K)TALDTFGR(I) 441.3168 880.619 85 92 95%     
(R)TSHAAPAATSGFVGAVGHK(L) 589.9918 1,766.95 312 330 95%     
(K)VDSEGISPNR(T) 537.8185 1,073.62 302 311 95%     
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(R)VVLVTGAGGGLGR(A) 578.6782 1,155.34 11 23 95%     
           Ahnak2, AHNAK 
nucleoprotein 2 
309272904 341 kDa (K)AGQVGVK(L) 658.4017 657.3944 681 687 95% 10 6 
(K)GEVSAPDLEVSLPGVEVDIQAPGAK(L) 827.1831 2,478.53 749 773 95%     
(K)LEGELALADK(D) 530.4949 1,058.98 774 783 95%     
(K)LEGELALADKDVAAK(D) 772.8368 1,543.66 774 788 95%     
(K)LPEGQLPEAELPAAQ(A) 782.3005 1,562.59 688 702 95%     
(K)LPEGQLPEAELPAAQAAAAAGAGLK(G) 782.7839 2,345.33 688 712 95%     
(K)mPSFGVSAPGKPSLEASLEVGAPK(V) 792.3599 2,374.06 626 649 95%     
(K)TPDLSVQLPSADLDLK(A) 856.9283 1,711.84 1345 1360 95%     
(K)TPDLSVQLR(S) 515.5115 1,029.01 1174 1182 95%     
(K)VEADVAPPQVQGDLK(T) 783.8997 1,565.78 650 664 95%     





183396774 51 kDa 
(R)AVAENQPFLIEAmTYR(I) 93598% 1,869.95 
31800
% 333 95% 21 59 
(R)DYPLELFmSQcYGNVNDPGK(G) 1,182.58 2,363.15 
16900
% 188 95%     
(R)EAGVLMYR(D) 469.668 937.3214 
16100
% 168 95%     
(R)GPGYGIMSIR(V) 526.8532 1,051.69 289 298 95%     
(R)HFVTISSPLATQIPQAVGAAYAAK(R) 814.6831 2,441.03 202 225 95%     
(R)HLQTYGEHYPLDHFDK(-) 667.6578 1,999.95 431 446 95%     
(R)IGHHSTSDDSSAYR(S) 767.1194 1,532.22 334 347 95%     
(R)ILYESQR(Q) 454.5604 907.1062 119 125 95%     
(R)KLKPNPSLLFSDVYQEmPAQLR(R) 864.9031 2,591.69 401 422 95%     
(K)KVmEAFEQAER(K) 677.5345 1,353.05 390 400 95%     
(K)LEFIQPNVISGIPIYR(V) 930.8169 1,859.62 66 81 95%     
(K)LKPNPSLLFSDVYQEMPAQLR(R) 816.9111 2,447.71 402 422 95%     
(R)NNGYAISTPTSEQYR(G) 851.6401 1,701.27 267 281 95%     
(R)QGQIINPSEDPHLPQEEVLK(F) 758.3151 2,271.92 86 105 95%     
(R)QYLLNQGWWDEEQEK(A) 984.4382 1,966.86 367 381 95%     
(R)RQQESLAR(H) 494.5188 987.023 423 430 95%     
(R)SMTLLNTmDR(I) 598.7708 1,195.53 109 118 95%     
(R)SVDEVNYWDK(Q) 628.5562 1,255.10 348 357 95%     
(R)TDLVFGQYR(E) 550.206 1,098.40 152 160 95%     
(R)VDGNDVFAVYNATK(E) 756.8093 1,511.60 299 312 95%     
(K)VMEAFEQAER(K) 606.2009 1,210.39 391 400 95%     
 
          








(Rpn1) 74315975 106 kDa (R)QGALIASALIMIQQTEITcPK(V) 1,143.33 2,284.65 685 705 95% 1 2 






40353220 36 kDa 
(R)AAVEQVPVEPYK(I) 66562% 1,329.23 
17600
% 187 95% 16 54 
(K)DPTAVIFGEDVAFGGVFR(C) 949.5188 1,897.02 1800% 35 95%     
(R)EVASmAQEK(L) 505.6213 1,009.23 
21600
% 224 95%     
(K)GLLLScIEDK(N) 574.4749 1,146.94 
15300
% 162 95%     
(K)GLLLScIEDKNPcIFFEPK(I) 1,140.78 2,279.55 
15300
% 171 95%     
(K)IPLSQAEVIQEGSDVTLVAWGTQVHVIR(E) 1,016.68 3,047.01 
18800
% 215 95%     
(K)LGVScEVIDLR(T) 631.0962 1,260.18 225 235 95%     
(-)mNLFQSITSALDNSLAK(D) 935.7461 1,869.48 1 17 95%     
(-)MNLFQSITSALDNSLAKDPTAVIFGE(D) 928.0989 2,781.27 1 26 95%     
(K)NPcIFFEPK(I) 577.2714 1,152.53 163 171 95%     
(R)SGDLFNcGSLTIR(A) 720.7242 1,439.43 101 113 95%     
(L)SQAEVIQEGSDVTLVAWGTQVHVIR(E) 909.2654 2,724.77 191 215 95%     
(R)TIVPWDVDTVcK(S) 717.0765 1,432.14 236 247 95%     
(R)VcGYDTPFPHIFEPF(Y) 913.9342 1,825.85 290 304 95%     
(R)VcGYDTPFPHIFEPFYIPDK(W) 815.3324 2,442.98 290 309 95%     
(R)VFNTPLcEQGIVGF(G) 791.0175 1,580.02 49 62 95%     




like protein 1 
21450323 96 kDa 
(R)AEPYcSVLPGFTFIQHLPLSER(I) 85498% 2,561.92 
38800
% 409 95% 19 30 
(K)AIVIcPTDEDLKDR(T) 82325% 1,644.48 
52900
% 542 95%     
(R)APQQQPPPQQPPPPQPPPQQPPPPPSYS
PAR(N) 111098% 3,329.93 
69400
% 724 95%     
(K)EALGGQALYPHVLVK(N) 79794% 1,593.87 
36200
% 376 95%     
(K)HAASNPSK(K) 406.8139 811.6133 
44200
% 449 95%     
(K)HLPSTEPDPHVVR(I) 742.6797 1,483.34 
27200
% 284 95%     
(K)INEEISVK(H) 466.988 931.9615 
26400
% 271 95%     
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(K)NcAVEFNFGQR(A) 671.8251 1,341.64 
37700
% 387 95%     
(R)NYILDQTNVYGSAQR(R) 871.6781 1,741.34 502 516 95%     
(K)QEAPPSFLPPEASQLK(T) 870.0521 1,738.09 148 163 95%     
(K)QENESSYDR(R) 564.7166 1,127.42 118 126 95%     
(R)QNQFYETPVIK(Q) 684.3629 1,366.71 107 117 95%     
(R)RPLDmEPQQQVYHPELK(T) 709.2852 2,124.83 127 143 95%     
(K)RTDEEGKDVPDHAVLEmK(A) 696.3472 2,086.02 546 563 95%     
(R)SSGYPLTIEGFAYLWSGAR(A) 1,038.47 2,074.92 230 248 95%     
(R)TDEEGKDVPDHAVLEmK(A) 643.9038 1,928.69 547 563 95%     
(K)TEmKQEAPPSFLPPEASQLK(T) 749.2635 2,244.77 144 163 95%     
(R)WDVLIQQATQcLNR(L) 873.3574 1,744.70 478 491 95%     
(K)YNILGTNAImDK(M) 685.4314 1,368.85 451 462 95%     
           Uba52, UBIQUITIN-
60S RIBOSOMAL 
PROTEIN L40 
9845265 15 kDa (K)ESTLHLVLR(L) 53445% 1,066.89 6400% 72 95% 3 27 
(K)TITLEVEPSDTIENVK(A) 89449% 1,786.98 1200% 27 95%     
(R)TLSDYNIQK(E) 541.6327 1,081.25 5500% 63 95%     




67625743 77 kDa (K)DSSTPGPGEGIPLSNGGGGSTSR(K) 1,044.69 2,087.36 29 51 95% 12 25 
(K)FSDLTDNFSSPHAR(R) 532.5734 1,594.70 335 348 95%     
(R)GLALNDcHAEIISR(R) 785.2285 1,568.44 387 400 95%     
(K)IESGEGTIPVR(S) 579.745 1,157.48 484 494 95%     
(R)IFSPHEPVLEEPADR(H) 868.7659 1,735.52 456 470 95%     
(R)ISNIEDLPPLYTLNKPLLSGISNAEAR(Q) 981.1102 2,940.31 564 590 95%     
(K)ITKPTTYHESK(L) 653.4811 1,304.95 652 662 95%     
(K)NPVMILNELRPGLK(Y) 532.5318 1,594.57 235 248 95%     
(R)SNASIQTWDGVLQGER(L) 881.9541 1,761.89 495 510 95%     
(R)TKIESGEGTIPVR(S) 694.8652 1,387.72 482 494 95%     
(K)VLSGVVMTTGTDVK(D) 704.8575 1,407.70 351 364 95%     
(K)YDFLSESGESHAK(S) 735.6663 1,469.32 249 261 95%     
           





118403322 45 kDa (K)AAQLGFGGVYVR(T) 619.7081 1,237.40 79 90 95% 12 38 
(R)AVIFEDcAVPVANR(I) 781.286 1,560.56 243 256 95%     
(K)DYAVQQYMR(D) 587.4801 1,172.95 379 387 95%     
(K)FASYcLTEPGSGSDAASLLTSAK(Q) 778.6967 2,333.07 153 175 95%     
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(K)GIScIVVEK(G) 503.2283 1,004.44 212 220 95%     
(R)IGTEGQGFLIAmK(G) 691.1015 1,380.19 257 269 95%     
(R)INVAScSLGAAHASVILTQEHLK(V) 807.6353 2,419.88 276 298 95%     
(R)SQYLQFQLADmATK(L) 831.1588 1,660.30 310 323 95%     
(R)TAAVALQEER(E) 544.8351 1,087.66 333 342 95%     
(R)TDVGGSGLSR(L) 475.0832 948.1518 91 100 95%     
(K)VAFDFAAR(E) 449.1587 896.3028 49 56 95%     
(R)VHQILEGSNEVmR(M) 510.2151 1,527.62 391 403 95%     




123240391 119 kDa (R)ENNQIGPSLR(L) 565.0961 1,128.18 381 390 95% 2 2 
(K)FTQEDEQLVQK(K) 682.8077 1,363.60 928 938 95%     
           Psmc2 -  26S 
Proteasome 
ATPase subunit 2 
(Rpn2) 33859604 53 kDa (R)ALDEGDIALLK(T) 579.3273 1,156.64 66 76 95% 1 2 
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           Ddi2 - DNA 
damage inducible 
protein 2 
63003917 45 kDa (K)AFVDSGAQMTIM(S) 636.4245 1270.8344 249 260 95% 35 72 
(K)AFVDSGAQMTImSQAcAER(C) 697.0444 2088.1115 249 267 95%     
(R)ALcELESGIPAAESQIVYAER(P) 769.9658 2306.8756 32 52 95%     
(R)ALcELESGIPAAESQIVYAERPLTDNHR(S) 1047.9945 3140.9617 32 59 95%     
(M)ASSPQGLDNPALLR(D) 720.3416 1438.6686 126 139 95%     
(K)DGDVVILR(Q) 887.6885 886.6812 68 75 95%     
(R)DLSEVTFSLQVDADFELHNFR(A) 829.0547 2484.1422 11 31 95%     
(R)DMLLANPHELSLLK(E) 798.0335 1594.0525 140 153 95%     
(R)EDIRPEEIADQELAEAIQK(S) 733.9521 2198.8346 371 389 95%     
(K)eRNPPLAEALLSGDLEK(F) 918.1919 1834.3692 154 170 95%     
(Q)HSSPGEMASSPQGLDNPALLR(D) 722.5809 2164.7208 119 139 95%     
(R)IDFSSIAVPGTSNPQQR(Q) 909.1754 1816.3363 94 110 95%     
(K)KNVLVIGTTGSQTTFLPEGELPEcAR(L) 939.9542 2816.8408 338 363 95%     
(R)LFSADPFDLEAQAK(I) 777.9904 1553.9662 192 205 95%     
(-)mLLTVYcVR(R) 586.4208 1170.827 1 9 95%     
(R)NPPLAEALLSGDLEK(F) 784.9762 1567.9378 156 170 95%     
(K)NVLVIGTTGSQTTFLPEGELPEcAR(L) 897.9843 2690.9309 339 363 95%     
(R)PAVQFSNLPR(I) 565.731 1129.4474 84 93 95%     
(P)PLAEALLSGDLEK(F) 679.6331 1357.2516 158 170 95%     
(N)PPLAEALLSGDLEK(F) 728.0932 1454.1718 157 170 95%     
(D)PRPAVQFSNLPR(I) 690.5706 1379.1266 82 93 95%     
(A)QHSSPGEMASSPQGLDNPALLR(D) 765.0068 2291.9987 118 139 95%     
(R)QKENADPRPAVQFSNLPR(I) 690.1108 2067.3107 76 93 95%     
(R)RDLSEVTFSLQVDADFELHNFR(A) 880.8362 2639.4867 10 31 95%     
(F)SADPFDLEAQAK(I) 647.237 1292.4594 194 205 95%     
(K)SAEDAER(Q) 777.8669 776.8597 390 396 95%     
(R)SLASYGLKDGDVVILR(Q) 854.2621 1706.5096 60 75 95%     
(S)SPGEMASSPQGLDNPALLR(D) 970.7396 1939.4647 121 139 95%     
(H)SSPGEMASSPQGLDNPALLR(D) 1014.1899 2026.3653 120 139 95%     
(R)TQAQHSSPGEMASSPQGLDNPALLR(D) 865.9633 2594.8679 115 139 95%     
(R)VHLAQVQIEGDFLAc(S) 850.7366 1699.4586 294 308 95%     
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(R)VHLAQVQIEGDFLAcSF(S) 967.6759 1933.3373 294 310 95%     
(R)VLVEQQQDR(A) 557.7312 1113.4478 174 182 95%     
(R)WAGIAK(G) 645.6434 644.6362 278 283 95%     
(R)WAGIAKGVGTQK(I) 609.2437 1216.4728 278 289 95%     





31980648 56 kDa (K)AHGGYSVFAGVGER(T) 704.7432 1407.4718 226 239 95% 13 36 
(R)AIAELGIYPAVDPLDSTSR(I) 994.976 1987.9374 388 406 95%     
(R)DQEGQDVLLFIDNIFR(F) 962.3201 1922.6256 295 310 95%     
(R)FLSQPFQVAEVFTGHMGK(L) 675.5938 2023.7596 463 480 95%     
(R)FTQAGSEVSALLGR(I) 719.209 1436.4035 311 324 95%     
(K)IGLFGGAGVGK(T) 489.0411 976.0676 202 212 95%     
(R)LVLEVAQHLGESTVR(T) 551.6302 1651.8687 95 109 95%     
(K)QFAPIHAEAPEFIEMSVEQEILVTGIK(V) 1010.4124 3028.2152 162 188 95%     
(K)TVLIMELINNVAK(A) 730.3951 1458.7757 213 225 95%     
(R)VALTGLTVAEYFR(D) 720.9205 1439.8265 282 294 95%     
(K)VLDSGAPIK(I) 450.8387 899.6629 125 133 95%     
(K)VLDSGAPIKIPVGPETLGR(I) 641.3276 1920.9611 125 143 95%     
(K)VVDLLAPYAK(G) 545.7843 1089.5541 189 198 95%     









170172520 53 kDa (K)AQIMNVSWSADHR(V) 758.9209 1515.8272 441 453 95% 13 34 
(K)DRTEPVTGFQK(A) 639.3469 1276.6793 251 261 95%     
(K)DRTFPTPIAKPPVFTGK(D) 625.2919 1872.8538 234 250 95%     
(K)DSEEDVVETPAVSHDEHTHQEIK(G) 878.3528 2632.0365 145 167 95%     
(K)EDILSFLEK(Q) 548.0388 1094.0631 203 211 95%     
(R)EELKPVALAR(G) 563.5911 1125.1676 292 301 95%     
(R)ILKEDILSFLEK(Q) 725.2795 1448.5445 200 211 95%     
(R)LAMENNIK(L) 467.5469 933.0792 180 187 95%     
(K)LGSSGQLGTTDLTGGTFTLSNIGSIGGTYA
K(P) 992.1195 2973.3367 380 410 95%     
(K)LREELKPVALAR(G) 466.0432 1395.1076 290 301 95%     
(K)LSDIGEGIR(E) 959.486 958.4787 69 77 95%     
(K)LSEVVGSGK(D) 438.6112 875.2078 188 196 95%     
(K)LSEVVGSGKDGR(I) 602.7032 1203.3919 188 199 95%     
(R)LYYNLDDIAYVGK(P) 774.8677 1547.7209 121 133 95%     
(R)LYYNLDDIAYVGKPLIDIETEALK(D) 924.179 2769.515 121 144 95%     
(K)PLIDIETEALK(D) 621.89 1241.7655 134 144 95%     
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(K)PVILPPEVAIGALGAIK(A) 553.8816 1658.6229 411 427 95%     
(K)QTGAILPPSPK(S) 555.0642 1108.1139 212 222 95%     
(R)RLAMENNIK(L) 545.3259 1088.6372 179 187 95%     
(K)SEITPPPPQPK(D) 596.2476 1190.4806 223 233 95%     
(K)SYLENPAFMLLDLK(-) 828.5388 1655.0631 469 482 95%     
(R)TEPVTGFQK(A) 504.3875 1006.7605 253 261 95%     
(R)TFPTPIAKPPVFTGK(D) 801.6519 1601.2892 236 250 95%     
(R)VIDGATMSR(F) 475.8932 949.7718 454 462 95%     
           Hsd17b4 - 
Peroxisomal 
multifunctional 
enzyme type 2 
31982273 79 kDa (K)AAVAVPNRPPDAVLR(D) 773.7782 1545.5418 479 493 95% 29 54 
(R)AAWDHMK(K) 429.8269 857.6393 133 139 95%     
(K)ALHGEQYLELYKPLPR(S) 643.5488 1927.6247 403 418 95%     
(K)ANAVFEWHITK(G) 658.5031 1314.9916 645 655 95%     
(K)AVANYDSVEAGEK(L) 677.6919 1353.3692 69 81 95%     
(R)AYALAFAER(G) 506.9815 1011.9485 24 32 95%     
(K)cEAVIADILDK(G) 624.5854 1247.1563 424 434 95%     
(R)DATSLNQAALYR(L) 663.3098 1324.605 494 505 95%     
(R)FAKPVYPGQTLQTEmWK(E) 681.1271 2040.3594 562 578 95%     
(K)FVYEGSADFScLPTFGVIVAQK(S) 812.9133 2435.7182 362 383 95%     
(R)GALVIVNDLGGDFK(G) 709.5963 1417.178 33 46 95%     
(R)GNImLSQK(L) 454.2733 906.5321 717 724 95%     
(K)GSGVVIVmDVYSYSGK(E) 840.6372 1679.2599 435 450 95%     
(R)HVLQQFADNDVSR(F) 765.6174 1529.2202 542 554 95%     
(K)IcDFSNASKPQTIQESTGGIVEVLHK(V) 954.1296 2859.3671 276 301 95%     
(R)IDVVVNNAGILR(D) 641.8379 1281.6612 93 104 95%     
(R)ILMTSSASGIYGNFGQANYSAAK(L) 785.082 2352.2243 146 168 95%     
(R)ISDEDWDIIHR(V) 700.7928 1399.5711 111 121 95%     
(K)LGILGLcNTLAIEGR(K) 801.1149 1600.2152 169 183 95%     
(K)LPSFSSSYTELQSImYALGVGASVK(N) 884.6567 2650.9484 331 355 95%     
(R)NQPmTPEAVR(D) 580.084 1158.1534 261 270 95%     
(K)PQTIQESTGGIVEVLHK(V) 613.0767 1836.2082 285 301 95%     
(K)SGSGEVYQGPAK(G) 590.7543 1179.494 669 680 95%     
(K)SmmNGGLAEVPGLSFNFAK(A) 1002.314 2002.6134 384 402 95%     
(K)TALDTFGR(I) 441.2425 880.4704 85 92 95%     
(R)TLGAIVR(K) 729.6303 728.623 252 258 95%     
(R)TSHAAPAATSGFVGAVGHK(L) 884.2516 1766.4886 312 330 95%     
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(K)VDSEGISPNR(T) 537.6899 1073.3653 302 311 95%     
(R)VVLVTGAGGGLGR(A) 579.1029 1156.1913 11 23 95%     
           Ahnak2 - AHNAK 
nucleoprotein 2 
309272904 341 kDa (K)AGQVGVK(L) 658.4348 657.4275 681 687 95% 11 6 
(K)FKmPSFGVSAPGKPSLEASLEVGAPK(V) 883.6356 2647.885 624 649 95%     
(K)GEVSAPDLEVSLPGVEVDIQAPGAK(L) 827.6949 2480.063 749 773 95%     
(K)LEGELALADK(D) 530.3378 1058.6611 774 783 95%     
(K)LEGELALADKDVAAK(D) 515.4941 1543.4606 774 788 95%     
(K)LPEGQLPEAELPAAQ(A) 782.7522 1563.4898 688 702 95%     
(K)LPEGQLPEAELPAAQAAAAAGAGLK(G) 782.5032 2344.4877 688 712 95%     
(K)mPSFGVSAPGKPSLEASLEVGAPK(V) 792.285 2373.8333 626 649 95%     
(K)TPDLSVQLPSADLDLK(A) 856.8209 1711.6273 1345 1360 95%     
(K)TPDLSVQLR(S) 514.8655 1027.7164 1174 1182 95%     
(K)VEADVAPPQVQGDLK(T) 783.5612 1565.1078 650 664 95%     








183396774 51 kDa (R)HFVTISSPLATQIPQAVGAAYAAK(R) 815.0022 2441.9848 202 225 95% 0.04 15 
(K)LKPNPSLLFSDVYQEmPAQLR(R) 821.9199 2462.7379 402 422 95%     
(R)RQQESLAR(H) 494.5246 987.0347 423 430 95%     
(R)VDGNDVFAVYNATK(E) 756.739 1511.4635 299 312 95%     





74315975 106 kDa (R)AAVESLGFILFR(T) 662.392 1322.7694 617 628 95% 11 18 
(R)DNLEWLAR(A) 509.2582 1016.5018 388 395 95%     
(K)DTSEDVEELVEPVAAHGPK(I) 675.0415 2022.1027 916 934 95%     
(K)FTATASLGVIHK(G) 622.7989 1243.5833 402 413 95%     
(K)IEEEEQEPEPPEPFEYIDD(-) 1168.2385 2334.4625 935 953 95%     
(K)KKEPEPNFQLLDNPAR(V) 633.2281 1896.6624 868 883 95%     
(R)NNNTDLmILK(N) 596.6334 1191.2523 345 354 95%     
(R)QGALIASALIMIQQTEITcPK(V) 1143.4802 2284.9459 685 705 95%     
(K)TPDASPEPK(D) 471.3529 940.6913 311 319 95%     
(R)TVGTPIASVPGSTNTGTVPGSEKDSDPmE
TEEK(T) 1112.4227 3334.2464 270 302 95%     





        





110347469 167 kDa (K)AAPLSLcALTAVDQSVLLLKPEAK(L) 837.3967 2509.1684 588 611 95% 38 36 
(K)AESPVFVQTDKPIYKPGQIVK(F) 782.3801 2344.1184 123 143 95%     
(K)AFAQAQSHIFIEK(T) 746.0593 1490.1041 1061 1073 95%     
(K)AINYLISGYQR(Q) 650.1057 1298.1968 1016 1026 95%     
(K)ALLAYAFALAGNK(A) 662.7816 1323.5487 1160 1172 95%     
(K)ALSFYQPR(A) 491.4033 980.7921 1206 1213 95%     
(K)APFALQVNTLPLNFDK(A) 894.9275 1787.8404 1358 1373 95%     
(R)APSAEVEmTAYVLLAYLTSESSRPTR(D) 954.1432 2859.4077 1214 1239 95%     
(K)DAVKEEDSLHWQRPGDVQK(V) 746.6787 2237.0143 1185 1203 95%     
(K)DHENcISGEDITHNGIVYTPK(H) 800.9015 2399.6826 638 658 95%     
(R)DLSSSDLSTASK(I) 606.5148 1211.0151 1240 1251 95%     
(K)DLTFYYLIK(A) 588.8309 1175.6473 491 499 95%     
(K)GSGSGcVYLQTSLK(Y) 729.0596 1456.1046 1334 1347 95%     
(R)GSIFNLGSHVLSLEQGNmK(G) 683.6458 2047.9156 502 520 95%     
(K)HSLGDNDAHSIFQSVGINIFTNSK(I) 868.2971 2601.8695 659 682 95%     
(R)IFQWQNIHLAGGLHQLSFPLSVEPALGIYK
(V) 1126.7368 3377.1886 173 202 95%     
(R)IHYLLNEDImK(N) 469.5282 1405.5629 477 487 95%     
(K)IKEEGTGIELTGIGScEIANALSK(L) 831.5839 2491.7298 325 348 95%     
(K)KIEHSFEVK(E) 559.207 1116.3994 212 220 95%     
(R)KTVSWAVTPK(S) 558.9353 1115.8561 866 875 95%     
(K)LLTDQAVDK(D) 502.089 1002.1635 73 81 95%     
(R)LPDLPGNYVTK(G) 609.1891 1216.3636 1323 1333 95%     
(K)LQDQPNIQR(T) 556.6218 1111.229 1418 1426 95%     
(K)LSPQSIYNLLPGK(T) 715.6846 1429.3546 612 624 95%     
(R)NALFcLETAWASISQSQESHVYTK(A) 924.6729 2770.9967 1136 1159 95%     
(R)PGLPFSGQVLLVDEK(G) 800.0133 1598.0121 360 374 95%     
(K)PVPGLVTLR(V) 477.1249 952.2352 257 265 95%     
(K)QQNSHGGFSSTQDTVVALQALSK(Y) 801.9332 2402.7779 1259 1281 95%     
(K)RSELLESLNK(D) 595.0046 1187.9946 1175 1184 95%     
(R)SELLESLNK(D) 517.3838 1032.753 1176 1184 95%     
(K)SVIVEPEGIEK(E) 601.0699 1200.1253 914 924 95%     
(R)TEVNTNHVLIYIEK(L) 558.7517 1673.2333 1427 1440 95%     
(K)TFHVNSGNR(L) 516.6491 1031.2837 1307 1315 95%     
(K)THITNAFNWLSmK(Q) 791.3682 1580.7218 1074 1086 95%     
(K)TVQGAFFGVPVYK(D) 706.9986 1411.9826 625 637 95%     
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(K)TVSWAVTPK(S) 494.8168 987.619 867 875 95%     
(K)VPDTITEWK(A) 544.8065 1087.5985 770 778 95%     
(K)YNILPVADGK(A) 545.9727 1089.9308 1348 1357 95%     







40353220 36 kDa (R)AAVEQVPVEPYK(I) 665.7338 1329.453 176 187 95% 3 14 
(K)GLLLScIEDKNPcIFFEPK(I) 761.2429 2280.7069 153 171 95%     
(R)SGDLFNcGSLTIR(A) 720.3898 1438.7651 101 113 95%     




9845265 15 kDa (K)cGHTNNLRPK(K) 599.2122 1196.4098 115 124 95% 4 34 
(K)ESTLHLVLR(L) 534.4146 1066.8147 64 72 95%     
(K)TITLEVEPSDTIENVK(A) 894.5645 1787.1144 12 27 95%     
(R)TLSDYNIQK(E) 541.2588 1080.503 55 63 95%     





19882201 100 kDa (R)AVPLALALISVSNPR(L) 761.4818 1520.9491 689 703 95% 16 24 
(K)cFAADIISVLAMTmSGER(E) 994.6466 1987.2787 120 137 95%     
(K)DKEQELSEEDKQLQDELEmLVER(L) 950.9592 2849.8559 40 62 95%     
(K)DPNNLFMVR(L) 553.6153 1105.216 755 763 95%     
(R)EDVLTLLLPVmGDSK(S) 823.7958 1645.577 495 509 95%     
(K)EWQELDDAEK(A) 631.7928 1261.5711 169 178 95%     
(K)FLRPHYGK(L) 509.8998 1017.785 98 105 95%     
(K)FSHDADPEVSYNSIFAmGmVGSGTNNAR(
L) 1003.2686 3006.7838 713 740 95%     
(R)HLAGEVAK(E) 413.0334 824.0523 161 168 95%     
(R)LGSIFGLGLAYAGSNR(E) 798.7317 1595.4488 479 494 95%     
(R)LNILDTLSK(F) 509.7458 1017.4771 704 712 95%     
(K)SETELKDTYAR(W) 657.1904 1312.3663 546 556 95%     
(K)THLENNR(F) 442.7417 883.4688 351 357 95%     
(K)TITGFQTHTTPVLLAHGER(A) 693.9703 2078.8892 861 879 95%     
(R)VGQAVDVVGQAGKPK(T) 485.4583 1453.3529 846 860 95%     
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123240391 119 kDa (R)ENNQIGPSLR(L) 564.8206 1127.6266 381 390 95% 4 5 
(R)IVIVEEAAEVLEAHTIATLSK(A) 746.5159 2236.5258 131 151 95%     
(K)VGFLQIPNR(I) 522.5795 1043.1444 337 345 95%     
(K)YQGEENDIILLSLVR(S) 881.4614 1760.9083 316 330 95%     
           Ndrg2 - isoform 1 
of protein NDRG2 
7305305 41 kDa (R)FGDmQEIIQNFVR(V) 807.2114 1612.4082 85 97 95% 7 37 
(R)GIIQHAPNLENIELYWNSYNNR(R) 887.1171 2658.3294 219 240 95%     
(K)GWMDWAAHK(L) 551.5619 1101.1092 177 185 95%     
(R)ILLDQGQTHSVETPYGSVTFTVYGTPK(P) 980.8151 2939.4234 33 59 95%     
(K)LTGLTSSIPDmILGHLFSQEELSGNSELIQK
(Y) 1126.2312 3375.6718 186 216 95%     
(K)RPAIFTYHDVGLNYK(S) 599.1879 1794.5418 62 76 95%     
(R)YALNHPDTVEGLVLINIDPNAK(G) 803.0105 2406.0097 155 176 95%     
           Ddb1 - DNA 
damage-binding 
protein 1 
7657011 127 kDa (R)IEVQDSSGGTTALRPSASTQALSSSVSSS
K(L) 980.5898 2938.7477 740 769 95% 4 6 
(R)IVVFQYSDGK(L) 578.5957 1155.1769 848 857 95%     
(R)KTEPATGFIDGDLIESFLDISRPK(M) 884.9985 2651.9738 1081 1104 95%     
(K)YNAcILEYK(Q) 587.6207 1173.2269 84 92 95%     





27754103 44 kDa (K)ALQSVGQIVGEVLK(Q) 721.16 1440.3054 49 62 95% 3 10 
(R)EVIELPLTNPELFQR(V) 899.4423 1796.87 147 161 95%     
(R)EVIELPLTNPELFQR(V) 900.1757 1798.3368 147 161 95%     
(K)HGEIDYEAIVK(L) 637.8087 1273.6028 323 333 95%     





134053905 47 kDa (K)ImLNTPEDVQALVSGK(L) 866.4888 1730.963 259 274 95% 3 9 
(K)TYHALSNLPK(A) 572.8973 1143.7801 176 185 95%     
(R)YQEALHLGSQLLR(E) 764.7944 1527.5743 143 155 95%     
           Psmc2 -  26S 
Proteasome 
ATPase subunit 2 
(Rpt2) 
33859604 53 kDa (K)QVEDDIQQLLK(K) 665.7025 1329.3905 89 99 95% 2 4 






         










46049022 46 kDa (K)AEYLcQIGDK(E) 599.0166 1196.0187 108 117 95% 4 9 
(K)DWLFAPHYR(Y) 603.4322 1204.8498 285 293 95%     
(K)KGDLLLNR(V) 465.7553 929.4961 372 379 95%     
(K)NLGESEIR(D) 459.6975 917.3805 94 101 95%     
           Vps26a - Isoform 




164518904 42 kDa (K)HYLFYDGESVSGK(V) 751.7944 1501.5742 71 83 95% 2 7 
(R)LFLAGYDPTPTmR(D) 750.368 1498.7214 282 294 95%     
           Psmd7 - 26S 
proteasome non-
ATPase regulatory 
subunit 7 (Rpn7) 
6754724 37 kDa (R)ITNQVHGLK(G) 505.7542 1009.4939 191 199 95% 2 8 
(K)VVVHPLVLLSVVDHFNR(I) 648.9263 1943.7572 9 25 95%     
 
 
 
 
